American Society of Hematology (ASH) Annual Meeting  
December 5-8, 2020  
http://www.hematology.org/Annual-Meeting/Program/  

**Case CCC Members in BOLD; Presenter UNDERLINED**  
Events listed in Eastern Standard Time (EST)  

### PRESENTATIONS/SESSION CHAIRS/MODERATORS

**Amar Desai, PhD**  
Case Comprehensive Cancer Center  
Speaker, [Regulation of the Hematopoietic Niche By 15-PGDH](#) and Live Q&A  
Wednesday, Dec 2, 2020, 10:05 AM-10:45 AM; Scientific Workshops @ ASH, Stem Cells

**Hetty E. Carraway, MD, MBA**  
Case Comprehensive Cancer Center, Cleveland Clinic  
Moderator, Blood Drop: Health Disparities  
Thursday, Dec 3, 2020, 10:15 AM-10:55 AM; ASH-a-Palooza  
Chair, [Myelodysplastic Syndromes: What We Have And What We Want](#)  
Speaker, [Therapy For Lower Risk MDS](#)  
Saturday, Dec 5, 2020, 12:30 PM-1:15 PM; Education Program  
ASH-a-Palooza Thank You Video (Available On-Demand beginning Dec 2)

**Keith R. McCrae, MD**  
Case Comprehensive Cancer Center, Cleveland Clinic  
Speaker, [MicroRNA and Role in Cancer Associated Thrombosis](#) and Live Q&A  
Thursday, Dec 3, 2020, 10:05 AM-10:29 AM; Scientific Workshops @ ASH  
Speaker, [Clinical Advances in Immune Thrombocytopenia: Integrating New Therapies](#)  
Friday, Dec 4, 2020, 2:00 PM-5:00 PM; Sattelite Symposia

**Lalitha V. Nayak, MD**  
Case Comprehensive Cancer Center, University Hospitals  
Speaker, [NLF-2, Cancer, and Thrombosis](#) and Live Q&A  
Thursday, Dec 3, 2020, 10:29 AM-11:17 AM; Scientific Workshops @ ASH, Interplay Between the Hematologic System and Solid Tumor Progression

**Shadi Swaidani, MD, PhD**  
Cleveland Clinic  
Speaker, [Elevated Systemic Myeloid-Derived Suppressor Cells and Interleukin 8 Correlate with Increased Incidence of Venous Thromboembolism in Cancer Patients Receiving Immune-Checkpoint Inhibitors](#) and Live Q&A  
Thursday, Dec 3, 2020, 11:55 AM-12:56 PM; Scientific Workshops @ ASH, Late-Breaking Research Presentations
Peng Zeng, MD  
Case Western Reserve University  
Speaker, **Ponatinib Induction of Vascular Inflammation** and Live Q&A  
Thursday, Dec 3, 2020, 10:29 AM-11:17 AM; Scientific Workshops @ ASH, Interplay Between the Hematologic System and Solid Tumor Progression

**Deepa Jagadeesh, MD, MPH**  
Case Comprehensive Cancer Center, Cleveland Clinic  
Speaker, **Blood Buddy Forum: Adult and Pediatric BMT**  
Thursday, Dec 3, 2020, 1:00-3:00 PM; ASH-a-Palooza  
Speaker, **Blood Buddies: Pediatric and Adult BMT**  
Friday, Dec 4, 2020, 1:00-3:00 PM; ASH-a-Palooza

Sanjay Ahuja, MD  
University Hospitals Rainbow Babies & Children’s  
Speaker, **Blood Buddy Forum: Pediatric Clinical Non-Malignant Hematology**  
Thursday, Dec 3, 2020, 1:00-3:00 PM; ASH-a-Palooza

**Marvin T. Nieman, PhD**  
Case Comprehensive Cancer Center  
Speaker, **Blood Buddy Forum: PhD Careers**  
Thursday, Dec 3, 2020, 1:00-3:00 PM; ASH-a-Palooza  
Speaker, **Leading Yourself**  
Monday, Dec 7, 2020, 2:20 PM-2:30 PM; Education Program, Junior Faculty Career Development Education Session

**Brian T. Hill, MD**  
Case Comprehensive Cancer Center, Cleveland Clinic  
Speaker, **Application of Individualized Treatment for Cll/Sll: Novel Agents, Combinations, and Sequencing Therapy**  
Friday, Dec 4, 2020, 10:00 AM-1:00 PM; **Friday Satellite Symposia – Register Here**

**Bhumika J. Patel, MD**  
Case Comprehensive Cancer Center, Cleveland Clinic  
Chair, **Mastering the Treatment of Myeloid Malignancies in the Era of Personalized Medicine**  
Friday, Dec 4, 2020, 10:00 AM-1:00 PM; **Friday Satellite Symposia – Register Here**

**Betty K. Hamilton, MD**  
Case Comprehensive Cancer Center, Cleveland Clinic  
Speaker, **Mastering the Treatment of Myeloid Malignancies in the Era of Personalized Medicine**  
Friday, Dec 4, 2020, 10:00 AM-1:00 PM; **Friday Satellite Symposia – Register Here**

**Jaroslaw P. Maciejewski, MD, PhD**  
Case Comprehensive Cancer Center, Cleveland Clinic  
Speaker, **Mastering the Treatment of Myeloid Malignancies in the Era of Personalized Medicine**  
Friday, Dec 4, 2020, 10:00 AM-1:00 PM; **Friday Satellite Symposia – Register Here**
**ORAL ABSTRACTS – CASE CCC PRESENTER**

**284 Characterization of the Blood and Bone Marrow Microbiome of MDS Patients and Associations with Clinical Features**
Program: Oral and Poster Abstracts
Type: Oral
Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies
Hematology Disease Topics & Pathways: Diseases, MDS, Biological Processes, Myeloid Malignancies, genomics, pathogenesis
Saturday, Dec 5, 2020: 5:00 PM

Jakob Woerner1**, Yidi Huang, MS2**, Yimin Huang3**, Janet Wang, BS4**, Jesus M Hernández-Sánchez, PhD5**, Jaroslaw P. Maciejewski, MD, PhD6, Mehmet Koyuturk, PhD7**, Stephan Hutter, PhD7**, Torsten Haferlach, MD7** and Thomas Leframboise, PhD4**

1 Case Western Reserve University, Cleveland
2 Case Western Reserve University, Cleveland, OH
3 Case Western Reserve University, Cleveland, OH
4 Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH
5 Universidad de Salamanca, IBSAL, Salamanca, Spain
6 Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
7 MLL Munich Leukemia Laboratory, Munich, Germany

**653 Efficacy and Safety of Pevonedistat Plus Azacitidine Vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes (MDS) from Study P-2001 (NCT02610777)**
Program: Oral and Poster Abstracts
Type: Oral
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Treatment of Higher Risk Myelodysplastic syndromes
Hematology Disease Topics & Pathways Follicular Lymphoma, ALL, multiple myeloma, Biological, Marginal Zone Lymphoma, Diseases, smoldering myeloma, CLL, Mantle Cell Lymphoma, LGCL, Therapies, CNS Lymphoma, MDS, DLBCL, enzyme inhibitors, Technology and Procedures, cytogenetics, Myeloid Malignancies
Monday, Dec 7, 2020: 2:30 PM


1 Leukemia Program, Cleveland Clinic, Cleveland, OH
2 University of Miami Sylvester Comprehensive Cancer Center, Cleveland, OH

738 CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity

Program: Oral and Poster Abstracts
Type: Oral
Session: 704. Immunotherapies: Therapeutic T cell Manipulation
Hematology Disease Topics & Pathways: Biological, CRS, Diseases, neurotoxicity, Mantle Cell Lymphoma, CAR-Ts, Therapies, Non-Hodgkin Lymphoma, Adverse Events, B-Cell Lymphoma, DLBCL, Lymphoid Malignancies, Clinically relevant
Monday, Dec 7, 2020: 5:00 PM


1 Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
2 Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
3 Pontificia Universidad Catolica de Chile, Santiago, CHL
4 Adult Hematologic Malignancies & Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Cleveland, OH
5 Lentigen Technology Inc., A Miltenyi Biotec Company, Gaithersburg, MD
6 Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
7 Pediatrics, University of Washington School of Medicine, Seattle, WA
8 Case Western Reserve University, Cleveland, OH

ORAL ABSTRACTS – NON-CASE CCC PRESENTER (with CASE CCC/CLEVELAND CO-AUTHORS)

24 A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Program: Oral and Poster Abstracts
Type: Oral
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel combination therapies in treatment of newly diagnosed AML
Hematology Disease Topics & Pathways: Adult, Diseases, Therapies, Combinations, Study Population, Clinically relevant, Myeloid Malignancies
Saturday, Dec 5, 2020: 10:30 AM

Keith W. Pratz, MD, Mohamad Cherry, MD, MS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark Levis, MD, PhD, Tara Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD, PhD, Gary J. Schiller, MD, Jason E. Hill, PhD, Angela James, PhD, Qiaoyang Lu, MS and Ramon V. Tiu, MD

1 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
2 Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK
3 Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
4 University Hospitals, Cleveland Medical Center, Cleveland, OH
5 Methodist Physician Practices, San Antonio, TX
6 Columbia University Medical Center, New York, NY
7 University of Kansas Medical Center, Kansas City, KS
8 Abramson Comprehensive Cancer Center, University of Pennsylvania, Philadelphia, PA
34 The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Type: Oral
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Single Cell Profiling and Novel molecular Markers
Hematology Disease Topics & Pathways: AML, Diseases, Myeloid Malignancies
Saturday, Dec 5, 2020: 11:30 AM

Hassan Awada, MD1, Arda Durmaz2*, Carmel Gurnari, MD3*, Ashwin Kishtagari, MBBS4, Manja Meggendorfer, PhD5, Cassandra M. Kerr, MS5*, Teodora Kuzmanovic5*, Jibrann Durrani, MD5*, Yasunobu Nagata, MD, PhD5*, Tomas Radivoyevitch, PhD56*, Anjali S Advani, MD5, Farhad Ravandi, MBBS5, Hetty E. Carraway, MD, MBA9, Aziz Nazha, MD10, Claudia Haferlach, MD11, Yogenthiran Saunthararajah, MD12, Jacob Scott, MD9*, Valeria Visconte, PhD7, Hagop M. Kantarjian, MD13, Tapan M. Kadia, MD9,

Mikkael A. Sekeres10, Torsten Haferlach, MD14 and Jaroslaw P. Maciejewski, MD, PhD5

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
2Translational hematology and Oncology research, Taussic Cancer Center, Cleveland Clinic, Cleveland
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland
4MLL Munich Leukemia Laboratory, Munich, Bavaria, Germany
5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
6Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
7Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
8Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
9Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
10Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland
11MLL Munich Leukemia Laboratory, Inning am Ammersee, Germany
12Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
13University of Texas MD Anderson Cancer Center, Houston, TX
14MLL Munich Leukemia Laboratory, Munich, Germany

51 A Phase 2 Study of the LSD1 Inhibitor IMG7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis

Program: Oral and Poster Abstracts
Type: Oral
Session: 634. Myeloproliferative Syndromes: Clinical: New Therapies and JAKi-based Combinations for Myelofibrosis
Hematology Disease Topics & Pathways: Adult, Diseases, Non-Biological, Therapies, MPN, Study Population, Myeloid Malignancies, Clinically relevant
Saturday, Dec 5, 2020: 10:30 AM

Abdulraheem Yacoub, MD1, Kristen M. Pettit, MD1, Terrence J Bradley, MD2, Aaron T. Gerds, MD, MS3, Maciej Tartaczuch, MD4,5, Jake Shortt, FRACP, FRCPA, PhD5, Natasha Joan Curtin, MD, FRACP, FRCPA7*, James M. Rossetti, DO8, Kate Burbury, MBBS, FRACP, FRCPA, DPhil8*, Adam J. Mead, MD, PhD10, Joachim R Göthert, MD11, Steffen Koschmieder, MD12, Amber Jones, MA13*, Jennifer Peppe, BS14*, Georges Natsoulis, Ph.D.13*, William S. Stevenson, MBBS, PhD15, Joanne Ewing, MD, PhD16*, Claire Harrison, DM, FRCP, FRCPath17, Alessandro M. Vannucchi, MD18, Justin M Watts, MD19, David M Ross, MBBS, PhD, FRACP, FRCPA20*, Moshe Talpaz, MD21 and Hugh Young Rienhoff Jr., MD22

1The University of Kansas Cancer Center, Leawood, KS
2Rogel Cancer Center, University of Michigan, Ann Arbor, MI
3University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
4Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
5School of Clinical Sciences, Monash University, Melbourne, Australia
75 A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transp

Program: Press Program Presentations
Session: Press Briefing on What’s on the Horizon: Practice-Changing Clinical Trials
Hematology Disease Topics & Pathways: Biological, Adult, bone marrow, Diseases, Therapies, Elderly, MDS, Study Population, Clinically relevant, Myeloid Malignancies, transplantation, stem cells
Friday, Dec 4, 2020, 12:30 PM-1:00 PM
Ryotaro Nakamura, M.D.1, Wael Saber, MD, MS2, Michael J Martens, PhD3*, Alyssa Ramirez3*, Bart L. Scott, MD4, Betul Oran, MD, MS5, Eric Leifer, Ph.D.6*, Roni Tamari, MD7, Asmita Mishra, MD8*, Richard T. Maziarz, MD9, Joseph P. McGuirk, DO10, Peter Westervelt, MD, PhD11, Sumithra Vasu, MD, MBBS12, Mrinal M. Patnaik, MD, MBBS13, Rammurti Kamble, MD14, Stephen J. Forman, MD15, Mikkael A. Sekeres15, Frederick R. Appelbaum, MD16, Adam M. Mendizabal, MS17*, Brent Logan, PhD18*, Mary M. Horowitz, MD, MS19 and Corey Cutler, MD, MPH, FRCPC20

1Department of Haematology, Monash Health, Clayton, Australia
2Monash Health, Monash University, Melbourne, Australia
3UPMC Hillman Cancer Center, Pittsburgh, PA
4Peter MacCallum Cancer Centre, Melbourne, Australia
5MRC Wetherall Institute of Molecular Medicine, Oxford, United Kingdom
6Department of Hematology, West German Cancer Center (WTZ), University Hospital Essen, Essen, Germany
7Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany
8Imago Biosciences, Inc., San Carlos, CA
9Imago Biosciences, Inc., San Carlos, CA
10Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, Australia
11University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
12Department of Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom
13CIBMTR; Center for Research and Innovation of Myeloproliferative Neoplasms, AOI Careggi, Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy
14University of Miami, Coral Gables, FL
15Department of Haematology, Flinders Medical Centre and University, Adelaide, SA, Australia
16University of Michigan Medical Center, Ann Arbor, MI
17Imago Biosciences, San Francisco

135 High Doses of Targeted Radiation with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractor

Program: Oral and Poster Abstracts
Type: Oral
Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities I
Hematology Disease Topics & Pathways: Biological, antibodies, HSCs, Adult, Therapies, Elderly, Cell Lineage, Study Population, Clinically relevant, stem cells
Saturday, Dec 5, 2020: 12:30 PM

**Boglarka Gyurkozzo**, MD, **Rajneesh Nath**, MD, **Hannah Choe**, MD, **Stuart Seropian**, MD, **Patrick J. Stiff**, MD, **Sunil Abhyankar**, MD, **Edward Agura**, MD, **Mark Litzow**, MD, **Benjamin K. Tomlinson**, MD, **George L. Chen**, MD, **Parameswaran Hari**, MD, **Johnnie Orozco**, MD, **Zaid S. Al-Kadhimi**, MD, **Camille Abboud**, MD, **Koen Van Besien**, MD, **Mitchell Sabloff**, MSc, MD, **FRCPC**, **Margarida Magalhaes Magalhaes-Silverman**, James M. Foran, MD, **Michael W. Schuster**, MD, **Partow Kebrizai**, MD, **Moshe Levy**, MD, **Hillard M Lazarus**, MD, **Sergio A. Giralt**, MD, **Qing Liang**, PhD, **Mark S. Berger**, MD, **Vijay Reddy**, MD, PhD and **John M. Pagel**, MD PhD

1. Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY
2. Banner MD Anderson Cancer Center, Gilbert, AZ
3. Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
4. Hematology, Yale University School of Medicine, New Haven, CT
5. Loyola University Chicago Stritch School of Medicine, Maywood, IL
6. University of Kansas Cancer Center, Kansas City, KS
7. Baylor University Medical Center at Dallas, Dallas, TX
8. Division of Hematology, Mayo Clinic, Rochester, MN
9. Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
10. Roswell Park Comprehensive Cancer Center, Buffalo, NY
11. Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
12. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
13. Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE
14. Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO
15. Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY
16. Hematology, The Ottawa Hospital General Campus, Ottawa, ON, Canada
17. Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA
18. Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL
19. Stony Brook University Hospital Cancer Center, Stony Brook, NY
20. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
21. Baylor University Medical Center, Dallas, TX
22. Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Cleveland Medical Center, Shaker Heights, OH
23. Memorial Sloan Kettering Cancer Center, New York, NY
25. Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

**170 Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings**

Program: Oral and Poster Abstracts

Type: Oral

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Advances in immunotherapeutics for management of AML

Hematology Disease Topics & Pathways: AML, Biological, Adult, Diseases, Therapies, checkpoint inhibitors, MDS, Study Population, Myeloid Malignancies

Saturday, Dec 5, 2020: 4:15 PM


1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2. Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
3. Case Western Reserve University, Cleveland, OH
4. UVA, Charlottesville, VA
5. Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Ludwig Center at Harvard, Harvard Medical School, Boston, MA, USA, Boston, MA
186 Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT)

Program: Oral and Poster Abstracts
Type: Oral
Session: 711. Cell Collection and Processing
Hematology Disease Topics & Pathways: Fanconi Anemia, iron deficiency, PNH
Saturday, Dec 5, 2020: 3:45 PM

Jack W. Hsu, MD1, Nosha Farhadfar, MD2, Hemant S. Murthy, MD3, Brent Logan, PhD4*, Stephanie Bo-Subait, MPH5, Noelle V. Frey, MD, MS6, Steven C. Goldstein, MD7, Mary M. Horowitz, MD, MS8, Hillard M Lazarus, MD9, Joshua Schwanke10*, Nirali N. Shah, MD11, Stephen R. Spellman, MS12*, Galen E. Switzer, PhD13, Steven M Devine, MD14, Bronwen E. Shaw, PhD, MRCP, FRCPath15 and John R. Wingard, MD16*

1Department of Medicine/Division of Hematology Oncology, University of Florida, Gainesville, FL
2Shands HealthCare & University of Florida, Gainesville, FL
3Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL
4Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
5CIBMTR (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN
6Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA
7Florida Hospital Cancer Institute, Orlando, FL
8Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI
9Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Cleveland Medical Center, Shaker Heights, OH
10NMDP, Minneapolis, MN
11Pediatric Oncology Branch, National Cancer Institute/Nih, Bethesda, MD
12CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI
13University of Pittsburgh, Pittsburgh, PA
14National Marrow Donor Program (NMDP)/Be The Match, Minneapolis, MN
15CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
16Division of Hematology & Oncology, Department of Medicine, Shands HealthCare & University of Florida, Gainesville, FL

188 Impact of Daratumumab on Stem Cell Collection, Graft Composition and Engraftment Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

Program: Oral and Poster Abstracts
Type: Oral
Session: 711. Cell Collection and Processing
Hematology Disease Topics & Pathways: Biological, antibodies, Therapies, transplantation, stem cells
Saturday, Dec 5, 2020: 4:15 PM

Shivaprasad Manjappa, MD, MBBS1, Robert Fox2*, Jane Reese2*, Amin Firoozamand, MD3, Hannah Schmikla, RN4*, Savannah Nall, RN5, Merle Kolk2, Paolo F Caimi, MD2, James J. Driscoll, MD, PhD6,7, Marcos de Lima, MD2 and Ehsan Malek, MD8

1Case Western Reserve University, BEACHWOOD, OH
2Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
3University Hospital Cleveland Medical Center/ Seidman Cancer Center, Cleveland, OH
4University Hospitals Cleveland Medical Center, Cleveland, OH
5University Hospital Cleveland Medical Center, Cleveland, OH
6Case Western Reserve University, Cleveland, OH
7Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
8Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH
193 Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [lomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment

Program: Oral and Poster Abstracts
Type: Oral
Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities II
Saturday, Dec 5, 2020: 4:00 PM
Boqgarka Gyurkoicz, MD, Rajneesh Nath, MD, Hannah Choe, MD, Stuart Seropian, MD, Patrick J. Stiff, MD, Sunil Abhynkarkar, MD, Edward Agura, MD, Mark Litzow, MD, Benjamin K. Tomlinson, MD, George L. Chen, MD, Parameswaran Hari, MD, MRCP, Johnnie Orozco, MD, Zaid S. Al-Kadhimi, MD, Camille Abboud, MD, Koen Van Besien, MD, PhD, Mitchell Sabloff, MSc, MD, FRCP, Margarita Magalhaes Magalhaes-Silverman, James M. Foran, MD, Michael W. Schuster, MD, Partow Kebrizel, MD, Moshe Y. Levy, MD, Hillard M Lazarus, MD, Sergio A. Giralt, MD, Qing Liang, PhD, Mark S. Berger, MD, Vijay Reddy, MD, PhD and John M. Pagel, MD PhD

1Memorial Sloan-Kettering Cancer Center, New York, NY
2Banner MD Anderson Cancer Center, Gilbert, AZ
3Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
4Hematology, Yale University School of Medicine, New Haven, CT
5Loyola University Chicago Stritch School of Medicine, Maywood, IL
6Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS
7Baylor University Medical Center at Dallas, Dallas, TX
8Division of Hematology, Mayo Clinic, Rochester, MN
9Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
10Roswell Park Comprehensive Cancer Center, Buffalo, NY
11Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
12Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
13Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE
14Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO
15Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY
16Hematology, The Ottawa Hospital General Campus, Ottawa, ON, Canada
17Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA
18Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL
19Stony Brook University Hospital Cancer Center, Stony Brook, NY
20Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
21Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
22Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Cleveland Medical Center, Shaker Heights, OH
23Memorial Sloan Kettering Cancer Center, New York, NY
24Actinium Pharmaceuticals, Inc., New York, NY
25Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA

196 Computer Vision and Deep Learning Assisted Microchip Electrophoresis for Integrated Anemia and Sickle Cell Disease Screening

Program: Oral and Poster Abstracts
Type: Oral
Session: 803. Emerging Diagnostic Tools and Techniques II
Hematology Disease Topics & Pathways: Anemias, sickle cell disease, Diseases, sickle cell trait, bioengineering, Hemoglobinopathies, Technology and Procedures, Clinically relevant, newborn screening
Saturday, Dec 5, 2020: 3:15 PM
Ran An, PhD, Yuncheng Man, Shamreen Iram, Erdem Kucukal, Muhammad Noman Hasan, PhD, Ambar Solis-Fuentes, Allison Bode, Ailis Hill, Kevin Cheng, Yuning Huang, Sanjay Ahuja, MD, Jane A. Little, PhD and Umut A. Gurkan, PhD

1Case Western Reserve University, Cleveland, OH
2University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH
3University of North Carolina at Chapel Hill, Chapel Hill, NC
202 Performance of Khorana Score to Predict One-Year Risk of Venous Thromboembolism in over Two Million Patients with Cancer

Program: Oral and Poster Abstracts
Type: Oral
Session: 904. Outcomes Research - Non-Malignant Conditions: Venous Thromboembolism Associated with Cancer and/or COVID-19
Hematology Disease Topics & Pathways: Diseases, Bleeding and Clotting, Non-Biological, Thrombosis, Clinically relevant, VTE
Saturday, Dec 5, 2020: 3:15 PM

Yasmin Arafah, MD1, Taha Al-Juhaishi, MD2, Ghaith Abu Zeinah, MD3, Lalitha V. Nayak, MD4 and Sadeer Al-Kindi, M.D.5*
1Department of Medicine, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, OH
2Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
3Richard T. Silver Myeloproliferative Neoplasms Center, NewYork-Presbyterian Weill Cornell Medical Center, New York, NY
4Department of Medicine, Division of Hematology and Oncology, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, OH
5Division of Cardiology, Harrington Heart and Vascular Institute, Case Western Reserve University and University Hospitals, Cleveland, OH

204 Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry

Program: Oral and Poster Abstracts
Type: Oral
Session: 904. Outcomes Research - Non-Malignant Conditions: Venous Thromboembolism Associated with Cancer and/or COVID-19
Saturday, Dec 5, 2020: 3:45 PM

Ang Li, MD, MS1, Nicole M. Kuderer, MD, MSc2, Jeremy L. Warner, MD, MS3, Aakash Desai, MD4, Dimpy P. Shah, MD, PhD5, Julie Fu, MD, MA6, Monica Li7, Rebecca Zon8, Shubhi Shah, MD9, Shuchi Gulati, MD10, Ali Raza Khaki, MD11, Amit Kulkarni, MD12, Amro Elshoury, MBBChir13, Michael A. Thompson, MD, PhD14, Petros Grivas, MD, PhD15*, Gilberto de Lima Lopes, MD, MBA16*, Yu Shyr, PhD17*, Nathan A Pennell, MD, PhD18, Andrew Schmidt, MD19, Christopher R Friese20*, Daniel Stover21*, Jaymin Patel22*, Balazs Halmo23*, Toni K. Choueiri, MD24*, Solange Peters, MD25*, Donna R. Rivera, PharmD26*, Corrie Painter, PhD27*, Brian Rini, MD28*, Gary H. Lyman, MD29, Jean M. Connors, MD30 and Rachel P. Rosovsky, MD, MPH31

1Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX
2Advanced Cancer Research Group, Seattle, WA
3Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN
4Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
5Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX
6Tufts Medical Center, Watertown, MA
7Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston
8Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
9University of Minnesota, Minneapolis, MN
10University of Cincinnati/Barrett Cancer Center, Cincinnati, OH
11Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
12Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN
13Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
14Aurora Cancer Care, Aurora Research Institute, Advocate Aurora Health, Delafield, WI
15Fred Hutchinson Cancer Research Center/University of Washington/Seattle Cancer Care Alliance, Seattle
16Sylvester Comprehensive Cancer Center at the University of Miami, Miami
17Biostatistics, Vanderbilt University School of Medicine, Nashville, TN
18Lung Program, Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
19Dana-Farber Cancer Institute, Boston, MA
20University of Michigan, Ann Arbor, MI
21Ohio State University Medical Center, Columbus, OH
22Breast Oncology Program, Beth Israel Deaconess Medical Center, Boston, MA
23Montefiore Medical Center, Bronx, NY
24Dana Farber Cancer Institute, Boston
25Lausanne University, Lausanne, Switzerland
207 Patient Selection Bias Limits the Real World Efficacy of Randomized Clinical Trials in Multiple Myeloma

Program: Oral and Poster Abstracts
Type: Oral
Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Outcomes Research Real World Data Healthcare Disparities
Hematology Disease Topics & Pathways: Adult, Study Population, Clinically relevant, Quality Improvement
Saturday, Dec 5, 2020: 3:00 PM
Augusta Eduafo, DO¹*, Leland Metheny III, MD², James Driscoll³*, Benjamin K. Tomlinson, MD², Kirsten M Boughan, DO², Molly M Gallogly, MD, PhD², Marcos de Lima, MD² and Ehsan Malek, MD⁴
¹Internal Medicine Department, St. John Medical Center, Cleveland, OH
²Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
³Case Western Reserve University, Cleveland, OH
⁴Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

215 Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub

Program: Press Program Presentations
Session: Press Briefing on Hematologic Aspects of the Pandemic: Advancing the Study of COVID-19
Hematology Disease Topics & Pathways: SARS-CoV-2/COVID-19, Coronaviruses, ALL, Lymphoma (any), CLL, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Clinically relevant
Saturday, Dec 5, 2020, 11:00 AM-11:30 AM
William A. Wood, MD, MPH¹, Donna S. Neuberg, ScD², John Colton Thompson³*, Martin S. Tallman, MD⁴, Mikkael A. Sekeres, MD, MS⁵, Laurie H. Sehn, MD, MPH⁶, Kenneth Anderson, MD⁷, Aaron D Goldberg, MD, PhD⁸, Nathan A Pennell, MD, PhD⁹, Charlotte M. Niemeyer, MD¹⁰, Emily Tucker, MS¹¹*, Kathleen Hewitt, DNP, CPHQ, AACC, RN¹²*, Robert M Plovnick, MD, MS¹², and Lisa K. Hicks, MD, MSc¹³
¹Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, NC
²Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
³ASH Research Collaborative, Washington, DC
⁴Memorial Sloan-Kettering Cancer Center, New York, NY
⁵Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁶BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada
⁷Jerome Lipper Multiple Myeloma Center, Lebow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁸Department of Medicine, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY
⁹Lung Program, Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
¹⁰University Children's Hospital, Freiburg, Germany
¹¹ASH Research Collaborative, Washington DC, DC
¹²American Society of Hematology, Washington DC, DC
¹³Division of Hematology/Oncology, St. Michael's Hospital, Toronto, ON, Canada

257 Impact of Pathogenic Germ Line Variants in Adults with Acquired Bone Marrow Failure Syndromes Vs. Myeloid Neoplasia

Program: Oral and Poster Abstracts
Type: Oral
Session: 508. Bone Marrow Failure: Advancing Our Biologic Understanding in Inherited and Acquired Bone Marrow Failure Disorders
259 Impact of HLA Evolutionary Divergence on Clinical Features of Patients with Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Program: Oral and Poster Abstracts
Type: Oral
Session: 508. Bone Marrow Failure: Advancing Our Biologic Understanding in Inherited and Acquired Bone Marrow Failure Disorders
Hematology Disease Topics & Pathways: Diseases, Bone Marrow Failure, Biological Processes, genomics, clinically relevant, immune mechanism
Saturday, Dec 5, 2020: 6:15 PM
Simona Pagliuca, MD1,2, Carmelo Gurnari, MD2,34, Diego Chowell, PhD5*, Chirag Krishna7*, Bhumika J. Patel, MD8, Hassan Awada, MD9, Cassandra M Kerr, MS2*, Sunisa Kongkiatkamon, MD2,7*, Ashwin Kishtagari, MBBS9, Thomas Laframboise, PhD8*, Yogenthiran Santhrararajah, MD8, Babal K. Jha, PhD2*, Valeria Visconte, PhD3, Timothy Chan, MD, PhD9* and Jaroslaw Maciejewski, PhD2*
1Université de Paris, Paris, France
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
3Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
4Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York
5Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York
6Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
7Department of hematology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
8Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
9Department of Genetics and Genome Sciences Department, Case Western Reserve University School of Medicine, Cleveland, OH

288 Clinical Impacts of Germline DDX41 Mutations on Myeloid Neoplasms
Program: Oral and Poster Abstracts
Type: Oral
Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies
Hematology Disease Topics & Pathways: Adult, Diseases, MDS, Biological Processes, Technology and Procedures, Study Population, Myeloid Malignancies, genomics, clinically relevant, NGS
Saturday, Dec 5, 2020: 6:00 PM
Hideki Makishima, MD, PhD3, Yasuhito Nannya, MD, PhD1, June Takeda, MD2*, Yukihide Momozawa, DVM, Ph.D3, Ryunosuke Saiki, MD1, Tetsuichi Yoshizato, MD, PhD3, Yoshiko Atsuta, MD, PhD5,6*, Yuka Iijima-Yamashita7*, Kenichi Yoshida, MD, PhD1, Yuichi Shiraishi, PhD8*, Yasunobu Nagata, MD, PhD1, Yusuke Shiozawa, MD, PhD9*, Makoto Onizuka, MD, PhD1, Kenichi Chiba11*, Hiroko Tanaka12*, Nobuyuki Kakiuchi, M.D, Yotaro Ochi, MD, Hiroo Ueno, MD, PhD9*, Hidehiro Itonaga, MD, PhD13*, Yoshinobu
Kanda, MD, PhD,14 Masashi Sanada, MD,15 Ayana Kon, MD, PhD,17 Y asushi Miyazaki, MD, PhD,16 Keizo Horibe, MD, PhD,15 Maria Creignou,17 Magnus Tobiasson, MD,18,19* Hisashi Tsurumi, MD, PhD,20 Senji Kasahara, MD, PhD,21 Chantana Polprasert, MD,22* Eva Hellstrom Lindberg, MD, PhD,23,24 Akifumi Kondo Takaori, MD, PhD,25*, Toru Kiguchi, MD, PhD,26*, Mario Cazzola,27 Fumihiko Matsuda, MD, PhD,28*, Kazuma Ohyashiki, MD, PhD,29 Jaroslaw P. Maciejewski, MD, PhD,30 Torsten Haferlach, MD,31 Yoichiro Kamatani, MD, PhD,32*, Michiaki Kubo, MD, PhD,33*, Satoru Miyano, PhD,34* and Seishi Ogawa, MD, PhD35

1Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan
2Department of Pathology and Tumor Biology, Kyoto University, KYO, Japan
3Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
4Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
5Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan
6Department of Healthcare Administration, Nagoya University, Nagoya, Japan
7Department of Advanced Diagnosis, Clinical Research Center, Nagoya Medical Center, Nagoya, Japan
8Center for Cancer Genomics and Advanced Therapeutics, National Cancer Center Research Institute, Tokyo, Japan
9Department of Biochemistry and Molecular Biology, Nippon Medical School, Tokyo, Japan
10Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan
11Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan
12Department of Integrated Data Science, M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan
13Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan
14Department of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan
15Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
16Atomic Bomb Disease Institute, Nagasaki University Hospital, Nagasaki, Japan
17Karolinska University Hospital, Stockholm, Sweden, Karolinska Institutet, Linköping, SWE
18Karolinska University Hospital, Stockholm, Sweden
19Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska University Hospital Huddinge, Karolinska Institute, Stockholm, Sweden
20Hematology, Gunma University Graduate School of Medicine, Gunma, Japan
21Hematology, Gifu Municipal Hospital, Gifu, Japan
22Division of Hematology, Department of Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
23Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
24HERM, Dept. of Medicine, Huddinge, Karolinska Institute, and PO Hematology, Karolinska University Hospital, Stockholm, Sweden
25Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
26Department of Hematology, Chugoku Central Hospital, Fukuyama, HIR, Japan
27Department of Molecular Medicine, University of Pavia, Pavia, Italy
28Kyoto University Graduate School of Medicine, Kyoto, JPN
29Department of Advanced Cellular Therapy, Tokyo Medical University, Tokyo, Japan
30Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
31MLL Munchner Leukamie Labor Gmbh, Munchen, Germany
32Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
33RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
34The University of Tokyo, Human Genome Centre, Institute of Medical Science, Tokyo, Japan
35Department of Medicine, Center for Haematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden

299 Comparison of Haploidentical Donor Hematoopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide to Matched-Sibling, Matched-Related, Mismatched-Related, and Umbilical Cord Blood Donor Transplantation in Adults with Acute Lymphoblastic Leukemia

Program: Oral and Poster Abstracts
Type: Oral
Session: 732. Clinical Allogeneic Transplantation Results III
Hematology Disease Topics & Pathways: Leukemia, ALL, Adult, Diseases, Young Adult, Lymphoid Malignancies, Clinically relevant
Saturday, Dec 5, 2020: 5:45 PM
Matthew J. Wieduwilt, MD, PhD,1 Leland Metheny II, MD,2 Mei-Jie Zhang, PhD,3*, Hai-Lin Wang, MPH,4*, Noel Estrada-Merly, MS,5*, Marcos de Lima, MD,6*, Mark Litzow, MD,7, Partow Kebriaei, MD,6, Chris S. Hourigan, MD, PhD,9, Daniel J. Weisdorf, MD,10 and Wael Saber, MD, MS,4

1Moore's Cancer Center, University of California, San Diego, La Jolla, CA
2Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
3Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
4CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
5CIBMTR (Center for International Blood and Marrow Transplant Research) Medical College of Wisconsin, Milwaukee, WI
317 Germline Gain-of-Function JAK3 Mutation in Familial Chronic Lymphoproliferative Disorder of NK Cells

Program: Oral and Poster Abstracts
Type: Oral
Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Hematologic Malignancies and COVID-19
Hematology Disease Topics & Pathways: autoimmune disorders, Leukemia, Diseases, LGLL, immunodeficiency, Biological Processes, Immune Disorders, Lymphoid Malignancies, genomics, Clinically relevant, Proliferative disorders, hematopoiesis, pathogenesis, signal transduction
Sunday, Dec 6, 2020: 1:45 PM

Harry Lesmana, MD1,2, Marcela Popescu, MD3, Sara Lewis, MS, LCGC4, Sushree Sangita Sahoo, PhD5, Charnise Goodings-Harris, PhD6, Mihaela Onciu, MD, FACP7, John Kim Choi, MD, FACP7, Clifford Takemoto, MD7*, Kim E. Nichols, MD8 and Marcin Wlodarski, MD, PhD9

1Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN
2Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH
3Department of Pediatrics, East Tennessee State University, Johnson City, TN
4St. Jude Children's Research Hospital, Memphis, TN
5Hematology, St. Jude Children's Research Hospital, Memphis, TN
6St Jude Children's Research Hospital, Memphis, TN
7Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN
8Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN
9Department of Hematology, St. Jude Children’s Research Hospital, Memphis, TN

331 Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Type: Oral
Session: 613. Acute Myeloid Leukemia: Novel Therapies and Treatment Approaches
Hematology Disease Topics & Pathways: AML, Biological, antibodies, Diseases, Therapies, Myeloid Malignancies, Clinically relevant
Sunday, Dec 6, 2020: 12:45 PM

Ibrahim Aldoss, MD1, Geoffrey L Uy, MD2, Norbert Vey, MD3, Ashkan Emadi, M.D., Ph.D.4, Peter H. Sayre, MD, PhD5, Roland B. Walter, MD, PhD6, Matthew C Foster, MD7, Martha L. Arellano, MD8, John E. Godwin, MD9, Matthew J. Wieduwilt, MD, PhD10, Michael T. Byrne, DO11, Laura C. Michaelis, MD12, Patrick J. Stiff, MD13, Matteo Giovanni Carrabba, MD14, Patrice Chevalier, MD, PhD15, Emmanuel Gyan, MD, PhD16, Christian Recher, MD, PhD17, Anjali S Advani, MD18, Martin Wermke19, Harry P. Erba20, Fabio Ciceri, MD21, Geert Huls, MD, PhD22, Mojca Jongen-Lavrencic, MD, PhD23, Max S. Topp, MD24, Antonio Curti, MD25, Farhad Ravandi, MBBS26, Michael P. Rettig, PhD27, John Muth, MS28, Mary Beth Collins29, Erin Timmeny30, Kuo Gao, MSc31, Jian Zhao, PhD31, Kathy Tran32, Patrick Kaminker, PhD32, Priyanka Patel, PharmD32, Ouiam Bakkacha, MD33, Teia Curtis34, Kenneth Jacobs, MD35, Maya Kostova, PhD31, Jennifer Seller, PhD, RAC39, Bob Lowenberg, MD, PhD36, Sergio Rutella, MD, PhD, FRCPath37, Ezio Bonvini, MD32, Jan K Davidson-Moncada, MD, PhD38 and John F. DiPersio, MD, PhD2

1Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA
2Washington University School of Medicine, Saint Louis, MO
3Hematologie clinique, Institut Paoli Clamettes, Marseille, France
4University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
5University of California, San Francisco, San Francisco, CA
6Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
408 The Genomic Landscape of Myeloid Neoplasms Evolved from AA/PNH

Program: Oral and Poster Abstracts
Type: Oral
Session: 636. Myelodysplastic Syndromes — Basic and Translational Studies
Hematology Disease Topics & Pathways: AML, Anemias, Diseases, aplastic anemia, Bone Marrow Failure, MDS, MPN, Biological Processes, PNH, Myeloid Malignancies, pathogenesis

Sunday, Dec 6, 2020: 3:30 PM
Carmelo Gurnari, MD1,2, Simona Pagliuca, MD2,3, Bhumika J. Patel, MD4, Hassan Awada, MD5, Cassandra M Kerr, MS6, Wenyi Shen, MD7, Sunisa Kongkiatkamon, MD7,8, Laila Terkawi7, Misam Zawit2, Jibran Durrani, MD2,7, Valeria Visconte, PhD2, Seth J. Corey, MD9, Maria Teresa Voso, MD1, Hetty E. Carraway, MD, MBA2,7 and Jaroslaw P. Maciejewski, MD, PhD8
1Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
3Université de Paris, Paris, France
4Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
6Departments of Pediatrics, Cancer Biology, THOR, Cleveland Clinic, Cleveland, OH
7Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
8Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

438 Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score

Program: Oral and Poster Abstracts
Type: Oral
Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Outcomes Research Real World Data Myeloma
Hematology Disease Topics & Pathways: multiple myeloma, Diseases, Adverse Events, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant
442 Prior History of Venous Thromboembolism Is a Significant Risk Factor for Recurrence of Thrombosis after Cancer Diagnosis

Program: Oral and Poster Abstracts
Type: Oral
Session: 331. Pathophysiology of Thrombosis I
Hematology Disease Topics & Pathways: Adult, Diseases, Bleeding and Clotting, Thromboembolism, Study Population, Clinically relevant
Sunday, Dec 6, 2020: 5:00 PM

Sargam Kapoor, MBBS1, Aman Opneja, MBBS1, Jahnavi Gollamudi, MD2 and Lalitha V. Nayak, MD3
1Division of Hematology Oncology, Alaska Native Medical Center, Anchorage, AK
2Department of Pathology and Medicine, Baylor College of Medicine, Houston, TX
3Department of Medicine, Division of Hematology and Oncology, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, OH

474 Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways: Diseases, Lymphoid Malignancies, Clinically relevant
Sunday, Dec 6, 2020: 6:00 PM

Alex F. Herrera, MD1, Carmelo Carlo-Stella, MD2, Graham P. Collins, MD, DPhil3, Kami J. Maddocks, MD4, Nancy L. Bartlett, MD5, Kerry J. Savage, MD MSc6, Paolo F Caimi7*, Brian T. Hess, MD8, Pier Luigi Zinzani, MD9, Hans G Cruz10, Luqiang Wang11*, Jay Feingold12*, Jens Wuerthner10* and Stephen M. Ansell, MD, PhD13
1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA
2Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas University, Milan, Italy
3Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
4Division of Hematology, Department of Internal Medicine, Ohio State University Hospital, Columbus, OH
5Division of Oncology, Washington University School of Medicine in St Louis, St. Louis, MO
6Department of Medical Oncology, BC Cancer and University of British Columbia, Vancouver, BC, Canada
7University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH
8Division of Hematology and Medical Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC
9Institute of Hematology “Seràgnoli” University of Bologna, Bologna, Italy
10Clinical Development, ADC Therapeutics SA, Epalinges, Switzerland
11ADC Therapeutics America, Inc., Murray Hill, NJ
12ADC Therapeutics America, Inc, Murray Hill, NJ
13Mayo Clinic, Rochester, MN

478 CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions

ASH 2020 Annual Meeting
Program: Oral and Poster Abstracts
Type: Oral
Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: PCNSL Treatment and Prognosis and CNS Prophylaxis in High-Risk Aggressive Lymphomas
Hematology Disease Topics & Pathways: antibodies, Adult, Diseases, Non-Biological, Therapies, Combinations, CNS Lymphoma, chemotherapy, DLBCL, B-Cell Lymphoma, immunotherapy, Lymphoid Malignancies, Study Population, Clinically relevant

Sunday, Dec 6, 2020: 5:30 PM

Victor M. Orellana-Noia, MD1, Daniel R Reed, MD2, Jeremy M Sen, PharmD, BCOP3, Christian Barlow, MD4, Mary-Kate Malecek, MD5, Brad S. Kahl, MD6, Michael A Spinner, MD7, Ranjana Advani, MD8, Timothy J Voorhees, MD9, Anson Snow, MD10, Natalie S Grover, MD9, Amy Ayers, MPH11, Jason T. Romancik, MD12, Yuxin Liu, MD12, Scott F. Huntington, MD, MPH12, Julio C. Chavez, MD13, Hayder Saeed, MD14, Aleksandr Lazaryan, MD, PhD, MPH15, Vikram Raghunathan, MD16, Stephen E. Spurgeon, MD17, Thomas A Ollila, MD18, Christopher Del Prete, MD18, Adam J Olszewski, MD18, Emily C. Ayers, MD19, Daniel J. Landsburg, MD20, Benjamin Echaller21, Jun Lee21, Manali Kamdar, MD22, Paolo F Caimi, MD23, Timothy Fu, MD24, Jieqi Liu, MD25, Kevin A. David, MD26, Hanan Alharthy, MD27, Jennie Y. Law, MD28, Reem Karmali, MD, MS29, Harsh Shah, DO30, Deborah M. Stephens, DO31, Ajay Major, MD, MBA32, Alexandra E Royek, MD33, Sonali M. Smith, MD34, Amulya Yellala, MBBS35, Avyakta Kallam, MD36, Shazia Nakhoda, MD37, Nadia Khan, MD37, Jonathan B. Cohen, MD, MS38 and Craig A. Portell, MD39

1Winship Cancer Institute, Emory University, Atlanta, GA
2Division of Hematology/Oncology, Wake Forest University, Winston-Salem, NC
3Department of Pharmacy Services, University of Virginia, Charlottesville, VA
4Division of Hematology and Oncology, University of Virginia, Charlottesville, VA
5Department of Medicine, Washington University School of Medicine, University City, MO
6Division of Medical Oncology, Washington University School of Medicine, Saint Louis, MO
7Division of Oncology, Department of Medicine, Stanford University, Stanford, CA
8Division of Oncology, Department of Medicine, Saul A. Rosenberg Professor of Lymphoma, Stanford Cancer Institute, Stanford, CA
9Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
10University of North Carolina, Chapel Hill, NC
11Department of Hematology and Medical Oncology, Emory University - Winship Cancer Institute, Atlanta, GA
12Yale University, New Haven, CT
13Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Lutz, FL
14H. Lee Moffitt Cancer Center, Tampa, FL
15Hematology, Oncology and Transplantation, Moffitt Cancer Center, Tampa, FL
16Division of Hematology and Oncology, Oregon Health Sciences University, Portland, OR
17Oregon Health & Science University, Portland, OR
18Brown University, Providence, RI
19Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA
20Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
21University of Colorado, Aurora, CO
22Division of Hematology, University of Colorado, Denver, CO
23Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
24Startrategies, Inc, Newark, NJ
25Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ
26Cancer Institute of New Jersey, New Brunswick, NJ
27University of Maryland, Baltimore, MD
28Division of Hematology and Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
29Division of Hematology Oncology, Northwestern University, Chicago, IL
30University of Utah/Huntsman Cancer Institute, Salt Lake City, UT, Salt Lake City, UT
31University of Utah/Huntsman Cancer Institute, Salt Lake City, UT
32Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
33Department of Medicine, University of Chicago, Chicago, IL
34Department of Oncology, University of Chicago, Chicago, IL
35Department of Hematology and Oncology, University Of Nebraska Medical Center, Omaha, NE
36University of Nebraska Medical Center, Omaha, NE
37Fox Chase Cancer Center, Philadelphia, PA
38Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA
39Division of Hematology/Oncology, University of Virginia, Charlottesville, VA
479 Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study

Program: Oral and Poster Abstracts
Type: Oral
Session: 634. Myeloproliferative Syndromes: Clinical: Clinical Trials in Polycythemia Vera
Hematology Disease Topics & Pathways: Diseases, Polycythemia vera, Myeloid Malignancies
Sunday, Dec 6, 2020: 5:00 PM
John Mascarenhas, MD1, Brian Higgins2*, Doreen Anders3*, Kate Burbury, MD4*, Tarec Christoffer El-Galaly5, Aaron T. Gerds, MD, MS5*, Vikas Gupta, MD, FRCP, FRCPath6, Bruno Kovic7**, Margherita Maffioli, MD8*, Ruben Mesa, MD9, Jeanne M. Palmer, MD10, Francesco Passamonti, MD11*, Alessandro Rambaldi, MD12, David M Ross, MBBS, PhD, FRACP, FRCPA13*, Alessandro M. Vannucchi, MD14 and Abdulraheem Yacoub, MD15
1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
2Genentech, Inc., South San Francisco, CA
3F. Hoffmann-La Roche, Ltd., Basel, Switzerland
4Peter MacCallum Cancer Centre, Melbourne, AUS
5Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
6Princess Margaret Cancer Centre, Toronto, ON, Canada
7F. Hoffmann-La Roche, Ltd., Mississauga, ON, Canada
8UT Health San Antonio Cancer Center, San Antonio, TX
9Mayo Clinic, Phoenix, AZ
10University of Insubria, Varese, Italy
11Department of Oncology and Hematology University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
12Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia
13The University of Kansas Cancer Center, Leawood, KS

516 Thromboembolism in Patients with Advanced Renal Cell Carcinoma Treated with Immunotherapy

Program: Oral and Poster Abstracts
Type: Oral
Session: 331. Pathophysiology of Thrombosis II
Hematology Disease Topics & Pathways: Biological, Diseases, Bleeding and Clotting, Therapies, checkpoint inhibitors, Adverse Events, Thrombosis, immunotherapy, Thromboembolism, Clinically relevant, VTE
Monday, Dec 7, 2020: 11:00 AM
Iris Yeong- Fung Sheng, MD1*, Shilpa Gupta, MD1*, Chandana A Reddy, MS2*, Dana E Angelini, MD3, Pauline Funchain, MD4*, Joanna Roopkumar, MBBS, MPH5*, Tamara A. Sussman, MD5*, Joseph Sleiman, MD6*, Timothy D Gilligan, MD6*, Moshe C Ornstein, MD, MA1* and Alok A Khorana, MD4
1Cleveland Clinic Foundation, Cleveland, OH
2Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH
3Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Avon Lake, OH
4Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
5Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
6Cleveland Clinic Foundation, Cleveland

540 Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

Program: Oral and Poster Abstracts
Type: Oral
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Personalized Clinical-Decision Tools and treatment of lower risk MDS
Monday, Dec 7, 2020: 11:00 AM
Johannes B Goll, MSc1*, Travis L Jensen, BS1*, R. Coleman Lindsley, MD, PhD2, Rafael Bejar, MD, PhD3, Jason Walker4*, Robert Fulton, MS5*, Gregory A. Abel, MD, MPH6, Tareq Al Baghdadi, MD7*, H. Joachim
Deeg, MD9, Amy E. DeZern, MD9, Benjamin L. Ebert, MD, PhD10, James M. Foran, MD11, Edward J. Gorak, DO, MBA, MS12, Steven D. Gore, MD13, Rami Komrokji, MD, MS14, Jane Jijun Liu, MD15*, Jaroslaw P. Maciejewski, MD, PhD16,17, Eric Padron, MD18, Wael Saber, MD, MS19, Daniel Starczynowski, PhD20, Myron Waclawiw, PhD21*, Steffanie H. Wilson, PhD1*, Donnie Hebert, PhD22*, Harrison Reed, MSc1*, Nancy L. DiFranzo, PhD21, Mikkael A. Sekeres, MD, MS23, Alexandra M. Harrington, MD, MT(ASCP)24, Steven H. Kraft, MD25*, Ling Zhang, MD26* and Matthew J. Walter, MD27

1The Emesse Company, LLC, Rockville, MD
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
3Moores Cancer Center, University of California, San Diego, La Jolla, CA
4Washington University School of Medicine, St. Louis, MO
5McDonnell Genome Institute, Washington University School of Medicine, Saint Louis, MO
6Dana-Farber Cancer Institute, Boston, MA
7IA Hematology Oncology Consultants, Ypsilanti, MI
8Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
9Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
10Division of Hematology, Harvard Medical School, Boston, MA
11Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL
12Baptist MD Anderson Cancer Center, Jacksonville, FL
13National Institutes of Health, National Cancer Institute, Rockville, MD
14H. Lee Moffitt Cancer Center, Tampa, FL
15Illinois Cancer Care, P.C., Peoria, IL
16Cleveland Clinic Main Campus, Department of Hematology/Oncology, Cleveland, OH
17Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
18Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
19CIBMTR, Medical College of Wisconsin, Milwaukee, WI
20Cincinnati Children's Hospital Medical Center, Cincinnati, OH
21National Heart, Lung, and Blood Institute, National Institutes of Health, Division of Blood Diseases & Resources, Bethesda, MD
22The Emesse Company, LLC, Hamburg, NY
23Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
24Medical College of Wisconsin, Milwaukee, WI
25Department of Pathology, Medical College of Wisconsin, Milwaukee, WI
26Department of Hematopathology and Laboratory Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
27Department of Medicine, Division of Oncology, Washington University In St. Louis, Saint Louis, MO

541 A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes

Program: Oral and Poster Abstracts
Type: Oral
Session: 637. Malignancies—Clinical Studies: Personalized Clinical-Decision Tools and treatment of lower risk MDS

Hematology Disease Topics & Pathways: Diseases, Bone Marrow Failure, CMMML, MDS, MPN, Myeloid Malignancies, Clinically relevant

Monday, Dec 7, 2020: 11:15 AM

Nathan Radakovich, BA1*, Manja Meggendorfer, PhD2, Luca Malcovati, MD3, Mikkael A. Sekeres4, Jacob Shreve, MD, MS5*, Cameron Beau Hilton, MD5, Yezan Rouphail7*, Wencke Walter, PhD8*, Stephan Hutter, PhD8*, Sudipto Mukherjee, MD, PhD, MPH9, Cassandra M. Kerr, MS10*, Babal K. Jha, PhD11*, Anna Galli12*, Sarah Pozzi13*, Aaron T. Gerds, MD, MS14, Cassandra M Kerr, MS15*, Claudia Haferlach, MD15, Jaroslaw P. Maciejewski, MD, PhD16, Torsten Haferlach, MD16* and Aziz Nazha, MD17

1Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
2MLL Munich Leukemia Laboratory, Munich, Bavaria, Germany
3Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Piazzale Golgi 2, Pavia, Italy
4Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
5Department of Internal Medicine, Cleveland Clinic, Cleveland, OH
6Department of Internal Medicine, Vanderbilt University, Nashville, TN
7Ohio State University, Rocky River, OH
8MLL Munich Leukemia Laboratory, Munich, Germany
9Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
10Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
11Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
12Department of Hematology Oncology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy
552 Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving

Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Initial Therapy
Hematology Disease Topics & Pathways: Non-Biological, Combinations, Therapies, Biological Processes, Clinically relevant, multi-systemic interactions

Monday, Dec 7, 2020: 11:00 AM
Raymond L. Comenzo, MD, Efstatios Kastritis, MD, Giovanni Palladini, MD, PhD, Monique C. Minnema, Ashutosh D. Wechalekar, MBBS, FRCP, FRCPath, DM, Arnaud Jaccard, MD, PhD, Vaishali Sanchorowala, MD, Hans C. Lee, MD, Simon D. Gibbs, FRACP, FRCPA, MBBS, MD, Peter Mollee, FRACP, MBBS, MSc, FRCPath, Christopher P. Venner, MD, Jin Lu, Stefan Schönland, MD, Moshe Gatt, MD, Kenshi Suzuki, MD, PhD, Kihyun Kim, MD, PhD, M. Teresa Cibeira, MD, PhD, Meral Beksaç, MD, Edward Libby, MD, Jason Valen, MD, Vania T. M. Hungria, MD, PhD, Sandy W. Wong, MD, Michael Rosenzweig, MD, Naresh Bumma, MD, Dominique Chauveau, MD, PhD, Meletios A Dimopoulos, MD, NamPhuong Tran, MD, Xiang Qin, MD, PhD, Sandra Y. Vasey, MSc, Brenda Tromp, MSc, Brendan M. Weiss, MD, PhD, Jessica Vermeulen, MD, PhD and Giampaolo Merlini, MD

1Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA
2Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, ATHENS, Greece
3Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy
4Department of Hematology, UMC Utrecht, Utrecht, Netherlands
5University College London, London, United Kingdom
6Centre Hospitalier Universitaire and Reference Center for AL Amyloidosis, Limoges, France
7Amyloidosis Center, Boston University School of Medicine, Boston, MA
8Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
9The Victorian and Tasmanian Amyloidosis Service, Department of Haematology, Monash University Easter Health Clinical School, Melbourne, VIC, Australia
10Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia
11Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
12Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Collaborative Innovation Center of Hematology, Beijing, China
13Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany
14Department of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
15Japanese Red Cross Medical Center, Department of Hematology, Tokyo, Japan
16Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
17Hospital Clinic of Barcelona, Barcelona, Spain
18Cebeci Yerleskesi Alikem, Ankara, Turkey
19Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA
20Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
21São Germaino Clinic, São Paulo, Brazil
22Tufts Medical Center, San Francisco, CA
23Department of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA
24Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH
25CHU de Toulouse-Hôpital Rangueil, Toulouse, France
26University of Athens School of Medicine, KIFISSIA, Greece
27Janssen Research & Development, LLC, Los Angeles, CA
28Janssen Research & Development, LLC, Spring House, PA
29Janssen Research & Development, LLC, Leiden, Netherlands
30Janssen Research & Development, LLC, Leiden, CB, Netherlands
31Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy
564 Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiopeta and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning C

Program: Oral and Poster Abstracts
Type: Oral

Session: 732. Clinical Allogeneic Transplantation Results II
Hematology Disease Topics & Pathways: sickle cell disease, HSCs, Adult, Diseases, Non-Biological, Therapies, chemotherapy, Pediatric, Hemoglobinopathies, Young Adult, Cell Lineage, Study Population, Clinically relevant

Monday, Dec 7, 2020; 8:15 AM

Adetola A. Kassim, MD, MS1,2,3, Josué de la Fuente4, Ali Debsan Alahmari, MBBS, MD, MNAMS5, Michael J. Eckrich, MD, MPH6, Rabi Hanna, MD2, Nathalie Dhedin, MD8*, Biljana Horn, MD9, Vandy Black, MD, MSc10,11, Roseane V Gouveia12*, Adriana Seber, MD, MS13, Belinda Pinto Simões, MD, PhD14,15*, Thalita Cristina de Mello Costa, MD16*, Renato Guerino-Cunha17*, Carmem M. S. Bonfim, MD PhD18,19*, Roberto Luiz da Silva20*, Nelson Hamerschlag, MD, PhD21,22, Juliana Folloni Fernandes, MD23*, Michael Kent, MD, BS24, Satya Prakash Yadav, MBBS, MD25,26, Erfan Nur, MD, PhD27,28, Moshen Alzahrani29,30*, Ben Carpenter, PhD31*, William Tse, MD32,33*, Maria Isabel34*, Hemalatha G Rangarajan, MD35,36,37, Ibrahim Ahmed, MD38, Adeseye Michael Akinsete, MBBS39*, Courtney D. Fitzhugh, MD40, Kathryn A. Culos, PharmD41*, Leena Karnik, FRCPath, MRCP42*, James Connelly, MD43*, Carrie Kitko, MD44,45, Jennifer Andrews, MD, MSc46, Karina L Wilkerson, NP, MSN47*, Robert Brodsky48,49*, Tatsuki Koyama50* and Michael R. DeBaun, MD, MPH51*

1Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease, Nashville, TN
2Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
3Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN
4Department of Paediatrics, St. Mary's Hospital/Imperial College London, London, United Kingdom
5King Faisal Hospital & Research Ctr., Riyadh, SAU
6Pediatric Blood and Marrow Transplantation Program, Texas Transplant Institute at Medical City Dallas, San Antonio, TX
7Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
8St-Louis Hospital, APHP, Adolescents and Young Adults Hematology Department, Paris, France
9UF Shand's Children Hospital, University of Florida, Gainesville, FL
10University of Florida College of Medicine, Newberry, FL
11Department of Pediatrics, Division of Pediatric Hematology and Oncology, University of Florida College of Medicine, Gainesville, FL
12Hospital Sao Camilo Pompeia, Pediatric Oncology and Hematopoietic Cell Transplantation, Sao Paulo, Brazil
13Hospital Samaritana, Sao Paulo, SP, Brazil
14Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil, Ribeirão Preto, Brazil
15Center for Cell-Based Therapy, Hemotherapy Center of Ribeirão Preto, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil, Ribeirão Preto, Brazil
16School of Medicine of Ribeirão Preto, University of São Paulo, São José Do Rio Preto, Brazil
17Ribeirão Preto Medical School, University of São Paulo, Departments of Medical Imaging and Hematology /Clinical Oncology, São Paulo, Brazil
18Federal University of Paraana, Curitiba, PR, Brazil
19Hospital Nossa Senhora das Graças, Curitiba, Brazil
20IBCC Oncologia (Instituto Brasileiro de Controle do Cancer), São Paulo, Brazil
21Hematology, Hospital Israelita Albert Einstein, São Paulo, Brazil
22Hospital Israelita Albert Einstein, Sao Paulo, Brazil
23Department of Hematology and Bone Marrow Transplantation, Hospital Israelita Albert Einstein, Hematology unit, São Paulo, Brazil
24Atrium Health/ Levine Children’s Hospital, Charlotte, NC
25Pediatric Hemato-Oncology & BMT, Medanta The Medicity, Gurgaon, India
26Pediatric Hemato-Oncology & BMT, Fortis Memorial Research Institute, Gurgaon, Haryana, India
27Department of Clinical Hematology, Slotervaart Hospital, Amsterdam, Netherlands
28Department of Clinical Hematology, Amsterdam University Medical Centers, Academic Medical Center, Amsterdam, Netherlands
29Saudi Society of Blood & Marrow Transplantation (SSBMT), Riyadh, Saudi Arabia
30Division of Adult Hematology and SCT, Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia
31University College London Hospital, London, United Kingdom
32Bone Marrow Transplant, University of Louisville, Louisville, KY
33University of Louisville, Louisville, KY
34Vall d’ Hebron Hospital, Department of Hematology / Oncology, Barcelona, Spain
35Hem/Onc/BMT, Nationwide Children’s Hospital, Columbus, OH
36Division of Pediatric Hematology, Oncology, Blood and Marrow Transplant, Nationwide Childrens Hospital, Columbus, OH
37Nationwide Childrens Hospital, Columbus, OH
**646 Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies**

Program: Oral and Poster Abstracts  
Type: Oral  
Hematology Disease Topics & Pathways: Biological, Follicular Lymphoma, Adult, Lymphoma (any), Diseases, Therapies, checkpoint inhibitors, Non-Hodgkin Lymphoma, B-Cell Lymphoma, DLBCL, Biological Processes, T-Cell Lymphoma, immunotherapy, Lymphoid Malignancies, Study Population, Clinically relevant, immune mechanism  
Monday, Dec 7, 2020: 12:00 PM  

Steven M. Horwitz, MD1, James M. Foran, MD2, Michael Maris, MD3,4, Ahmed Sawas, MD5, Craig Okada, MD, PhD6, Tatyana A. Feldman, MD7, Mark D. Minden8, Lubomir Sokol, MD, PhD9, Matthew Mei, MD10, Ian W. Flinn, MD, PhD11,12, Diego Villa, MD MPH13, Mary-Elizabeth M. Percival, MD14,15, Deepa Jagadeesh, MD, MPH16, Kerry J. Savage, MD MS17, Oleg E. Akilov, MD, PhD18, Catherine Diefenbach, MD18, Youn H. Kim, MD19, Gloria H. Y. Lin, PhD20*, Tina Catalano, MS20*, Penka S. Petrova, PhD20*, Bob Uger, PhD20*, Naomi Molloy, BS20*, Kathleen Large, RN, MS20*, Yaping Shou, MD, PhD20 and Stephen M. Ansell, MD, PhD21  

1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY  
2Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL  
3Colorado Blood Cancer Institute, Denver, CO  
4Sarah Cannon Research Institute, Denver, CO  
5Center for Lymphoid Malignancies, Columbia University Irving Medical Center, New York, NY  
6Oregon Health and Science University, Portland, OR  
7Hackensack University Medical Center, NY, NY  
8Leukemia Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada  
9Moffitt Cancer Center, Tampa, FL  
10City of Hope National Medical Center, Duarte, CA  
11Sarah Cannon Research Institute, Nashville, TN  
12Tennessee Oncology, Nashville, TN  
13British Columbia Cancer Agency, Vancouver, BC, Canada  
14Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA  
15Division of Hematology, Department of Medicine, University of Washington, Seattle, WA  
16Tisch Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Solon, OH  
17University of Pittsburgh Medical Center, Pittsburgh, PA  
18Perlmutter Cancer Center at NYU Langone Health, New York, NY  
19Department of Dermatology, Stanford University School of Medicine, Stanford, CA  
20Trillium Therapeutics Inc., Mississauga, ON, Canada  
21Mayo Clinic, Rochester, MN

**655 Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)**

Program: Oral and Poster Abstracts  
Type: Oral
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Treatment of Higher Risk Myelodysplastic syndromes
Hematology Disease Topics & Pathways: Diseases, CMML, MDS, MPN, Myeloid Malignancies, Clinically relevant
Monday, Dec 7, 2020: 3:00 PM

Nathan Radakovich, BA1, David A. Sallman, MD2, Rena J. Buckstein, MD, FRCP-C3, Andrew M. Brunner, MD4, Sudipto Mukherjee, MD, PhD, MPH5, Rami Komrokji, MD2, Najla Al Ali, M.Sc6*, Jacob Shreve, BS, MD, MS7, Yazan Rouphail8*, Cassandra M Kerr, MS9*, Yihong Guan, PhD10*, Teodora Kuzmanovic, BA10*, Metis Hasipek, PhD10*, Babal K. Jha, PhD9, Jaroslaw P. Maciejewski, MD, PhD10, Mikaela S. Sekeres, MD, MS11 and Aziz Nazha, MD12

1 Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Bellingham, WA
2 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
3 Dana-Farber Cancer Institute, Boston, MA
4 Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
6 Cleveland Clinic, Cleveland, OH
7 Ohio State University, Rocky River, OH
8 Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
9 Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
10 Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
11 Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Quantitative Health Sciences, Avon Lake, OH

705 The Burkitt Lymphoma International Prognostic Index (BL-IPI)
Program: Oral and Poster Abstracts
Type: Oral
Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Front-Line Treatment and Prognostication of Burkitt Lymphoma, Plasmablastic Lymphoma, and DLBCL
Hematology Disease Topics & Pathways: Adult, Diseases, Lymphoma (any), Non-Hodgkin Lymphoma, DLBCL, B-Cell Lymphoma, Lymphoid Malignancies, Study Population, Clinically relevant
Monday, Dec 7, 2020: 4:30 PM

Adam J Olszewski, MD1, Lasse H. Jakobsen, PhD7, Graham P. Collins, MD, DPhil8, Kate Cwynarski7, Veronika Bachanova, MD, PhD5, Kristie A. Blum, MD1, Kirsten M Boughan, DO7, Mark Bower, MD8, Alessia Dalla Pria, MD10, Alexey Danilov, MD10, Kevin A. David, MD11, Catherine Diefenbach, MD12, Fredrik Eliin, MD, PhD13, Narendranath Epperla, MD, MS14, Umar Farooq, MD15, Tatyana A. Feldman, MD16, Alina S. Gerrie, MD, MPH17, Deepa Jagadeesh, MD, MPH18, Manali Kamdar, MD, MDDS19, Reem Karmali, MD, MSc20, Shireen Kassam, MBBS, FRCPath, PhD11*, Vaishalee P. Kenkre, MD22, Nadia Khan, MD23, Andreas Klein, MD24, Izidore S. Lossos, MD25, Matthew A. Lunning, DO, FACP26, Peter Martin, FRCP, MD, MS27, Nicolas Martinex-Calle28*, Silvia Montoto, MD29, Seema Naik, MD30*, Neil Palmisano, MD, MS31, David Peace, MD32, Elizabeth H Phillips, MBBS, BSc33*, Tyeel J. Phillips, MD34, Craig A. Portell, MD35, Nishitha Reddy, MD36, Anna Santarsieri, MBBS37*, Maryam Sarraf Yazdy, MD38, Knut B. Smeland39*, Scott E. Smith, MD, PhD40, Stephen D. Smith, MD41, Suchitra Sundaram, MD42, Parameswaran Venugopal, MD43, Adam Zayac, MD44, Xiao-Yin Zhang, PhD45, Catherine Zhu46*, Chan Yoon Cheah, MBBS47, Tarek Christoffer El-Galaly48 and Andrew M. Evans, DO, MMSc49

1 Lifespan Cancer Institute, Warren Alpert Medical School of Brown University, Providence, RI
2 Department of Haematology, Aalborg University Hospital, Aalborg, Denmark
3 Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
4 Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
5 Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
6 Winship Cancer Institute, Emory University, Atlanta, GA
7 Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
8 National Centre for HIV Malignancy, Chelsea & Westminster Hospital, London, United Kingdom
9 Chelsea & Westminster Hospital, London, United Kingdom
10 Toni Stephenson Lymphoma Center, City of Hope Comprehensive Cancer Center, Duarte, CA
706 Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis

Program: Oral and Poster Abstracts
Type: Oral

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Front-Line Treatment and Prognostication of Burkitt Lymphoma, Plasmablastic Lymphoma, and DLBCL

Hematology Disease Topics & Pathways: Adult, Diseases, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Lymphoid Malignancies, Study Population, Clinically relevant

Monday, Dec 7, 2020: 4:45 PM

Juan Pablo Alderuccio, MD4, Adam J Olszewski, MD2, Andrew M. Evens, DO, MMSc3, Graham P. Collins, MD, DPhil2, Alexey Danilov, MD, MD5, Mark Bower, MD, MD5, Deepa Jagadeesh, MD, MPH1, Catherine Zhu1, Amy Sperling, BS9, Seo-Hyun Kim, MD10, Ryan Vaca, MD11, Catherine Wei12, Suchitra Sundaram, MD13, Nishitha Reddy, MD14, Alessia Dalla Pria, MD15, Christopher D'Angelo, MD15, Umar Farooq, MD13, David A. Bond, MD, BS18, Stephanie Berg, DO19, Michael C. Churnetski20, Amandeep Godara, MD21, Nadia Khan, MD22, Yun Kyong Choi, MD23, Shireen Kassam, MBBS, FRCPath, PhD24, Maryam Sarraf Yazdy, MD25, Emma Rabinovich, MD26, Frank Post27, Gaurav Varma, MD, MPH28, Reem Karmali, MD, MSc29, Madelyn Burkart, MD30, Peter Martin, FRCP, MD, MS31, Albert Ren32, Ayushi Chauhan, MBBS, MD33, Catherine Diefenbach, MD34, Allandria Straker-Edwards, MS35, Andreas Klein, MD34, Kristie A. Blum, MD4
MD35, Kirsten M Boughan, DO36, Agrima Mian, MBBS, MD37, Bradley Haverkos, MD, MPH, MS38, Victor M. Orellana-Noia, MD39, Vaishalee P. Kenkre, MD16, Adam Zayac, MD40, Seth M Maliske, MD17, Narendranath Epperla, MD, MS41, Paolo F Caimi, MD42, Scott E. Smith, MD, PhD43, Manali Kamdar, MD44, Parameswaran Venugopal, MD45, Tatyana A. Feldman, MD46, Daniel Rector47, Stephen D. Smith, MD48, Andrzej Stadnik, MPH, BS49, Craig A. Portell, MD50, Yong Lin, PhD52, Seema Naik, MD51, Silvia Montoto, MD52, Izidore S. Lossos, MD5 and Kate Cwynarski53*

1 Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL
2 Brown University, Providence, RI
3 Rutgers Cancer Institute of New Jersey, Warren, NJ
4 Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
5 Toni Stephenson Lymphoma Center, City of Hope Comprehensive Cancer Center, Duarte, CA
6 National Centre for HIV Malignancy, Chelsea & Westminster Hospital, London, United Kingdom
7 Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Solon, OH
8 University College London Hospitals, London, United Kingdom
9 Fred Hutch Cancer Center, University of Washington, Seattle, UT
10 Rush University Medical Center, Chicago, IL
11 Penn State Cancer Institute, Penn State University College of Medicine, Hershey, PA
12 Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
13 Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
14 Vanderbilt University Medical Center, Nashville, TN
15 Chelsea & Westminster Hospital, London, United Kingdom
16 Carbone Cancer Center, University of Wisconsin, Madison, WI
17 Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA
18 Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
19 Department of Cancer Biology, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL
20 Winship Cancer Institute, Emory University Medical Center, Atlanta, GA
21 Tufts Medical Center, Boston, MA
22 Fox Chase Cancer Center, Philadelphia, PA
23 New York University School of Medicine, NYU Cancer Institute, New York, NY
24 King's College Hospital, London, United Kingdom
25 Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC
26 University of Illinois at Chicago, Cleveland Heights, OH
27 King's College Hospital NHS Foundation Trust, London, United Kingdom
28 Weill Cornell Medical College-New York Presbyterian Hospital, New York, NY
29 Division of Hematology Oncology, Northwestern University, Chicago, IL
30 Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago
31 Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY
32 University of Illinois At Chicago, Chicago, IL
33 Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC
34 Division of Hematology and Oncology, Tufts Medical Center, Boston, MA
35 Emory University, Atlanta, GA
36 Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
37 Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
38 University of Colorado Cancer Center, Aurora, CO
39 Winship Cancer Institute, Emory University, Atlanta, GA
40 Department of Medicine, Alpert Medical School of Brown University, Providence, RI
41 The Ohio State University James Comprehensive Cancer Center, Columbus, OH
42 University Hospitals of Cleveland, Cleveland, OH
43 Loyola University Medical Center, Maywood, IL
44 Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Denver, CO
45 Division of Hematology Oncology, Rush University Medical Center, Chicago, IL
46 Hackensack University Medical Center, NY, NY
47 John Theuer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
48 University of Washington, Seattle, WA
49 Knight Cancer Institute, Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR
50 Division of Hematology/Oncology, University of Virginia, Charlottesville, VA
51 Penn State Cancer Institute, Penn State Hershey Medical Center, Hershey, PA
52 Department of Haemato-oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom
53 Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom

729 Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis

Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation; Novel Approaches for Relapsed/Refractory Myeloma and Amyloidosis  
Hematology Disease Topics & Pathways: Biological, antibodies, Therapies, immunotherapy  
Monday, Dec 7, 2020: 5:45 PM  
Jack Khouri, MD\textsuperscript{1}, Faiz Anwer, MD\textsuperscript{2}, Christy J. Samaras, DO\textsuperscript{3}, Alex V. Mejia Garcia, MD\textsuperscript{1}, Omer N. Koc, MD\textsuperscript{3}, Beth M. Faiman, PhD, CNP\textsuperscript{2}, Kimberly Hamilton, CNP\textsuperscript{2\*}, Saveta Mathur, CNP\textsuperscript{2\*}, Cynthia Scott, CNP\textsuperscript{2\*}, Kathleen Stefunek, RN\textsuperscript{2\*}, Josephine Sgobbo, RN\textsuperscript{2\*}, Sherry Fada\textsuperscript{2\*}, Brittany Lewis\textsuperscript{2\*}, Kelly Shepherd\textsuperscript{2\*}, Naqib Ahmad\textsuperscript{2\*}, Madeleine Knebusch\textsuperscript{2\*}, Susan B. Sobolov, PhD\textsuperscript{4\*}, Janet Jobes\textsuperscript{4\*}, Eileen Daniel\textsuperscript{4\*}, Michael Spector, BS\textsuperscript{4\*} and Jason Valent, MD\textsuperscript{2}\textsuperscript{1}Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH\textsuperscript{2}Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH\textsuperscript{3}Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH\textsuperscript{4}Caelum Biosciences, Bordentown, NJ

**POSTER PRESENTATIONS**

762 Identification of a Warm Autoimmune Hemolytic Anemia (wAIHA) Population Using Predictive Analytics of a Known Clinically Profiled Cohort  
Program: Oral and Poster Abstracts  
Hematology Disease Topics & Pathways: autoimmune disorders, Adult, Anemias, Diseases, Non-Biological, Therapies, Immune Disorders, Study Population, Clinically relevant  
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM  
Keith R. McCrae, MD\textsuperscript{1,2}, Jennifer Beachell\textsuperscript{3\*}, Tricia Gooljarsingh, PhD\textsuperscript{4\*}, Mary Lee Tjoa, PhD\textsuperscript{5\*}, Graham K Jones, PhD\textsuperscript{6\*} and Julieanna K Gubitosa\textsuperscript{7\*}  
\textsuperscript{1}Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH\textsuperscript{2}Cardiovascular & Metabolic Sciences, Cleveland Clinic, Cleveland, OH\textsuperscript{3}Momenta Pharmaceuticals, Inc, Cambridge, MA\textsuperscript{4}Medical Affairs and Communications, Cambridge, MA\textsuperscript{5}Director of Medical Affairs, Momenta Pharmaceuticals, Boston, MA\textsuperscript{6}Director of Client Engagement, IPM.ai, Cambridge, MA\textsuperscript{7}Director of Integration and Analytics, IPM.ai, Cambridge, MA

787 Thrombin-Induced Endothelial Cell Damage Is Mitigated By Human Anti-Thrombin III in a Microfluidic Device  
Program: Oral and Poster Abstracts  
Session: 113. Hemoglobinopathies, Excluding Thalassemia—New Genetic Approaches to Sickle Cell Disease: Poster I  
Hematology Disease Topics & Pathways: sickle cell disease, Adult, Diseases, sickle cell trait, bioengineering, Hemoglobinopathies, Technology and Procedures, Study Population, Clinically relevant  
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM  
William Wulfange\textsuperscript{2\*}, Erdem Kucukal, PhD\textsuperscript{1\*}, Yuncheng Man\textsuperscript{1\*}, Ran An, PhD\textsuperscript{1}, Karamoja Monchamp\textsuperscript{1\*}, Olabimpe Olayiwola, MS\textsuperscript{1\*}, Jane A. Little, MD\textsuperscript{2}, Nigel S. Key, MD\textsuperscript{2} and Umut A. Gurkan, PhD\textsuperscript{1}  
\textsuperscript{1}Case Western Reserve University, Cleveland, OH\textsuperscript{2}University of North Carolina at Chapel Hill, Chapel Hill, NC

815 Nanoparticle-Directed Targeting of Clustered PSGL-1 Mitigates Neutrophil-Derived Thrombosis in Antiphospholipid Antibody Syndrome  
Program: Oral and Poster Abstracts  
Session: 201. Granulocytes, Monocytes, and Macrophages: Poster I  
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM
835 Consistent Efficacy Demonstrated By Avatrombopag in Immune Thrombocytopenia (ITP) Regardless of the Number of Lines of Prior ITP Treatment
Program: Oral and Poster Abstracts
Session: 311. Disorders of Platelet Number or Function: Poster I
Hematology Disease Topics & Pathways: Diseases, Bleeding and Clotting, ITP, Platelet Disorders, Thrombocytopenias, Clinically relevant
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM
Morey Blinder, MD1*, Michael Vredenburg, PhD2*, Wei Tian, PhD2*, Brian Jamieson, MD, BA2 and Keith R. McCrae, MD3
1Washington University, Saint Louis, MO
2Dova Pharmaceuticals, Durham, NC
3Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH

845 Patients’ Reported Perceptions on Satisfaction with Immune Thrombocytopenia Treatments: Results from the ITP World Impact Survey (I-WISh)
Program: Oral and Poster Abstracts
Session: 311. Disorders of Platelet Number or Function: Poster I
Hematology Disease Topics & Pathways: Biological, Adult, Diseases, Bleeding and Clotting, Non-Biological, Therapies, Combinations, ITP, Study Population, Clinically relevant
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM
Waleed Ghanima1, James B. Bussel2*, Drew Provan3*, Alexandra Kruse4*, Caroline Kruse4*, Yoshiaki Tomiyama5, Ming Hou6, Cristina Santoro7*, Serge Laborde8*, Mervyn Morgan9*, Barbara Lovrencic10*, Tom Bailey, MSci11*, Jens Haeng12* and Nichola Cooper, MD13
1Department of Medicine, Østfold Hospital Trust, Kånes, Norway
2Division of Hematology/Oncology, Weill Cornell Medical College, New York, NY
3Barts and The London School of Medicine and Dentistry, London, United Kingdom
4Platelet Disorder Support Association, Cleveland, OH
5Osaka University Hospital, Osaka, Japan
6Department of Hematology, Qilu Hospital of Shandong University, Jinan, China
7Hematology, University Hospital Policlinico Umberto I, Rome, Italy
8O’Cyto, Saint Loubès, France
9ITP Support Association, Bohnhurst, United Kingdom
10Italian Association for Immune Thrombocytopenic Purpura, Caprino Veronese, Italy
11Adelphi Real World, Bollington, United Kingdom
12Novartis Pharma AG, Basel, Switzerland
13Hammersmith Hospital, Imperial College London, London, United Kingdom

Program: Oral and Poster Abstracts
Session: 322. Disorders of Coagulation or Fibrinolysis: Poster I
Hematology Disease Topics & Pathways: Biological, Adult, Diseases, Bleeding and Clotting, Therapies, Pediatric, Study Population, Clinically relevant, VWD
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM
Margaret V. Ragni, MD, MPH1*, Frederico Xavier, MD, MS2*, Craig D. Seaman3, Suchitra Acharya, MD4*, Catherine E. McGuinn, MD5, Eric J. Werner, MD6*, Courtney Elizabeth Lawrence, MD, MS7*, Allison P.
Wheeler, MD, Ulrike Reiss, MD, Irmel Ayala, MD, Erin Cockrell, DO, Cristina Tarango, MD, Amy Dunn, Roshi Kulkarni, MD, Sanjay P Ahuja, MD, Meera B. Chitlur, MD, Steven W. Pipe, MD, Lynn M Malec, MD, Vilmarie Rodriguez, MD, Shelley Crary, MD, MS, Deborah Brown, MD, Rosa Diaz, MD, Maria Velez, MD, Cindy A. Leissinger, MD, Shannon L Carpenter, MD, Christine M. Knoll, MD, Michael Wang, MD, Guy Young, MD, Courtney D Thornburg, MD, Joseph L Lasky III, MD, Tiffany Lin Lucas, MD, Nina Hwang, MD, Deborah Vehec, MSN, RN, Dana Ivanco, Tamara L. Haller, BS, Marnie Bertolet, PhD, and Maria M Brooks, PhD

1University of Pittsburgh Medicine, Division Hematology/Oncology, Pittsburgh, PA
2Children’s Hospital of Pittsburgh, University of Pittsburgh Medical Center and Hemophilia Center of Western PA, Pittsburgh, PA
3University of Pittsburgh, Warrendale, PA
4Pediatric Hematology, Oncology and Cellular Therapy, Cohen Children’s Medical Center of New York, New Hyde Park, NY
5Weill Cornell Medical College, New York, NY
6Children’s Hospital of The King’s Daughters, Norfolk, VA
7Division of Pediatric Hematology / Transfusion Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
8Dept. of Pediatric Hem./Onc., Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, TN
9Department of Surgery, St. Jude Children’s Research Hospital, Memphis, TN
10Pediatric Cancer and Blood Disorders Center, Johns Hopkins All Children’s Hospital, St. Petersburg, FL
11St. Joseph’s Children’s Hospital, Tampa, FL
12Division of Hematology, Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
13Nationwide Children’s Hospital, Columbus, OH
14Michigan State University Center for Bleeding and Clotting Disorders, East Lansing, MI
15University Hospitals Cleveland Medical Center, Rainbow Babies and Children’s Hospital, Cleveland, OH
16Hemostasis and Thrombosis Center, Children’s Hospital of Michigan, Detroit, MI
17Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI
18Blood Research Institute, Versiti, Milwaukee, WI
19Division of Pediatric Hematology, Mayo Clinic, Rochester, MN
20University of Arkansas for Medical Sciences, Little Rock, AR
21Department of Pediatrics - Hematology Division, University of Texas Health Science Center at Houston, Houston, TX
22Texas Children’s Hospital, Houston, TX
23Children’s Hospital New Orleans, Louisiana State University, New Orleans, LA
24Tulane University, New Orleans, LA
25Children’s Mercy Hospital, Kansas City, MO
26Arizona Hemophilia and Thrombosis Center, Phoenix Children’s Hospital, Phoenix, AZ
27Anschutz Medical Campus, University of Colorado, School of Medicine, Hemophilia and Thrombosis Center, Aurora, CO
28University of California Los Angeles, Children’s Hospital Los Angeles, Los Angeles, CA
29Rady Children’s Hospital, San Diego, CA
30University of Nevada, Cure 4 the Kids Foundation, Las Vegas, NV
31University of California, San Francisco, San Francisco, CA
32CHOC Children’s Hospital, Orange County, Center for Inherited Blood Disorders (CIBD), Orange, CA
33Hemophilia Center of Western PA, Institute for Transfusion Medicine, Vitalant, Pittsburgh, PA
34Institute for Transfusion Medicine, Hemophilia Center of Western PA, Pittsburgh, PA
35Department of Epidemiology, Epidemiology Data Center, University of Pittsburgh, Pittsburgh, PA
36Epidemiology Data Center, University of Pittsburgh Medicine, Pittsburgh, PA
37Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA

874 Improvement of Efficacy Outcomes in Patients Who Switched from Sucrose-Formulated rFVIII to BAY 81-8973 Prophylaxis in the LEOPOLD Clinical Trials

Program: Oral and Poster Abstracts
Session: 322. Disorders of Coagulation or Fibrinolysis: Poster I
Hematology Disease Topics & Pathways: Hemophilia, Adult, Diseases, Bleeding and Clotting, Non-Biological Therapies, Pediatric, coagulant drugs, Study Population, Clinically relevant
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM
Gili Kenet, Thomas Moulton, MD, Erika Soltes Rak, Brian M. Wicklund, MD, MPH and Sanjay P Ahuja, MD

1National Hemophilia Center, Sheba Medical Center, Tel HaShomer, Israel
2The Amalia Biron Thrombosis Research Institute, Tel Aviv University, Tel Aviv, Israel
3Bayer, Whippany, NJ
4Children’s Mercy-Kansas City, Kansas City, MO
5Rainbow Babies & Children’s Hospital, Cleveland, OH

887 Efficacy and Safety of Tinzaparin in CAT Patients with Metastatic Disease

ASH 2020 Annual Meeting
929 Immunogenomics of Aplastic Anemia: The Role of HLA Somatic Mutations and the HLA Evolutionary Divergence

Program: Oral and Poster Abstracts
Session: 508. Bone Marrow Failure: Poster I
Hematology Disease Topics & Pathways: Diseases, Bone Marrow Failure, Biological Processes, Cell Lineage, Study Population, immune mechanism
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM
Simona Pagliuca, MD1,2, Carmelo Gurnari, MD1,2, Hassan Awada, MD1, Cassandra M Kerr, MS1, Bhumika J. Patel, MD2, Laila Terkawi1, Misam Zawit, MBBS2, Sunisa Kongkiatkamon, MD1, Pedro H Prata, MD2, Ashwin Kishtagari, MBBS1, Adam Wahida6, Thomas Laframboise, PhD7, Valeria Visconte, PhD1, Regis Peffault De Latour, MD, PhD8,9 and Jaroslaw P. Maciejewski, MD, PhD9
1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
2Université de Paris, Paris, France
3Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
4Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
5Department of Hematology and Transplantation, Hôpital Saint Louis, Paris, France
6MLL Munich Leukemia Laboratory, Munich, Germany
7Genetics and Genome Sciences Department, Case Western Reserve University, Cleveland, OH
8French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Assistance Publique – Hôpitaux de Paris, Université de Paris, Paris, France
9Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

930 Immunogenomics of Paroxysmal Nocturnal Hemoglobinuria: A Model of Immune Escape

Program: Oral and Poster Abstracts
Session: 508. Bone Marrow Failure: Poster I
Hematology Disease Topics & Pathways: Anemias, Diseases, Bone Marrow Failure, Biological Processes, PNH, genomics, immune mechanism
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM
Carmelo Gurnari, MD1,2, Simona Pagliuca, MD2,3, Cassandra M Kerr, MS2, Hassan Awada, MD2, Sunisa Kongkiatkamon, MD2, Laila Terkawi1, Neetha Parameswaran, PhD1, Misam Zawit, MBBS2, Adam Wahida6, Valeria Visconte, PhD1 and Jaroslaw P. Maciejewski, MD, PhD5
1Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
3Université de Paris, Paris, France
4MLL Munich Leukemia Laboratory, Munich, Germany
5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

934 Safety and Demonstrated Efficacy of Placenta-Derived Cell Therapy PLX-R18 in Subjects with Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation: A Phase I International Multi-Center Study

ASH 2020 Annual Meeting 29
942 Aberrant Telomere Length and Composition Are Recurrent Features of Myeloid Disorders

Program: Oral and Poster Abstracts
Session: 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster I
Hematology Disease Topics & Pathways: AML, Diseases, Technology and Procedures, Myeloid Malignancies, NGS, WGS
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Adam Wahida1*, Stephan Hutter, PhD2*, Manja Meggendorfer, PhD2, Claudia Haferlach, MD2, Wolfgang Kern, MD2, Jaroslaw P. Maciejewski, MD, PhD3 and Torsten Haferlach, MD2
1Torsten Haferlach Leukaemiadiagnostik Stiftung, Munich, Germany
2MLL Munich Leukemia Laboratory, Munich, Germany
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

1028 A Multi-Center Open-Labeled Phase II Study of Intensive Salvage Therapy Followed By Enasidenib Maintenance for Patients with Relapsed/Refractory IDH2mutant AML

Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster I
Hematology Disease Topics & Pathways: therapy sequence, Therapies, Combinations
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Swapna Thota, MD1, Terrence J Bradley, MD2, Hetty E. Carraway, MD, MBA3 and Elizabeth A. Griffiths, MD4
1Roswell Park Comprehensive Cancer Center, Buffalo, NY
2University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
3Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

1029 Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Systematic Review

Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster I
Hematology Disease Topics & Pathways: AML, Non-Biological, Diseases, Therapies, chemotherapy, MDS, Myeloid Malignancies
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

**1040 A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS)**

**Program:** Oral and Poster Abstracts

**Session:** 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways: Biological, AML, Diseases, Therapies, CAR-Ts, MDS, Myeloid Malignancies, Clinically relevant, NK cells

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Carlos Bachier, MD1, Gautam Borthakur, MD2, Chitra Hosing, MD3, William Blum, MD4*, Marcello Rotta, MD5, Paulius Ojeras6*, Brian Barnett, MD6*, Kanya Rajangam, MD, PhD6*, Navneet S. Majhail, MD, MS7 and Sarah Nikiforow, MD, PhD8*

1Sarah Cannon Blood Cancer Network, Sarah Cannon Center for Blood Cancer, Nashville, TN
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX
4Winship Cancer Institute of Emory University, Atlanta, GA
5Sarah Cannon Blood Cancer Network, Colorado Blood Cancer Institute, Denver, CO
6Nkarta Therapeutics, South San Francisco, CA
7Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
8Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

**1047 A Phase 1b/2 Study of IMGN632, a CD123-Targeting Antibody-Drug Conjugate (ADC), As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia**

**Program:** Oral and Poster Abstracts

**Session:** 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways: AML, Biological, antibodies, Adult, Diseases, Therapies, Elderly, Study Population, Myeloid Malignancies, Clinically relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Naval Daver, MD1, Kendra L. Sweet, MD, MS2*, Pau Montesinos, MD, PhD3*, Eunice S. Wang, MD4, Ahmed Aribi, MD5, Daniel J. DeAngelo, MD, PhD6, Harry P Erba, MD PhD7, Giovanni Martinelli, MD8, Roland P Walter, MD PhD9, Jessica K Altman, MD10, Anjali S Advani, MD11, Antonio Curti, MD PhD12, Callum M Sloss, PhD13, Kara E Malcolm, RN13* and Patrick A Zweidler-McKay, MD, PhD14

1The University of Texas MD Anderson Cancer Center, Houston, TX
2H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
3Hospital Universitari i Politècnic La Fe, Valencia, Spain
4Roswell Park Comprehensive Cancer Center, BUFFALO, NY
5City of Hope National Medical Center, Duarte, CA
1066 Comparative Genomic Analysis of Adolescents and Young Adults Versus Elderly with Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I
Hematology Disease Topics & Pathways: AML, Diseases, Myeloid Malignancies
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Hassan Awada, MD1*, Carmelo Gurnari, MD2*, Arda Durmaz3*, Simona Pagliuca, MD4, Misam Zawit, MBS5, Cassandra M Kerr, MS4* and Valeria Visconte, PhD4
1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Department of Systems biology and Bioinformatics, CWRU, Cleveland
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

1080 Role of Oligoadenylate Synthetases in Myeloid Neoplasia

Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I
Hematology Disease Topics & Pathways: AML, Diseases, MDS, Biological Processes, DNA damage, Technology and Procedures, DNA repair, Cell Lineage, Study Population, Myeloid Malignancies
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Metis Hasipek, PhD1*, Yihong Guan, PhD1*, Dale Grabowski, BS1*, Xiaorong Gu, PhD1*, Yogenthiran Saunthararajah, MD1, Robert Silverman, PhD2*, George R Stark, PhD3*, Jaroslaw Maciejewski, PhD4* and Babal K. Jha, PhD4*
1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
2Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH

1120 One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Program: Oral and Poster Abstracts
Session: 623. Mantle Cell and Follicular Lymphomas—Clinical Studies: Poster I
Hematology Disease Topics & Pathways: Adult, Biological, Lymphoma (any), Diseases, CAR-Ts, Therapies, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, Study Population, Lymphoid Malignancies
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Michael Wang, MD1, Javier Munoz, MD2, Andre H. Goy, MD3, Frederick L. Locke, MD4, Caron A. Jacobson, MD5*, Brian T. Hill, MD6, John M. Timmerman, MD7, Houston Holmes8*, Samantha Jaglowski, MD, MPH9, Ian W. Flinn, MD, PhD10*, Peter A. McSweeney, MD11*, David B. Miklos, MD, PhD12, John M. Pagel, MD, PhD13, Marie José Kersten, MD, PhD14, Noel Milpied15*, Henry C.H. Fung, MD16*, Max S. Topp, MD17, Roch Houot, MD, PhD18*, Amer Beitinjaneh, MD, MPH, MSc19*, Weimin Peng, PhD20*, Lianqing Zheng, PhD20*, John M. Rossi, MS20*, Swaminathan Murugappan, MD, PhD20*, Ioana Kloos, MD20* and Patrick M. Reagan, MD21
1The University of Texas MD Anderson Cancer Center, Houston, TX
2Banner MD Anderson Cancer Center, Gilbert, AZ
Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I

Hematology Disease Topics & Pathways: Biological, Adult, Diseases, Lymphoma (any), Therapies, CAR-Ts, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Lymphoid Malignancies, Study Population

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Michael Wang, MD1, John M. Rossi, MS2*, Javier Munoz, MD3, Andre H. Goy, MD4, Frederick L. Locke, MD5, Patrick M. Reagan, MD6, Caron A. Jacobson, MD7, Brian T. Hill, MD8, Houston Holmes9*, Samantha Jaglowski, MD, MPH10, Weiming Peng, PhD11*, Lianqing Zheng, PhD11*, Xiang Fang, PhD11*, Allen Xue, PhD11*, Ioana Kloos, MD11* and Adrian Bot, MD, PhD12*

1The University of Texas MD Anderson Cancer Center, Houston, TX
2Kite, a Gilead Company, Santa Monica, CA
3Banner MD Anderson Cancer Center, Gilbert, AZ
4John Theurer Cancer Center, Hackensack, NJ
5Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL
6Wilmot Cancer Institute, University of Rochester Medical Center, Fairport, NY
7Dana-Farber Cancer Institute, Boston, MA
8Cleveland Clinic Foundation, Cleveland, OH
9Texas Oncology, Dallas, TX
10The Ohio State University, Comprehensive Cancer Center, Columbus, OH

1126 Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I

Hematology Disease Topics & Pathways: Cliniclly relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Narendranath Epperla, MD, MS1, Qiuohong Zhao, MS2**, Sayan Mullick Chowdhury, PhD3**, Tamara K. Moyo, MD4*, Lauren Shea, MD5*, Nishitha Reddy, MD, MSCf6*, Julia Sheets, MD7*, David M. Weiner, BA8*, Praveen Ramakrishnan Geethakumari, MD, MS9, Malathi Kandarpa, PhD10*, Ximena Jordan Bruno, MD11*, Colin Thomas, MD12*, Michael C. Churnetski13*, Andrew Hsu, MD14*, Joseph Maakaron, MD15*, Paolo Caimi, MD16, Pollawi Torka, MD17*, Celeste Bello, MD18*, Cherie Tan, MD19*, Kevin A. David, MD19, Kathryn Lindsey, MD20*, Irl Brian Greenwell, MD21, Murali Janakiram, MD22, Adam J Olszewski, MD23 Jonathon B. Cohen, MD, MS24*, Neil Palmisano, MD, MS25, Elvira Umayrava, MD26, Ryan A. Wilcox, MD26, Farrukh T
1155 A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma

Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I
Hematology Disease Topics & Pathways: Adult, Diseases, Therapies, Combinations, T-Cell Lymphoma, Lymphoid Malignancies, Study Population
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Swami P. Iyer, MD1, Auris Huen, MD2*, Bradley Haverkos, MD, MPH, MS3*, Weiyun Z. Ai4, Craig Okada, MD, PhD5, Timothy M. Kuzel, MD6, Mary Jo Lechowicz, MD7, Juan Pablo Alderuccio, MD8, Ann Mohrbacher, MD9, Don A. Stevens, MD10, Ryan A. Wilcox, MD11, Tatyana A. Feldman, MD12, Suchitra Sundaram, MD13*, Deepa Jagadeesh, MD, MPH14*, Nishitha Reddy, MD, MSCI15*, Kasi Viswanath Routhu, PhD16*, Prajak Barde, MD16*, and Ajit Mohanchandran Nair, PhD17*

1Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX
2The University of Texas MD Anderson Cancer Center, Houston, TX
3University of Colorado Cancer Center, Aurora, CO
4Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA
5Oregon Health and Science University, Portland, OR
6Rush University Medical Center, Chicago, IL
7Department of Hematology, Winship Cancer Institute, Atlanta, GA
8Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL
9Department of Medicine, Division of Hematology, University of Southern California, Keck School of Medicine of USC, Los Angeles, CA
10Norton Cancer Institute - St Matthews Campus, Louisville, KY
11Rogel Cancer Center, University of Michigan, Ann Arbor, MI
12John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
13Roswell Park, Buffalo, NY
14Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Solon, OH
1183 Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Program: Oral and Poster Abstracts
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I
Hematology Disease Topics & Pathways: Diseases, Lymphoid Malignancies
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Paolo F Caimi1, Weiyn Z. Ai1, Juan Pablo Alderuccio, MD3, Kirit M. Ardesna4, Mehdi Hamadani, MD5, Brian T. Hess, MD6, Brad S. Kahl, MD7, John A. Radford, MD, FMedSci8,9, Melhem Solh, MD9, Anastasios Stathis, MD10, Pier Luigi Zinzani, MD11, Jay Feingold12,13, David Ungar13, Yajuan Qin13, Shui He13 and Carmelo Carlo-Stella, MD14

1 University Hospitals Cleveland Medical Center/Cleveland Clinic Foundation, Cleveland, OH
2 Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, CA
3 Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL
4 Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
5 Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
6 Division of Hematology and Medical Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC
7 Department of Medicine, Oncology Division, Washington University, St. Louis, MO
8 The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
9 Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA
10 Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
11 Institute of Hematology “Seràgnoli” University of Bologna, Bologna, Italy
12 ADC Therapeutics America, Inc, Murray Hill, NJ
13 Clinical Development, ADC Therapeutics America, Inc, Murray Hill, NJ
14 Department of Oncology and Hematology, Humanitas Clinical and Research Center - IRCCS, Humanitas University, Rozzano, Italy

1187 Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)

Program: Oral and Poster Abstracts
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I
Hematology Disease Topics & Pathways: Biological, Adult, Diseases, Therapies, CAR-Ts, Non-Hodgkin Lymphoma, Biological Processes, Lymphoid Malignancies, Study Population, immune mechanism
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Caron Jacobson, MD, MMSc2, Frederick L. Locke, MD2, Armin Ghabadi, MD3, David B. Miklos, MD, PhD4, Lazaros J. Lekakis, MD5, Olalekan O. Oluwol, MBBS, MPH6, Yi Lin, MD, PhD7, Ira Braunschweig, MD8, Brian T. Hill, MD9, John M. Timmerman, MD10, Abhinav Deol, MD11, Patrick M. Reagan, MD12, Patrick J. Stiff, MD13, Ian W. Flinn, MD, PhD14, Umar Farooq, MD15, Andre H. Goy, MD16, Peter A. McSweeney, MD17, Javier Munoz, MD18, Tanya Siddiqi, MD19, John M. Rossi, MS20, Adrian Bot, MD, PhD20, Lianqing Zheng, PhD20, Remus Vezan, MD, PhD20, Zahid Bashir, MBBS20, Jenny J. Kim, MD, MS20, Rong Chu, PhD20 and Sattva S. Neelapu, MD21

1 Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
2 Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL
3 Washington University School of Medicine, St Louis, MO
4 Stanford University School of Medicine, Stanford, CA
5 Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL
6 Vanderbilt-Ingram Cancer Center, Nashville, TN
7 Division of Hematology, Mayo Clinic, Rochester, MN
8 Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
9 Cleveland Clinic Foundation, Cleveland, OH
10 UCLA David Geffen School of Medicine, Los Angeles, CA
11 Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI
12 University of Rochester School of Medicine, Rochester, NY
13 Loyola University Chicago Stritch School of Medicine, Maywood, IL
1190 A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen

Program: Oral and Poster Abstracts
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I
Hematology Disease Topics & Pathways: Diseases, Therapies, Combinations, Non-Hodgkin Lymphoma, DLBCL, B-Cell Lymphoma, Lymphoid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM
Carlos Galvez, MD, Reem Karmali, MD, MSc*, Mehdi Hamadani, MD, Leo I. Gordon, MD, Jane N. Winter, MD, Shuo Ma, MD, PhD, Valerie Nelson, MD, MBA, Brett Alan Palmer, BS**, Timothy S. Fenske, MD, Nirav N. Shah, MD, Deepa Jagadeesh, MD, MPH, Andreas Klein, MD, Irene Helenowski, PhD*, Borko Jovanovic, PhD*, Adam M Petrich, MD**, Andrew M. Evens, DO, MMS*, and Barbara Pro, MD

1Department of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL
2Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
3Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
4Division of Hematology and Oncology, Northwestern University, Chicago, IL
5Medical College of Wisconsin, Brookfield, WI
6Fauqis Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Solon, OH
7Division of Hematology and Oncology, Tufts Medical Center, Boston, MA
8Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
9Daichi-Sankeyo, Inc., Basking Ridge, NJ
10Rutgers Cancer Institute of New Jersey, Warren, NJ

1201 Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A post-Hoc Analysis of the Sadal Pivotal Study

Program: Oral and Poster Abstracts
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I
Hematology Disease Topics & Pathways: Diseases, Non-Biological, Therapies, DLBCL, B-Cell Lymphoma, Lymphoid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM
Michael W. Schuster, MD, Miguel A Canales, MD, PhD, Jason Westin, MD, José M Zijlstra, MD, PhD, George A Follows, MD, PhD, Reem Karmali, MD, MSc, Nagesh Kalakonda, MD*, Andre H. Goy, MD, Rene-Olivier Casasnovas, MD, Joost Vermaat, MD, PhD, Eric Van Den Neste, MD, Sylvain Choquet, MD, Catherine Thieblemont, MD, PhD, Federica Cavollo, MD, PhD, Maria de Fatima De La Cruz, MD, Brian T. Hill, MD, Herve Tilly, MD, PhD, Shireen Kassam, MBBS, FRCP, PhD, Reda Bouabdallah, MD, Ulrich Jaeger, MD, Ronit Gurion, MD, Paolo Caimi, MD, Peter Martin, FRCPC, Andrew Davies, MD, PhD, Sonali M. Smith, MD, Graham P. Collins, MD, DPhil, Fritz Offner, MD, PhD, Gilles Salles, MD, PhD, Xiwen Ma, Kelly Corona, Jean-Richard Saint-Martin, Anita A. Joshi, Kamal Chamoun, Hongwei Wang, MD, PhD, Jatin J. Shah, MD, Sharon Shacham, PhD, MBA, Michael G Kauffman, MD, PhD and Marie Maerevoet, MD

1Stony Brook University, Stony Brook, NY
2La Paz University Hospital, Madrid, Spain
1207 Risk of Non-Hodgkin’s Lymphoma in HCV Patients in the United States between 2013 and 2020: A Population-Based Study

Program: Oral and Poster Abstracts

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster I

Hematology Disease Topics & Pathways:
- viral, Follicular Lymphoma, Adult, Diseases, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, DLBCL, B-Cell Lymphoma, T-Cell Lymphoma, Infectious Diseases, Lymphoid Malignancies, Study Population, Clinically relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Akram Alkrekshi, MD1*, Ahmad Kassem, MD2*, Changsu Park, MD3* and William Tse, MD4
1Department of Hematology and Oncology, The MetroHealth System campus of Case Western Reserve University, Westlake, OH
2Department of Hematology and Oncology, The MetroHealth System campus of Case Western Reserve University, Cleveland
3Department of Hematology and Oncology, The MetroHealth System campus of Case Western Reserve University, Cleveland

1210 Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma

Program: Oral and Poster Abstracts

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster I

Hematology Disease Topics & Pathways: Adult, Diseases, Lymphoma (any), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Plasma Cell Disorders, Study Population, Lymphoid Malignancies, Clinically relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Brian T. Hess, MD1*, Anshu Giri, MD2*, Yeonhee Park, PhD3*, Krina K. Patel, M.D.4*, Brian K. Link, MD5, Grzegorz S. Nowakowski, MD6, Seth M Maliske, MD6, Sonia Fortin5*, Julio C. Chavez, MD6, Hayden Saeed, MD7, Brian T. Hill, MD8, Alex V. Mejia Garcia, MD9, Kami J. Maddocks, MD10, Walter Hanel, MD10*, Nina D. Wagner-Johnston11, Marcus Raymond Messmer, MD11*, Brad S. Kahl, MD12, Marcus Watkins, PhD13*, Juan Pablo Alderuccio, MD14, Izidore S. Lossos, MD14, Sunita Nathan, MD15, Victor M. Orellana-Noia, MD16, Craig A. Portell, MD17, Daniel J. Landsburg, MD18, Emily C. Ayers, MD19 and Jorge J. Castillo, MD20
1218 Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma Program: Oral and Poster Abstracts

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster I

Hematology Disease Topics & Pathways: Adult, Diseases, Non-Biological, Therapies, Non-Hodgkin Lymphoma, chemotherapy, DLBCL, Lymphoid Malignancies, Study Population, Clinically relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Mohammad Ahsan Sohail, MD1*, Hong Li2*, Wei Wei, MS3*, Sebastian Cerdena, PharmD3*, Marcus Watkins, PhD3*, Marissa Olson, PharmD3*, Gray Jodon, MD4, Jeff Kaiser, PharmD5, Bradley Haverkos, MD, MPH, MS6*, Mitchell E. Hughes, PharmD7, Natalie S Grover, MD8, Anson Snow, MD9, Victor M. Orellana-Noia, MD10, Magdalena A Rainey, MS11, Matthew J Cortese, MD, MPH12, Jolsyn Rudoni, PharmD9*, Craig A. Portell, MD13, Timothy J Voorhees, MD14, Daniel J. Landsburg, MD15, Manali Kamdar, MD, MDDS16, Brad S. Kahl, MD17 and Brian T. Hill, MD18

1 Cleveland Clinic, Cleveland, OH
2 Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
3 Barnes-Jewish Hospital, Washington University in St. Louis, St. Louis, MO
4 University of Colorado Cancer Center, Aurora, CO
5 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
6 Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
7 Winship Cancer Institute, Emory University, Atlanta, GA
8 Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
9 Department of Pharmacy, Cleveland Clinic, Cleveland, OH
10 Division of Hematology/Oncology, University of Virginia, Charlottesville, VA
11 Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
12 Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

1254 Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

Program: Oral and Poster Abstracts

Session: 634. Myeloproliferative Syndromes: Clinical: Poster I

Hematology Disease Topics & Pathways: Biological, Adult, Diseases, Therapies, blood banking, MPN, thrombocytethemia, Study Population, Myeloid Malignancies, Clinically relevant, pathways

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

John Mascarenhas, MD1,2,3,4,5*, Heidi E. Kosiorek, MS6,7*, Lilian Varricchio, PhD8*, Rupali Bhave, M.D.9*, Andrew T. Kuykendall, MD10,11,12,13*, Rami Komrokji, MD14, Aaron T. Gerds, MD, MS15,16,17,18,19,20,21,22,23,24*, Jeanne M. Palmer, Md15,16,25,26,27, Amelia R. Gable1,28,29,30,31,32*, Lonette Sandy33*, Anna Rita Migliaccio, PhD34,35,36,37*, Mohamed E Salama, MD38,39, Rona Singer Weinberg, PhD40, Maureen O’Connor-McCourt,
1277 Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I
Hematology Disease Topics & Pathways: Anemias, Adult, Diseases, Non-Biological, Therapies, Biological Processes, erythropoiesis, Study Population, Clinically relevant
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

David H. Henry, MD1, John Glaspy, MD, MPH2*, Rosemary Anne Harrup3*, Moshe Mittelman, MD4, Amy Zhou, MD5, Hetty E. Carraway, MD, MBA6, Charles Bradley, Ph.D.7, Gopal Saha, MD7*, Pamela Bartels7*, Robert Leong7* and Peony Yu, MD8
1294 The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I
Hematology Disease Topics & Pathways: AML, Biological, antibodies, Diseases, Therapies, MDS, Myeloid Malignancies
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM
Amer M. Zeidan, MBBS, MHS1, Jordi Esteve, MD, PhD2, Aristoteles Giagounidis3, Hee-Je Kim, M.D., Ph.D.4∗, Yasushi Miyazaki, MD, PhD5, Uwe Platzbecker, MD6, Andre C. Schuh7, Mikkael A. Sekeres8, Jörg Westermann9∗, Zhijian Xiao10∗, Kamel Malek11∗, Jeffrey Scott12∗, Julie Niolat13∗, Severine Peyrard13∗, Fei Ma12∗, Flavia Kiertsmann12∗, Mario Stegert11∗, Sabine Hertle11∗, Pierre Fenaux, MD, PhD14 and Valeria Santini15
1Yale University and Yale Cancer Center, New Haven, CT
2Hospital Clinic, Barcelona, Spain
3Marien Hospital Düsseldorf, Düsseldorf, Germany
4Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
5Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan
6Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany
7Princess Margaret Cancer Centre, Toronto, ON, Canada
8Cleveland Clinic, Cleveland, OH
9Charité-University Medical Center Berlin, Campus Virchow Clinic, Berlin, Germany
10Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China
11Novartis Pharma AG, Basel, Switzerland
12Novartis Pharmaceuticals Corporation, East Hanover, NJ
13Novartis Pharma SAS, Rueil-Malmaison, France
14Hôpital Saint-Louis, Paris, France
15MDS Unit, Hematology, AOU Careggi, University of Florence, Florence, Italy

1349 Analysis of Racial Differences in the Incidence of a Targetable Biomarker, t(11; 14), in Patients with Multiple Myeloma

Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I
Hematology Disease Topics & Pathways: Adult, Study Population, Clinically relevant
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM
Fang Liu, MD1, Jeries Kort, MD2, Shashirekha Shetty, PhD3, Ravikumar Kyasaram4∗, John Shanahan5∗ and Timothy E. O’Brien, MD5
1University hospitals, Cleveland, OH
2University Hospitals Cleveland Medical Center, Cleveland, OH
3University hospitals cleveland medical center, cleveland, OH
4University Hospital Cleveland Medical Center, Cleveland, OH
5Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH

1355 Whole-Exome Sequencing Identifies a Somatic Cell Mutation Signature that Predicts Relapse Risk and Survival Probability in Multiple Myeloma

Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I
Hematology Disease Topics & Pathways: multiple myeloma, Diseases, Technology and Procedures, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant, genetic profiling

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

**Ehsan Malek, MD,¹ E. Ricky Chan, PhD,²,³, Daniel Qu,⁴, Jane Reese,⁵, Robert Fox,⁵, Byung-Gyu Kim, PhD, DVM,⁶, Paolo F Caimi, MD,²,³, Marcos de Lima, MD,²,³ and James J. Driscoll, MD, PhD²,³**

¹Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH
²Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
³Institute for Computational Biology, Case Western Reserve University School of Medicine, Cleveland, OH
⁴Case Western Reserve University School of Medicine, Cleveland, OH
⁵Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
⁶Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH

**1376 Therapeutic Activity of Combining BCL-2 and HMG-CoA Reductase Inhibition in Systemic Light-Chain Amyloidosis**

Program: Oral and Poster Abstracts

Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways: Biological, Diseases, Therapies, enzyme inhibitors, Plasma Cell Disorders, Lymphoid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

**Ping Zhou, MD, PhD¹, Hashim Mann, MD², Xun Ma, DMD, MSc, PhD³, Teresa Fogaren, NP³, Yifei Zhang, MD³, Denis Toskic, BS⁴, Chakra P Chaulagain, MD⁵, Cindy Varga, MD, BSc⁶, Raymond L. Comenzo, MD⁶ and Amandeep Godara, MD³**

¹John C Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA
²Hematology/Oncology, Tufts Medical Center, Boston, MA
³Tufts Medical Center, Boston, MA
⁴John C Davis Myeloma and Amyloid Program, Tufts Medical Center, Revere, MA
⁵Department of Hematology and Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL
⁶Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA

**1384 Selinexor Efficacy and Safety are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study**

Program: Oral and Poster Abstracts

Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways: Diseases, Non-Biological, Therapies, DLBCL, B-Cell Lymphoma, Lymphoid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

**Michael W. Schuster, MD¹, Miguel A Canales, MD, PhD², Jason Westin, MD³, José M Zijlstra, MD, PhD⁴, George A Follows, MD, PhD⁵, Reem Karmali, MD, MSc⁶, Nagesh Kalakonda, MD⁷, André H. Goy, MD⁵, Rene-Olivier Casasnovas, MD⁸, Joost Vermaat, MD, PhD⁹, Eric Van Den Neste, MD¹⁰, Sylvain Choquet, MD¹¹, Catherine Thieblemont, MD, PhD¹²,¹³, Federica Cavallo, MD, PhD¹⁵, Malta De Fatima De La Cruz, MD¹⁶, Brian T. Hill, MD¹⁷, Herve Tilly, MD, PhD¹⁸, Shireen Kassam, MBBS, FRCPath, PhD¹⁹, Reda Bouabdallah, MD²⁰, Ulrich Jaeger, MD²¹, Ronit Gurion, MD²²,²³, Paolo Caimi, MD²⁴, Peter Martin, FRCP, MD, MS²⁵, Andrew Davies, MD, PhD²⁶, Sonali M. Smith, MD²⁷, Graham P. Collins, MD, DPhil²⁸, Fritz Offner, MD, PhD²⁹, Gilles Salles, MD, PhD³⁰, Xiwen Ma³¹, Kelly Corona³¹, Jean-Richard Saint-Martin³¹, Anita A. Joshi³², Kamal Chamoun, MD³¹, Hongwei Wang, MD, PhD³², Jatin J. Shah, MD³¹, Sharon Shacham, PhD, MBA³¹, Michael G Kauffman, MD, PhD³¹ and Marie Maerevoet, MD³³**

¹Stony Brook University, Stony Brook, NY
²Hematology and Hemotherapy Unit, La Paz University Hospital-IdiPaz, Madrid, Spain
³Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands
⁵Division of Hematology, Northwestern Medical Faculty Foundation, Chicago, IL
⁶University of Liverpool, Liverpool, United Kingdom

ASH 2020 Annual Meeting
1421 Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/II HLA Mutations

Program: Oral and Poster Abstracts
Session: 701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster I
Hematology Disease Topics & Pathways: AML, Diseases, MDS, Biological Processes, Myeloid Malignancies, genomics, immune mechanism
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Simona Pagliuca, MD1,2, Carmelo Gurnari, MD2,3*, Sanghee Hong, MD1, Cassandra M Kerr, MS2,*, Sunisa Kongkiatkamon, MD2,3*, Hassan Awada, MD2, Ashwin Kishtagari, MBBS2, Misam Zawit, MBBS2,*, Laila Terkawi*, Valeria Visconte, PhD2, Eric D. Hsi, MD3, Betty K. Hamilton, MD4, Hetty E. Carraway, MD, MBA3, Navneet S. Majhail, MD, MS7 and Jaroslav P. Maciejewski, MD, PhD8
1 Université de Paris, Paris, France
2 Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
3 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
4 University Hospitals/Case Western Reserve University, Cleveland, OH
5 Department of hematology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
6 Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH
7 Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
8 Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

1447 Unbiased Metabolomic Screening Reveals Pre-Existing Plasma Signatures in Large B-Cell Lymphoma Patients Treated with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cells: Association with Cytokine Release Syndrome (CRS) and Neurotoxicity (ICANS)

Program: Oral and Poster Abstracts
Session: 704. Immunotherapies: Poster I
Hematology Disease Topics & Pathways: CRS, Diseases, neurotoxicity, Adverse Events, B-Cell Lymphoma, Lymphoid Malignancies
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Akansha Jalota, PhD, MSc, BSc1*, Courtney E. Hershberger, PhD2, Manishkumar S. Patel, PhD, MS, BPharm3, Agrima Mian, MBBS, MD4, Daniel M. Rotroff, PhD2,*, Brian T. Hill, MD3 and Neetu Gupta, PhD, MSc, BSc1
1473 Reduced-Intensity Versus Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials & Cohort Studies

Program: Oral and Poster Abstracts

Hematology Disease Topics & Pathways: Biological, Diseases, Therapies, MDS, Clinically relevant, Myeloid Malignancies, transplantation

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM


1 Holy Family Hospital, Rawalpindi, Pakistan
2 Department of Internal Medicine, Louis A Weiss Memorial Hospital, Chicago, IL
3 King Edward Medical University, Lahore, Pakistan
4 Department of Internal Medicine, King Edward Medical University, Lahore, Pakistan
5 Dow university of Health Sciences, karachi, Pakistan
6 Army medical College, Rawalpindi, Pakistan
7 Xinjiang Medical University, Urumqi, China
8 Shaikh Zayed Medical College, Lahore, Pakistan
9rawalpindi medical university, rawalpindi, Pakistan
10 allama iqbal medical college, lahore, Pakistan
11 Department of Internal Medicine, Louis A Weiss memorial hospital, chicago
12 Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

1479 Final Results of a Dual-Institution Phase I Clinical Trial of Targeted Marrow Irradiation (TMI) Intensification of Reduced-Intensity Fludarabine/Busulfan (Flu/Bu) Conditioning for Allogeneic Hematopoietic Cell Transplantation for Medically Frail Patients with High-Risk Hematological Malignancies

Program: Oral and Poster Abstracts

Hematology Disease Topics & Pathways: Biological, bone marrow, Therapies, transplantation, stem cells

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Naveed Ali, MD, Ana Carolina Pires de Rezende, MD, Folashade Otegbeye, MBChir, MPH, Mariana Nassif Kerbauy, MD, Brenda W. Cooper, MD, David Mansur, MD, Giselle Pereira, PhD, Roberto Sakuraba, MD, Benjamin K. Tomlinson, MD, Kirsten M Boughan, DO, Cinthya Correa Silva, MD, Leland Metheny III, MD, Andreza Feitosa Ribeiro, MD, Molly M Gallogly, MD, PhD, Ehsan Malek, MD, Eduardo Weltman, MD, Marcos de Lima, MD, Nelson Hamerschlag, MD, PhD and Paolo F Caimi, MD

1 Case Western Reserve University, University Heights, OH
2 Department of Radiation Oncology, Hospital Israelita Albert Einstein, São Paulo, Brazil
3 Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
4 Hospital Albert Einstein / HSCT Program, Hospital Israelita Albert Einstein, São Paulo, BRA
5 Department of Radiation Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH
6 Oncology and Hematology, Hospital Israelita Albert Einstein, São Paulo, Brazil
7 Hospital Israelita Albert Einstein, Sao Paulo, Sp, BRA
8 Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH
9 Hematology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil
1481 Acute Non-Infectious Complications of Pediatric Hematopoietic Stem Cell Transplantation: An in-Hospital Nationwide Study in the United States from 2001-2019

Program: Oral and Poster Abstracts
Hematology Disease Topics & Pathways: Adverse Events, Clinically relevant
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM
Maria Alejandra Pereda, MD1, Sindhoosha Malay, MPH, PharmD2* and Jignesh Dalal, MD3
1University Hospitals Rainbow Babies & Children’s Hospital, Cleveland, OH
2School of Medicine, Case Western Reserve University, Cleveland, OH
3Rainbow Babies & Children’s Hospital, Cleveland, OH

1484 Anti-Thymocyte Globulin (ATG) for Prophylaxis of Severe Graft Vs. Host Disease after Hematopoietic Stem Cell Transplant: A Systematic Review and Meta-Analysis

Program: Oral and Poster Abstracts
Hematology Disease Topics & Pathways: Biological, antibodies, Therapies, Adverse Events, Clinically relevant, transplantation, stem cells
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM
Muhammad Ashar Ali, MD1*, Muhammad Yasir Anwar1, Sobia Aamir, MD, FCPS2*, Saad Ur Rahman, MBBS1*, Richi Kashyap, MD3*, Sana Irfan Khan, MD4*, Usman Ali Akbar, MBBS5*, Anum Waqar, MBBS6*, Anam Khan7*, Wajeema Aiman, MD5* and Faiz Anwer, MD8
1King Edward Medical University, Lahore, Pakistan
2Children hospital and Institute of Child Health, Lahore, Pakistan
3Maulana Azad Medical College, New Delhi, India
4All India Institute Of Medical Sciences, Delhi, India
5Nishtar Medical University, Multan, Pakistan
6Fatima Jinnah Medical University, Lahore, Pakistan
7Jawaharlal Nehru Medical College, Delhi, India
8Taussig Cancer Institute, Cleveland Clinic, Cleveland

1500 Safety and Efficacy of Salvage Therapies for Relapse/Refractory AML/MDS after First Allogeneic Hematopoietic Stem Cell Transplant: A Systematic Review

Program: Oral and Poster Abstracts
Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster I
Hematology Disease Topics & Pathways: AML, Biological, Diseases, bone marrow, Non-Biological, Bone Marrow Failure, Therapies, Combinations, MDS, chemotherapy, infusion, Myeloid Malignancies, Clinically relevant, transplantation, stem cells
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM
1Lahore Medical and Dental College, Lahore, Pakistan
2King Edward Medical University, Lahore, Pakistan
3Rawalpindi Medical University, Rawalpindi, Pakistan
4Nishtar Medical University, Multan, Pakistan
5Shifa College of Medicine, Islamabad, Pakistan
6Department of Hematology/Medical Oncology, Medical University of South Carolina, Charleston, SC
7Taussig Cancer Institute, Cleveland Clinic, Cleveland
1504 Post-Transplant Lymphoproliferative Disorder after Solid Organ Transplant in the Pediatric Population: A Systematic Review
Program: Oral and Poster Abstracts
Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster I
Hematology Disease Topics & Pathways: Lymphoma (any), Diseases, Combinations, Therapies, Hodgkin Lymphoma, Pediatric, Non-Hodgkin Lymphoma, Adverse Events, B-Cell Lymphoma, DLBCL, T-Cell Lymphoma, Lymphoid Malignancies, Study Population, Clinically relevant, Quality Improvement
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM
Mobeen Zaka Haider, MD, MBBS*, Zarlakhta Zamani, MBBS*, Muhammad Taqi, MBBS*, Hafsa Shahid*, Zahoor Ahmed, MD*, Hasan Mahmood Mirza*, Aneeza Irfan, MD*, Khadija Noor Sami, MD*, Deepak Kumar, MD*, Fnu Kiran, MD*, Mydah Sajid Hashmi, MD* and Faiz Anwer, MD
1King Edward Medical University, Lahore, Pakistan
2Mayo Hospital, Lahore, Pakistan
3Department of Internal Medicine, King Edward Medical University, Lahore, Pakistan
4Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, Boston, MA
5University of Missouri Kansas City, Kansas City
6Services Institute Of Medical Sciences, Lahore, Pakistan
7Jinnah Postgraduate Medical Center, Karachi, Pakistan
8Sindh institute of urology and transplantation, Karachi, Pakistan
9Army Medical College, Islamabad, Pakistan
10Department of Hematology & Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Moreland Hills, OH

1520 Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster I
Hematology Disease Topics & Pathways: Diseases, Lymphoid Malignancies
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM
Hemant S. Murthy, MD1, Kwang Woo Ahn, PhD2,3, Noel Estrada-Merly, MS4, Lohith Gowda, MD5, Bhagirathbhai Dholaria, MBBS6, Susan Bal, MD, MBBS7, Hassan B. Alkhateeb, MD*, Deepa Jagadeesh, MD, MPH*, Betul Oran, MD, MS10, Ryotaro Nakamura, M.D.11, Bart L. Scott, MD12, Craig S. Sauter, MD13, Francine M. Foss, MD14, Mohamed A kharfan-Dabaja, MD, MBA15 and Wael Saber, MD, MS16
1Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL
2Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI
3Department of Medicine, CIBMTR (Center for International Blood and Marrow Transplant Research) Medical College of Wisconsin, Milwaukee, WI
4CIBMTR (Center for International Blood and Marrow Transplant Research) Medical College of Wisconsin, Milwaukee, WI
5Hematology, Yale University School of Medicine, New Haven, CT
6Division of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical center, Nashville, TN
7O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL
8Division of Hematology, Mayo Clinic, Rochester, MN
9Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Solon, OH
10Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX
11Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
12Fred Hutchinson Cancer Center, Seattle, WA
13Memorial Sloan Kettering Cancer Center, New York, NY
14Hematology, Yale Cancer Center, New Haven, CT
15Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL
16CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

1561 Development of a Machine Learning Algorithm for Rapid, Point-of-Care Prediction of Serum Monoclonal Proteins in Multiple Myeloma
Program: Oral and Poster Abstracts
Session: 803. Emerging Diagnostic Tools and Techniques: Poster I
Hematology Disease Topics & Pathways: Technology and Procedures, Clinically relevant, Quality Improvement

ASH 2020 Annual Meeting 45
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM


1. Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH
2. University Hospitals Cleveland Medical Center, Cleveland, OH
3. Department of Population and Quantitative Health Sciences, Case Western Reserve University, School of Medicine, Cleveland, OH
4. Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
5. Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
6. Case Western Reserve University, Cleveland, OH

**1574 Addressing Recruitment Challenges in the Engage-HU Trial in Young Children with Sickle Cell Disease**

Program: Oral and Poster Abstracts
Session: 901. Health Services Research—Non-Malignant Conditions: Poster I

Hematology Disease Topics & Pathways: sickle cell disease, Diseases, Pediatric, Hemoglobinopathies, Study Population

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM


1. Great Ormond Street Institute of Child Health, University College London, London, OH
2. Division of Behavioral Medicine & Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
3. Oklahoma State University, Stillwater, OK
4. 3333 Burnet Ave, MLC 7039, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
5. College of Medicine/Department of Pediatrics, University of Cincinnati, Cincinnati, OH
6. Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
7. Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH
8. Washington University School of Medicine, St. Louis, MO
9. Division of Pediatric Hematology/Oncology, Washington University School of Medicine in St Louis, St Louis, MO
10. 4th Floor Seashore House, Children's Hosp. of Phila. Division of Hematology, Philadelphia, PA
11. Center for Innovation in Pediatric Practice, Division of Pediatric Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH
12. Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH
13. Adolescent and Transition Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
14. Children's Hosp. of Illinois St. Francis Medical Center, Peoria, IL
15. University of Illinois College of Medicine- Peoria, Peoria, IL
16. University Hospitals Rainbow Babies and Children's Hospital, Cleveland, OH
17. Center for Child Health Policy and Advocacy, Baylor College of Medicine, Houston, TX
18. Vanderbilt University, Nashville, TN
19. Center for Healthcare Delivery Science, Nemours Children's Health System, Wilmington, DE
20. Nemours Children's Health System, Wilmington
21. Howard University, Washington DC, DC
22. Division of Hematology/Oncology, University of California San Francisco, Oakland, CA
23. Texas Children's Hospital, Houston, TX
24. Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, TX
25. Department of Pediatrics, Division of Hematology/Oncology/Stem Cell Transplant, Ann & Robert Lurie Children's Hospital, Chicago, IL
26. Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago
27. Northwestern University, Chicago, IL
28. Division of Hematology, Oncology & Stem Cell Transplant, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
29. Pediatric Hematology and Oncology, Boston Medical Center, Boston, MA
30. Pediatric Hematology/Oncology, Boston Medical Center / Boston University, Boston, MA
31. Indiana Hemophilia and Thrombosis Center, Indianapolis, IN
32. Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH
33. Cincinnati Children's Hospital, Cincinnati
1610 Outcomes of Cardiac Diffuse Large B-Cell Lymphoma in the Rituximab Era
Program: Oral and Poster Abstracts
Session: 902. Health Services Research—Malignant Conditions (Lymphoid Disease): Poster I
Hematology Disease Topics & Pathways: Adult, Study Population
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM
Taha Al-Juhaishi, MD1, Ghait Abu Zeinah, MD2 and Sadeer Al-Kindi, M.D.3
1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
2Richard T. Silver Myeloproliferative Neoplasms Center, NewYork-Presbyterian Weill Cornell Medical Center, New York, NY
3Division of Cardiology, Harrington Heart and Vascular Institute, Case Western Reserve University and University Hospitals, Cleveland, OH

1611 Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Study
Program: Oral and Poster Abstracts
Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster I
Hematology Disease Topics & Pathways: Biological, Diseases, Therapies, MDS, Myeloid Malignancies, transfusion, Quality Improvement
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM
Esther Natalie Oliva, MD1, Uwe Platzbecker, MD2, Guillermo Garcia-Manero, MD3, Ghulam J. Mufti, Professor4, Valeria Santini5, Mikkael A. Sekeres6, Rami S. Komrokji, MD7, Jeevan K. Shetty8, Derek Tang9, Shien Guo9, Weiqin Liao9, George Zhang8, Xianwei Ha8, Rodrigo Ito8, Jennifer Lord-Bessen8, Jay T. Backstrom10 and Pierre Fenaux, MD, PhD11
1Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy
2Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany
3The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Haematology-Oncology, King’s College London, London, United Kingdom
5MDS Unit, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy
6Cleveland Clinic Foundation, Cleveland, OH
7 Moffitt Cancer Center, Tampa, FL
8 Bristol Myers Squibb, Princeton, NJ
9 Evidera, Waltham, MA
10 Acceleron Pharma, Cambridge, MA
11 Service d’Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris and Université Paris 7, Paris, France

1613 Early Mortality and Overall Survival in Acute Promyelocytic Leukemia: Do Real-World Data Match Results of the Clinical Trials?
Program: Oral and Poster Abstracts
Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster I
Hematology Disease Topics & Pathways: AML, Biological, Adult, Diseases, bone marrow, Non-Biological, Therapies, chemotherapy, Pediatric, Young Adult, Study Population, Myeloid Malignancies, Clinically relevant, Quality Improvement, transplantation
Saturday, Dec 5, 2020, 10:00 AM-6:30 PM
Prajwal Dhakal, MBBS1, Elizabeth R. Lyden, MS2, Venkat Rajasurya, MD3, Krishna Gundabolu, MBBS4, Chakra P Chaulagain, MD5 and Vijaya R. Bhatt, MD1
1 Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE
2 Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE
3 Multicare Health System, Puyallup, WA
4 Division of Oncology and Hematology, University of Nebraska Medical Center - Fred & Pamela Buffett Cancer Center, Omaha, NE
5 Department of Hematology and Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL

1617 Changing Molecular Diagnostic Testing Patterns for Patients (Pts) with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) in the Connect MDS/AML Disease Registry
Program: Oral and Poster Abstracts
Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster I
Hematology Disease Topics & Pathways: AML, Diseases, MDS, Myeloid Malignancies
1622 Thrombotic Events and Mortality Risk in Patients Newly Diagnosed with Intermediate- to High-Risk Essential Thrombocythemia in the United States

Program: Oral and Poster Abstracts
Session: 904. Outcomes Research—Non-Malignant Conditions: Poster I
Hematology Disease Topics & Pathways: Diseases, thrombocythemia, Myeloid Malignancies

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Naveen Pemmaraju, MD\textsuperscript{1}, Aaron T. Gerds, MD, MS\textsuperscript{2}, Jingbo Yu, MD, PhD\textsuperscript{3}, Shreekant Parasuraman, BPharm, PhD\textsuperscript{3*}, Anne Shah\textsuperscript{4*}, Ann Xi, PharmD\textsuperscript{4*}, Shambhavi Kumar, MS\textsuperscript{4*}, Robyn M. Scherber, MD\textsuperscript{3} and Srdan Verstovsek, MD, PhD\textsuperscript{1}

\textsuperscript{1}Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
\textsuperscript{2}Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
\textsuperscript{3}Incyte Corporation, Wilmington, DE
\textsuperscript{4}Avalere Health, Washington, DC

1629 Bleeding Outcomes of Gastrointestinal Cancer Patients Treated with Direct Oral Anticoagulants Vs. Low Molecular Weight Heparin

Program: Oral and Poster Abstracts
Session: 904. Outcomes Research—Non-Malignant Conditions: Poster I
Hematology Disease Topics & Pathways: Clinically relevant

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Dana E Angelini, MD\textsuperscript{1}, Doaa Attia, MD\textsuperscript{3}, Wei Wei, MS\textsuperscript{3*}, Mailey L Wilks, DNP, MSN, APRN\textsuperscript{2*}, Barbara Tripp, APRN, CNS\textsuperscript{2*}, Christopher D'Andrea, PA-C\textsuperscript{2*}, Keith R. McCrae, MD\textsuperscript{2} and Alok A Khorana, MD\textsuperscript{2}

\textsuperscript{1}Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Avon Lake, OH
\textsuperscript{2}Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
\textsuperscript{3}Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

1640 Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

Program: Oral and Poster Abstracts
Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster I
Hematology Disease Topics & Pathways: Non-Biological, Combinations, Therapies, Biological Processes, Clinically relevant, multi-systemic interactions

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

ASH 2020 Annual Meeting 48
1647 Risk of Secondary Malignancy in CLL Patients Treated with Novel Targeted Agents

Program: Oral and Poster Abstracts

Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster I

Hematology Disease Topics & Pathways: Leukemia, Adult, survivorship, Diseases, CLL, Lymphoid Malignancies, Study Population, Clinically relevant, Quality Improvement

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Anna Eversman1*, Shufen Cao1*, Kirsten M Boughan, DO2, Molly M Gallogly, MD, PhD3, Ehsan Malek, MD3, Leland Metheny III, MD2, Timothy E. O’Brien, MD2, Folashade Otegbeye, MBChir, MPH2, Brenda W. Cooper, MD2, Pingfu Fu1*, Marcos de Lima, MD2 and Paolo F Caimi, MD2

1Case Western Reserve University, Cleveland, OH
2Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
3Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

1663 Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study

ASH 2020 Annual Meeting 49
1665 Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP)

Program: Oral and Poster Abstracts
Session: 906. Outcomes Research—Malignant Conditions (Myeloid Disease): Poster I
Hematology Disease Topics & Pathways: Biological, Diseases, CML, Therapies, Myeloid Malignancies, Clinically relevant, TKI

Saturday, Dec 5, 2020, 10:00 AM-6:30 PM

Sudipto Mukherjee, MD, PhD, MPH, Xiting Cao*, Islam Sadek*, Rodrigo Maegawa, MD**, Dominick Latremouille-Viau, MSc**, Irina Pivneva**, Annie Guerin** and B. Douglas Smith, MD***

1 Cleveland Clinic, Cleveland, OH
2 Novartis Pharmaceuticals Corporation, East Hanover, NJ
3 Analysis Group, Inc., Montreal, QC, Canada
4 Division of Hematologic Malignancies Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD

1701 Effect of Nicotinamide, 1-Methylnicotinamide, and N′-Methylnicotinamide on Erythroid Colony Formation and y-Globin Expression in Cultured Baboon CD34+ Cells

Program: Oral and Poster Abstracts
Session: 112. Thalassemia and Globin Gene Regulation: Poster II
Hematology Disease Topics & Pathways: sickle cell disease, Diseases, thalassemia, Hemoglobinopathies

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Donald Lavelle, PhD, Vinzon Ibanez, B.S., Kestis Vaitkus**, Yogenthiran Saunthararajah, MD and Robert E. Molokie, MD***

1 Department of Medicine, University of Illinois at Chicago, Jesse Brown VA Medical Center, Chicago, IL
2 Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3 Jesse Brown VA Medical Center, Chicago, IL
4 Department of Medicine, Division of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL


Program: Oral and Poster Abstracts
Session: 113. Hemoglobinopathies,
Excluding Thalassemia—Basic and Translational Science: Poster II
Hematology Disease Topics & Pathways: sickle cell disease, Diseases, bioengineering, Hemoglobinopathies, Technology and Procedures, Clinically relevant

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Ran An, PhD1, Yuncheng Man1, Erdem Kucukal, PhD1*, Kevin Cheng1*, William Wulftange1*, Jane A. Little, MD2 and Umut A. Gurkan, PhD1

1Case Western Reserve University, Cleveland, OH
2University of North Carolina at Chapel Hill, Chapel Hill, NC

1730 The Grndad Registry: Contemporary Natural History Data and an Analysis of Real-World Patterns of Use and Limitations of Disease Modifying Therapy in Adults with SCD

Program: Oral and Poster Abstracts
Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster II
Hematology Disease Topics & Pathways: sickle cell disease, Adult, Diseases, Hemoglobinopathies, Study Population, Clinically relevant, Quality Improvement

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Alexandra Boye-Doe1, Elizabeth Brown2*, Charu Puri-Sharma, MS3*, Anjulika Chawla, MD4, Joshua J Field4*, Lynne D. Neumayr, MD5, Susan Padrino, MD6*, Payal Desai, MD7, Deepa Manwani, MD8, Sophie M. Lanzkron, MD, MHS9 and Jane A. Little, MD10

1Department of Medicine, University of North Carolina, Chapel Hill, NC
2Johns Hopkins University, Baltimore, MD
3bluebird bio, Cambridge, MA
4Bloodcenter of Wisconsin, Milwaukee, UMI
5Dept. of Hematology/Oncology, UCSF Benioff Children’s Hospital Oakland, Oakland, CA
6University Hospital Cleveland Medical Center, Cleveland, OH
7The Ohio State University, Columbus, OH
8Division of Pediatric Hematology/Oncology, Department of Pediatrics, Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY
9Department of Medicine, Johns Hopkins Medicine, Baltimore, MD
10University of North Carolina at Chapel Hill, Chapel Hill, NC

1739 Clinical Outcomes of Malignancy-Related Neutropenic Fever Admissions in the United States: A 10-Year National Study

Program: Oral and Poster Abstracts
Session: 201. Granulocytes, Monocytes, and Macrophages: Poster II
Hematology Disease Topics & Pathways: Diseases, white blood cells, Infectious Diseases, Cell Lineage, Clinically relevant

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Moataz Ellithi, MBBCh1, Hafez M Abdullah, MD1*, Waqas Ullah, MD2*, Radowan Elnair, MD3, Fouad Khalil, MD1* and Faiz Anwer, MD4

1Department of Internal Medicine, University of South Dakota School of Medicine, Sioux Falls, SD
2Department of Internal Medicine, Abington Hospital - Jefferson Health, Abington, PA
3University of Nebraska Medical Center, Omaha, NE
4Fauissig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

1745 Analyzing Risk of Infection with Anti-CD38 Monoclonal Antibody Therapy for Patients with Multiple Myeloma

Program: Oral and Poster Abstracts
Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster II
Hematology Disease Topics & Pathways: Clinically relevant, Quality Improvement

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Augustine Hong, MD1, Augusta Eduafo, DO2*, Hannah Schmikla, RN1*, George Brown3*, Gayathri Ravi, MD4, Marcos de Lima, MD5 and Ehsan Malek, MD6

ASH 2020 Annual Meeting
1755 Acute Coronary Syndrome in Patients with Thrombotic Thrombocytopenic Purpura
Program: Oral and Poster Abstracts
Session: 311. Disorders of Platelet Number or Function: Poster II
Hematology Disease Topics & Pathways: apheresis, Diseases, Bleeding and Clotting, Technology and Procedures, TTP
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Moataz Ellithi, MBBCh, Fouad Khalil, MD, Smitha N Gowda, MD, Waqas Ullah, MD and Faiz Anwer, MD
1Department of Internal Medicine, University of South Dakota School of Medicine, Sioux Falls, SD
2Department of Internal Medicine, Abington Hospital - Jefferson Health, Abington, PA
3University of Nebraska Medical Center, Omaha, NE
4Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

1797 BAY 94-9027 Provides Safe and Effective Long-Term Prophylaxis in Pediatric Patients: Results from the PROTECT VIII Kids Extension Study
Program: Oral and Poster Abstracts
Session: 322. Disorders of Coagulation or Fibrinolysis: Poster II
Hematology Disease Topics & Pathways: Diseases, Bleeding and Clotting
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Sanjay Ahuja, MD, Kathelijn Fischer, Tina Biss, Monika Maas Enriquez, Maria-Elisa Mancuso, MacGregor Steele, MD, Maria Wang and Gili Kenet
1Case Western Reserve University, Cleveland, OH
2Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
3Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
4Bayer, Wuppertal, Germany
5Center for Thrombosis and Hemorrhagic Diseases, Humanitas Clinical and Research Center – IRCCS, Rozzano, Milan, Italy
6Cumming School of Medicine, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada
7Bayer, Whippany, NJ
8Israel National Hemophilia Center and Thrombosis Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel

1817 Risk of Recurrent Venous Thromboembolism and Bleeding in Patients with Cancer Associated Thrombosis
Program: Oral and Poster Abstracts
Session: 332. Anticoagulation and Antithrombotic Therapy: Poster II
Hematology Disease Topics & Pathways: anticoagulant drugs, Diseases, Non-Biological, Bleeding and Clotting, Therapies, Thrombosis, Thromboembolism, VTE
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Doaa Attia, MD, Xuefei Jia, MS, Mailey L Wilks, DNP, MSN, APRN, Barbara Tripp, APRN, CNS, Christopher D'Andrea, PA-C, Keith R. McRae, MD, Alok A Khorana, MD and Dana E Angelini, MD
1Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
2Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
3Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH

1819 Development and Baseline Characterization of a Thrombosis Risk Alert Tool: A Quality Assessment Project
Program: Oral and Poster Abstracts
Session: 332. Anticoagulation and Antithrombotic Therapy: Poster II
**1850 TET2 Inhibitory Effects of Eltrombopag Contribute its Hematopoietic Activity**

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster II

Hematology Disease Topics & Pathways: Anemias, Diseases, aplastic anemia, Bone Marrow Failure

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Yihong Guan, PhD\(^1\), Metis Hasipek, PhD\(^1\), Bhimika J. Patel, MD\(^2\), Dale Grabowski, BS\(^3\), Anand D. Tiwari, PhD\(^4\), Sunisa Kongiatkamon, MD\(^5\), Cassandra M Kerr, MS\(^6\), Aziz Nazha, MD\(^7\), Yogenthiran Saanthararajah, MD\(^8\), Mikkael A. Sekeres, MD, MS\(^9\), Jaroslaw P. Maciejewski, MD, PhD\(^10\) and Babal K. Jha, PhD\(^11\)

\(^1\)Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
\(^2\)Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
\(^3\)Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
\(^4\)Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
\(^5\)Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

**1853 Targeting of Calbindin 1 (CALB1) Rescues Erythropoiesis in a Human Model of Diamond Blackfan Anemia: Implications for Novel Therapies**

Program: Oral and Poster Abstracts

Session: 508. Bone Marrow Failure: Poster II

Hematology Disease Topics & Pathways: Diseases, Bone Marrow Failure, red blood cells, Cell Lineage

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Nan of Wang, PhD\(^1\), Corinne Marie Lavasseur, BA\(^2\), Hongxia Yan, MS\(^3\), Scott Younger, PhD\(^4\), Bertil Glader, MD, PhD\(^5,6\), Kathleen M. Sakamoto, MD, PhD\(^7\), Lionel Blanc, PhD\(^8,9\) and Anupama Narla, MD\(^7,10,11\)

\(^1\)Department of Pediatrics - Division of Hematology/Oncology, Stanford University School of Medicine, Palo Alto, CA
\(^2\)School of Medicine, Case Western Reserve University, Cleveland, OH
\(^3\)Laboratory of Red Cell Physiology, New York Blood Center, New York, NY
\(^4\)Children’s Mercy Kansas City, Children’s Mercy Research Institute, Kansas City, MO
\(^5\)Department of Pediatrics, Division of Hematology/Oncology, Stanford University School of Medicine, Stanford, CA
\(^6\)Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA
\(^7\)Department of Pediatrics, Stanford University School of Medicine, Stanford, CA
\(^8\)Feinstein Institute for Medical Research, Manhasset, NY
\(^9\)The Feinstein Institutes For Medical Research, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY
\(^10\)Stanford University, Stanford, CA
\(^11\)Stanford University, Hillsborough, CA

**1866 Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia**

Program: Oral and Poster Abstracts

Session: 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster II

Hematology Disease Topics & Pathways: AML, Diseases, Non-Biological, Therapies, chemotherapy, Myeloid Malignancies

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
June Takeda, MD, Kenichi Yoshida, MD, PhD, Akinori Yoda, PhD, Lee-Yung Shih, MD, Yasuhito Nannya, MD, PhD, Yotaro Ochi, MD, Ayana Kon, MD, PhD, Kenichi Chiba, PhD, Yusuke Shiozawa, MD, PhD, Tetsuichi Yoshizato, MD, PhD, Cassandra M Kerr, MS, Yasunobu Nagata, MD, PhD, Toshiyuki Kitano, MD, PhD, Akira Hangaishi, MD, PhD, Ken Ishiyama, MD, PhD, Hisashi Tsurumi, MD, PhD, Yasushi Miyazaki, MD, PhD, Nobuhiro Hiramoto, MD, Takayuki Ishikawa, MD, PhD, Masahiro Marshall Nakagawa, MD, PhD, Akifumi Takaori-Kondo, MD, PhD, Shigeru Chiba, MD, PhD, Hideyuki Nakazawa, MD, PhD, Ming-Chung Kuo, M.D., Keisuke Kataoka, MD, PhD, Ryunosuke Saiki, MD, Hiroko Tanaka, MD, Kenseki Usuki, MD, PhD, Shuichi Miyawaki, MD, PhD, Satoru Miyano, PhD, Jaroslaw P. Maciejewski, MD, PhD, Arnold Ganser, MD, PhD, Felicitas Tholl, Hideki Makishima, MD, PhD, and Seishi Ogawa, MD, PhD.

1Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan
2Kyoto University, Kyoto, Japan
3Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
4Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital-Linkou, Taoyuan, Taiwan
5Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan
6The University of Tokyo, Human Genome Centre, Institute of Medical Science, Tokyo, Japan
7The University of Tokyo, Department of Pediatrics, Graduate School of Medicine, Tokyo, Japan
8Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
9Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
10Department of Hematology, Medical Research Institute Kitano Hospital, Osaka, Japan
11Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan
12Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan
13Hematology, Gifu University Graduate School of Medicine, Gifu, Japan
14Atomic Bomb Disease Institute, Nagasaki University Hospital, Nagasaki, Japan
15Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan
16Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
17Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
18Department of Hematology, Shinshu University School of Medicine, Matsumoto, Japan
19Department of Integrated Data Science, M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan
20Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan
21Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
22Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
23Department of Medicine, Center for Haematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden
24Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan

1918 Routine Laboratory Values Can Predict Therapy-Related Myeloid Neoplasms in Patients with New Cytopenias after Treatment for Breast Cancer

Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster II
Hematology Disease Topics & Pathways: Clinically relevant
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Giulia Petrone, MD, MBBS, Charles Gaulin, MBBS, Andriy Derkach, PhD, Sean M. Devlin, PhD, Ashwin Kishtagari, MBBS, Rekha Parameswaran, MD and Eytan M. Stein, MD

1Internal Medicine, Icahn School of Medicine/Mount Sinai Morningside and West Hospital, New York City, NY
2Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ
3Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
5Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY
6Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

1923 SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial

Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster II
Hematology Disease Topics & Pathways: AML, Diseases, Biological Processes, Technology and Procedures, Myeloid Malignancies, flow cytometry, pathways
1962 A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemia: Novel Therapy, Excluding Transplantation: Poster II

Hematology Disease Topics & Pathways: AML, Adult, Diseases, Non-Biological, Therapies, Combinations, chemotherapy, Study Population, Myeloid Malignancies, Clinically relevant

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Aziz Nazha, MD1, Sudipto Mukherjee, MD, PhD, MPH2, Caitlin Siebenaller, PharmD3*, Madeline Waldron, PharmD, BCOP3*, Eric Parsons, RN5*, Jenna Thomas5*, Hetty E. Carraway, MD, MBA6, Dale Grabowski, BS7*, Yihong Guan, PhD7*, Aaron T. Gerds, MD, MS8, Bhumika J. Patel, MD9, Anjali S Advani, MD10, Jaroslav P. Maciejewski, MD, PhD11 and Mikkael A. Sekeres, MD, MS12

1Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH
2Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Department of Pharmacy, Cleveland Clinic, Cleveland, OH
4Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
6Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
7Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
8Tausssig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
9Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
10Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
11Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
12Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

1990 Genomic Landscape of Splicing Factor Mutant Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II

Hematology Disease Topics & Pathways: AML, Diseases, Myeloid Malignancies

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Hassan Awada, MD1, Arda Durmaz2*, Cassandra M. Kerr, MS3*, Jaroslav P. Maciejewski, MD, PhD3 and Valeria Visconte, PhD1

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
2Department of Systems biology and Bioinformatics, CWRU, cleveland
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

ASH 2020 Annual Meeting 55
2001 TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II
Hematology Disease Topics & Pathways: Biological, antibodies, AML, Adult, Diseases, Therapies, Biological Processes, Technology and Procedures, immunotherapy, Study Population, genetic profiling, Clinically relevant, Myeloid Malignancies, immune mechanism, microenvironment
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Catherine Lai, MD, MPH, Jayakumar Vadakkekathu, PhD, Stephen Reeder, BSc, Sarah E. Church, PhD, Carmen Ballesteros-Merino, PhD, Ibrahim Aldoss, M.D., Anjali S Advani, MD, John E. Godwin, MD, Matthew J. Wieduwilt, MD, PhD, Martha L. Arellano, MD, Geoffrey L Uy, MD, Farhad Ravandi, MBBS, Matthew C Foster, MD, Emmanuel Gyan, MD, PhD, Patrick J. Stiff, MD, Norbert Vey, MD, Ashkan Emadi, M.D., Ph.D., Matteo Giovanni Carrabba, MD, Roland B. Walter, MD, PhD, MS, Peter H. Sayre, MD, PhD, Kathy Tran, MD, Erin Timmery, MD, Michael P. Rettig, PhD, Patrick Kaminker, PhD, John Muth, MS, Kuo Guo, MS, Tung On Yau, MD, Peter J.M. Valk, PhD, Bob Lowenberg, MD, PhD, Ivana Gojo, MD, Martin Bornhäuser, MD, John F. DiPersio, MD, PhD, Jan K Davidson-Moncada, MD, PhD, and Sergio Rutella, MD, PhD, FRCPATH

1Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC
2John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom
3NanoString Technologies, Inc., Seattle, WA
4Providence Cancer Center, Earl A. Chiles Research Institute, Portland, OR
5Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA
6Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
7Providence Portland Medical Center, Portland, OR
8Moore Cancer Center, University of California, San Diego, La Jolla, CA
9Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
10Washington University School of Medicine, Saint Louis, MO
11Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
12Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, Chapel Hill, NC
13Centre Hospitalier Universitaire, Service D’Hematologie Et Therapie Cellulaire, Tours Cedex, France
14Loyola University Chicago Stritch School of Medicine, Maywood, IL
15Hematologie clinique, Institut Paoli Clamettes, Marseille, France
16University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
17Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
18Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
19University of California, San Francisco, San Francisco, CA
20MacroGenics, Inc., Rockville, MD
21MacroGenics, Inc., Rockville, MD
22Department of Internal Medicine, Division of Oncology, Washington Univ. School of Med., Saint Louis, MO
23MacroGenics, Inc., Rockville, MD
24Erasmus University Medical Center, Rotterdam, Netherlands
25Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands
26Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
27Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
28Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO
29Centre for Health, Ageing and Understanding Disease (CHAUD), Nottingham Trent University, Nottingham, United Kingdom

2006 Molecular and Clinical Aspects of Acute Myeloid Leukemia with Inv(3) (q21q26)/t(3;3)(q21;q26) Carrying Spliceosomal Mutations

Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II
Hematology Disease Topics & Pathways: AML, Diseases, Myeloid Malignancies
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Hassan Awada, MD, Cassandra M Kerr, MS, Heesun J. Rogers, MD, PhD, Jaroslaw P. Maciejewski, MD, PhD and Valeria Visconte, PhD

ASH 2020 Annual Meeting 56
2023 Integrative DNA Methylation and Gene Expression Analysis Reveals Candidate Biomarkers Associated with Dichotomized Response to Chemoimmunotherapy in Diffuse Large B-Cell Lymphoma
Program: Oral and Poster Abstracts
Session: 621. Lymphoma—Genetic/Epigenetic Biology: Poster II
Hematology Disease Topics & Pathways: Diseases, Non-Hodgkin Lymphoma, DLBCL, Biological Processes, Technology and Procedures, epigenetics, Lymphoid Malignancies, genetic profiling, genomics, integrative -omics, RNA sequencing
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Ellen K. Kendall, BA1, Manishkumar S. Patel, PhD, MS, BPharm1, Sarah Ondrejka, DO2*, Agrima Mian, MBBS, MD3*, Yazeed Sawalha, MD4, Bo Hu, PhD5*, Eric D. Hsi, MD6, Brian T. Hill, MD3 and Neetu Gupta, PhD, MSc, BSc1
1Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH
2Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH
3Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
4Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH
5Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
6Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH

2027 Gene Expression and Epigenetic Analysis in Relapsed/Refractory Diffuse Large B Cell Lymphoma Provides Insights into Evolution of Treatment Resistance to R-CHOP
Program: Oral and Poster Abstracts
Session: 621. Lymphoma—Genetic/Epigenetic Biology: Poster II
Hematology Disease Topics & Pathways: Adult, Diseases, Therapies, Combinations, biopsy, Elderly, Non-Hodgkin Lymphoma, DLBCL, Biological Processes, Technology and Procedures, immune cells, epigenetics, Cell Lineage, Lymphoid Malignancies, Study Population, genomics, Clinically relevant, RNA sequencing
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Manishkumar S. Patel, PhD, MS, BPharm1, Ellen K. Kendall, BA1, Sarah Ondrejka, DO2*, Agrima Mian, MBBS, MD3*, Yazeed Sawalha, MD4, Bo Hu, PhD5*, Eric D. Hsi, MD6, Brian T. Hill, MD3 and Neetu Gupta, PhD, MSc, BSc1
1Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH
2Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH
3Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
4Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH
5Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
6Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH

2046 Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study
Program: Oral and Poster Abstracts
Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II
Hematology Disease Topics & Pathways: Adult, Study Population, Clinically relevant
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Giselle K. Perez, PhD1*, Fangxin Hong, PhD2, Andrew M. Evens, DO, MMSc3, Thomas M. Habermann, MD4, Ranjana Advani, MD5, Stephen M. Ansell, MD, PhD6, Puneet S. Cheema, MD7*, Philip A. Dy, MD8*, Timothy E. O’Brien, MD9, Jane N. Winter, MD10, Julie E. Chang, MD11, David Cell, PhD12*, Brad S. Kahl, MD13 and Lynne I. Wagner, PhD14*
1Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH
2Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH
3Department of Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
4Department of Hematopathology, Cleveland Clinic, Cleveland
2049 Results of a Phase I Trial of Lenalidomide, Rituximab (R²) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma

Program: Oral and Poster Abstracts
Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II
Hematology Disease Topics & Pathways: Non-Biological, Therapies
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

**Brian T. Hill, MD, Deepa Jagadeesh, MD, MPH², Alex V. Mejia Garcia, MD³, Robert M. Dean, MD³, Omer N. Koç, MD⁴, Matt Kalaycio, MD⁵, Kirsten M Boughan, DO⁶, Brenda W. Cooper, MD⁷, Allison M. Winter, MD⁸, Wesam B. Ahmed, MD⁹**, Brad Pohlmans, MD, Christopher D’Andrea, PA-C¹⁰, Kelsey Holkovic, RN¹¹, Ashley Morrison, RN¹¹, **Paolo Caimi, MD⁵** and Mitchell R Smith, MD, PhD⁸

¹Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
²EUSA Pharma, Boston, MA
³HVH Precision Analytics, Wayne, PA
⁴University of Pennsylvania, Philadelphia, PA
⁵Castleman Disease Collaborative Network, Philadelphia, PA

2059 A Longitudinal Population Level Analysis of Healthcare Resource Utilization, Comorbidity, and Survival in Idiopathic Multicentric Castleman Disease Patients

Program: Oral and Poster Abstracts
Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II
Hematology Disease Topics & Pathways: Diseases, Lymphoma (any), Lymphoid Malignancies
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

**Sudipto Mukherjee, MD, PhD, MPH¹, Rabecka Martin, PhD²**, Brenda Sande², Chad Glen, PhD³, Jeremy Paige, MD, PhD³, Suresh Yarlagadda, MD, MPH³ and David C Fajgenbaum, MD, MBA, MSc⁴,⁵

¹Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
²EUSA Pharma, Boston, MA
³HVH Precision Analytics, Wayne, PA
⁴University of Pennsylvania, Philadelphia, PA
⁵Castleman Disease Collaborative Network, Philadelphia, PA

2126 A Multi-Center Analysis of the Impact of Dose Level of R-EPOCH on Outcomes of Patients with Double/Triple-Hit B-Cell Lymphoma

Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster II
Hematology Disease Topics & Pathways: Adult, Diseases, Lymphoma (any), drug-drug interaction, Therapies, Combinations, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Lymphoid Malignancies, Study Population, Clinically relevant, Quality Improvement
2184 Molecular and Expression Characterization of Monosomy 7 and Del(7q)
Program: Oral and Poster Abstracts
Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II
Hematology Disease Topics & Pathways: Diseases, MDS, Myeloid Malignancies
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Vera Adema, PhD\textsuperscript{1,2}, Cassandra M Kerr, MS\textsuperscript{3}, Hassan Awada, MD\textsuperscript{1}, Sunisa Kongkiatkamon, MD\textsuperscript{2,3}, Bhumika J. Patel, MD\textsuperscript{1,2,3}, Mikkael A. Sekeres, MD, MS\textsuperscript{4}, Valeria Visconte, PhD\textsuperscript{5}, John Barnard\textsuperscript{5,6}, Jaroslaw P. Maciejewski, MD, PhD\textsuperscript{1,6,7} and Torsten Haferlach, MD\textsuperscript{7}
\textsuperscript{1}Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
\textsuperscript{2}Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
\textsuperscript{3}Leukemia Program, Department of Hematology and Medical Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
\textsuperscript{4}Leukemia Program, Department of Hematology and Medical Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
\textsuperscript{5}Leukemia Program, Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
\textsuperscript{6}Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
\textsuperscript{7}MLL Munich Leukemia Laboratory, Munich, Germany

2185 Co-Existence of Splicing Factor Mutations in Myeloid Malignancies
Program: Oral and Poster Abstracts
Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II
Hematology Disease Topics & Pathways: AML, Diseases, MDS, Myeloid Malignancies
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Vera Adema, PhD\textsuperscript{1,2}, Hassan Awada, MD\textsuperscript{3}, Laila Terkawi\textsuperscript{3}, Sunisa Kongkiatkamon, MD\textsuperscript{1,3}, Cassandra M Kerr, MS\textsuperscript{3} and Valeria Visconte, PhD\textsuperscript{4}
\textsuperscript{1}Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
\textsuperscript{2}Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2187 Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia
Program: Oral and Poster Abstracts
Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster II
Hematology Disease Topics & Pathways: AML, Diseases, CMML, MDS, MPN, Myeloid Malignancies
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Sunisa Kongkiatkamon, MD\textsuperscript{1,2,3}, Yasunobu Nagata, MD, PhD\textsuperscript{4,7}, Vera Adema, PhD\textsuperscript{4}, Hassan Awada, MD\textsuperscript{1,3}, Misam Zawit, MD\textsuperscript{5}, Laila Terkawi\textsuperscript{3}, Simona Pagliuca, MD\textsuperscript{3}, Carmelo Gurnari, MD\textsuperscript{5,6}, Cassandra M Kerr, MS\textsuperscript{7}, Mikkael A. Sekeres, MD, MS\textsuperscript{4,7}, Hetty E. Carraway, MD, MBA\textsuperscript{8}, Yogenthiran Saunthararajah, MD\textsuperscript{1,2}, Bhumika J. Patel, MD\textsuperscript{1,9}, Jaroslav P. Maciejewski, MD, PhD\textsuperscript{1,6} and Valeria Visconte, PhD\textsuperscript{4}
Three Fold Risk of Atrial Fibrillation in Ibrutinib Treated CLL Patients without Increased Risk of Stroke: A SEER-Medicare Database Analysis

Program: Oral and Poster Abstracts
Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster II
Hematology Disease Topics & Pathways: Leukemia, Adult, Diseases, CLL, Adverse Events, Lymphoid Malignancies, Study Population
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Akiva Diamond, MD1, Wyatt P. Bensken, BS2*, Weichuan Dong, Ph.D.2*, Sarah C. Markt, ScD, MPH2*, Siran M. Koroukian, Ph.D.2* and Paolo Caimi, MD3
1Department of hematology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144)

Program: Oral and Poster Abstracts
Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II
Hematology Disease Topics & Pathways: Biological, antibodies, CRS, Therapies, Adverse Events, Clinically relevant
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Jason Valent, MD1, John Silowsky, RN BSN2*, Michael R. Kurman, MD3, Eileen Daniel2*, Janet Jobes2*, Mark Harnett, MS4*, Margaret Ziola, MD2*, Jessica Roviwong2*, Sherry Fada1*, Michael Spector, BS2* and Susan B. Sobolov, PhD2*
1Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Caelum Biosciences, Bordentown, NJ
3Michael Kurman Consulting, LLC, Upper Saddle River, NJ
4Caelum Biosciences, Stow, MA

Outcomes in AL Amyloidosis: A Single Institution Experience

Program: Oral and Poster Abstracts
Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II
Hematology Disease Topics & Pathways: Diseases, Therapies, Clinically relevant
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

Diana Basali, MD1*, Jennifer Tran, DO2*, Wei Wei, MS3*, Sherry Fada4*, Brittany Lewis4* and Jason Valent, MD4
1Department of Internal Medicine, Cleveland Clinic, Pepper Pike, OH
2Department of Internal Medicine, Cleveland Clinic, Cleveland, OH
3Cleveland Clinic, Cleveland, OH
4Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

Maintenance Therapy in Newly Diagnosed and Transplant Ineligible Multiple Myeloma Patients: A Meta-Analysis

Program: Oral and Poster Abstracts
Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II
2314 Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

Program: Oral and Poster Abstracts
Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II

Hematology Disease Topics & Pathways: Combinations, Therapies, Adverse Events, Clinically relevant

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM

David S. Siegel, MD1, Gary J. Schiller, MD2, Christy J. Samaras, DO3, Michael Sebag, MD, PhD, FRCPC4, Jesus G. Berdeja, MD5, Siddhartha Ganguly, MD6, Jeffrey V. Matous, MD7, Kevin W Song, MD, FRCPC8, Christopher S. Seet, MD, PhD9, Mirelis Acosta-Rivera9, Michael Bar10, Donald P. Quick, MD11, Bertrand M. Anz III, MD12, Gustavo A. Fonseca, MD13, Donna E. Reece, MD14, Kim Lee15, Weiyuan Chung15, Amit Agarwal, MD, PhD15 and Nizar Bahlis, MD16

1Hackensack Univ. Med. Ctr., Hackensack, NJ
2David Geffen School of Medicine at University of California, Los Angeles, CA
3Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Division of Hematology, McGill University Health Centre, Montreal, QC, Canada
5Sarah Cannon Research Institute and Tenessee Oncology, Nashville, TN
6The University of Kansas Cancer Center, Fairway, KS
7Colorado Blood Cancer Institute, Denver, CO
8Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver General Hospital, Vancouver, BC, Canada
9Fundación de Investigación, San Juan, Puerto Rico
10Stamford Hospital, Stamford, CT
11Joe Arrington Cancer Research and Treatment Center, Lubbock, TX
12Tennessee Oncology, Chattanooga, TN
13Florida Cancer Specialists, St Petersburg, FL
14Princess Margaret Cancer Centre, Toronto, ON, Canada
15Bristol Myers Squibb, Princeton, NJ
16Tom Baker Cancer Center, Calgary, AB, Canada

2373 Efficacy and Safety of Recombinant Thrombomodulin for the Prophylaxis of Vaso-Occlusive Complications in Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

Program: Oral and Poster Abstracts

Hematology Disease Topics & Pathways: anticoagulant drugs, Bleeding and Clotting, Non-Biological, Therapies, Thrombotic Disorders

Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Richi Kashyap, MD1*, Muhammad Ashar Ali, MD2*, Taaha Muddassir Mirza, MBBS3*, Anum Javaid, MD3*, Aniqa Raheem, MBBS4*, Rohail Gul, MBBS5*, Muhammad Tayyeb, MD6*, Muhammad Yasar Anwar7*, Abdul Jabbar Dar, MD7*, Qasim Khurshid, MD8*, Karun Neupane, MBBS, MD9* and Faiz Anwer, MD10

1Maulana Azad Medical College, New Delhi, India
2King Edward Medical University, Lahore, Pakistan
3Rawalpindi Medical University, Rawalpindi, Pakistan
4Shalamar Medical and Dental College, Lahore, Pakistan
5Shafla College of Medicine, Islamabad, Pakistan
6Department of Internal Medicine, King Edward Medical University, Lahore, Pakistan
7Shaikh Zayed Medical College, Lahore, Pakistan
8Xinjiang Medical University, Urumqi, China
9Manipal College of Medical Sciences, Pokhara, Nepal
10Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2377 Risk Factors, Mortality & Cost Analysis of Sinusoidal Obstructive Syndrome in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

Program: Oral and Poster Abstracts
Hematology Disease Topics & Pathways: Diseases, Pediatric, Study Population, Lymphoid Malignancies, Clinically relevant, Myeloid Malignancies
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Archana Ramgopal, DO1, James Zullo2*, Jignesh Dalal, MD3, Meghan McCormick, MD4 and Ram Kalpatthi, MD5

1UPMC, Department of Pediatrics, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA
2UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA
3Rainbow Babies & Children’s Hospital, Cleveland, OH
4Department of Pediatric Hematology/Oncology, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA
5Department of Pediatric Hematology/Oncology, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA

2382 Efficacy and Safety Profile of Proteasome Inhibitor Based Drug Regimens for Treatment of Newly Diagnosed AL Amyloidosis: A Systematic Review

Program: Oral and Poster Abstracts
Hematology Disease Topics & Pathways: Diseases, Non-Biological, neurotoxicity, Therapies, Adverse Events, chemotherapy, Myeloid Malignancies
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Saad Javed, MD1*, Tarig Iqtiidar Sadiq Syed, MD2*, Hejab Fatima, MBBS3*, Syed Hashim Ali Inam, MBBS4*, Tayyab Rehan, MBBS5*, Syed Maaz Abdullah, MBBS6*, Mohammed Musa Najmuddin, MBBS7*, Moebeen Zaka Haider, MD, MBBS8*, Karun Neupane, MBBS, MD9*, Muhammad Khawar Sana, MD10*, Abdul Jabbar Dar, MD11*, Ali Jaan, MD12*, Muhammad Ali Mirza, MD13* and Faiz Anwer, MD14

1Department of Internal Medicine, Allama Iqbal Medical College, Lahore, Pakistan
2Internal Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY
3Allama Iqbal Medical College, Lahore, Pakistan
4Internal Medicine, Army Medical College, Rawalpindi, Pakistan
5Nishtar Medical University, Multan, Pakistan
6King Edward Medical University, Lahore, Punjab, Pakistan
7King Edward Medical University, Sartell, MN
8Manipal College of Medical Sciences, Pokhara, Nepal
9King Edward Medical University, Lahore, Pakistan
10Department of Internal Medicine, King Edward Medical University, Lahore, AL, Pakistan
11Shaikh Zayed Medical College, Lahore, Pakistan
12Department of Medicine, Frontier Medical And Dental College, Abbottabad, ON, Pakistan
13Department of Hematology & Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Moreland Hills, OH
2426 Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee

Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster II
Hematology Disease Topics & Pathways: Leukemia, Biological, Diseases, Therapies, Lymphoid Malignancies, transplantation, stem cells
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Antonio M. Jimenez, MD, MS1*, Trent Wang, DO, MPH2, Marcos de Lima, MD3, Krishna V Komanduri, MD4, Partow Kebriaei, MD5, Mark Litzow, MD6, Vijaya Raj Bhatt, MBBS7*, Frédéric Baron, MD, PhD8, Ayman Saad, MD, MSc9*, Nandita Khera, MD10, Joseph Maakaron, MD9, Hemant S. Murthy, MD11, Edward A Copelan12, Zachariah Deflipp, MD13, Christopher Bredeson, MD, FRCP, MSc14, Rodrigo Martino, MD15*, Maxwell Krem16*, Taiga Nishihori, MD17, Mei-Jie Zhang, PhD18,19*, Daniel J. Weisdorf, MD20, Karen Chen, MS21* and Wael Saber, MD, MS22

1 Section of Stem Cell Transplantation & Cell Therapy, Sylvester Cancer Center, University of Miami, Miami, FL
2 Sylvester Comprehensive Cancer Center, Miami Springs, FL
3 University Hospitals Seidman Cancer Center, Cleveland, OH
4 Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL
5 Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
6 Division of Hematology, Mayo Clinic, Rochester, MN
7 University of Nebraska Medical Center, Omaha, NE
8 Hematology Department, CHU and University of Liège, Liège, Belgium
9 James Cancer Center, Ohio State Medical Center, Columbus, OH
10 Department of Hematology/Oncology, Mayo Clinic Arizona and Phoenix Children's Hospital, Phoenix, AZ
11 Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL
12 Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
13 Massachusetts General Hospital / Harvard Medical School, Boston, MA
14 Hematology, The Ottawa Hospital General Campus, Ottawa, ON, Canada
15 Department of Hematology. Hospital Sant Creu i Sant Pau, Barcelona, Spain
16 Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY
17 Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL
18 Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI
19 Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
20 Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN
21 CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI
22 CIBMTR, Medical College of Wisconsin, Milwaukee, WI

2432 Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience

Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster II
Hematology Disease Topics & Pathways: Biological, Diseases, Therapies, MPN, Technology and Procedures, Myeloid Malignancies, Clinically relevant, transplantation
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Siddharth Jayant Kunte, MD1, Lisa Rybicki, MS2*, Auro Viswabandya, MD3, Asad Bashey, MD, PhD4, Madiha Iqbal, MBBS5, Michael R. Grunwald, MD6, Bhagirathbhui Dholaria, MBBS7, Hany Elmariah, MD, MS8, Michael Ozga, MD9, Anurag K. Singh, MD10, Sameem Abedin, MD11, Vikas Gupta, MD, FRCP, FRCPath12, Amy E. DeZern, MD13*, Richard J. Jones, MD14, Aaron T. Gerds, MD, MS15* and Tania Jain, MD15

1 Cleveland Clinic, Cleveland, OH
2 Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH
3 Messer Allogeneic Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
4 Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA
5 Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL
6 Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
2469 A Deep Learning Framework for Sickle Cell Disease Microfluidic Biomarker Assays
Program: Oral and Poster Abstracts
Session: 803. Emerging Diagnostic Tools and Techniques: Poster II
Hematology Disease Topics & Pathways: sickle cell disease, Diseases, sickle cell trait, bioengineering, Hemoglobinopathies, Technology and Procedures
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Niksa Praljak1,2*, Brandon Shipley1*, Ayesha Gonzales1*, Utku Goreke, MSc1*, Shamreen Iram1*, Gundeep Singh1*, Ailis Hill1*, Umut A. Gurkan, PhD1 and Michael Hinczewski, PhD1
1Case Western Reserve University, Cleveland, OH
2Cleveland State University, Cleveland, OH

2485 Thrombocytopenia and Anemia Among Patients with Cerebral Palsy: A Big-Data Analysis
Program: Oral and Poster Abstracts
Session: 901. Health Services Research—Non-Malignant Conditions: Poster II
Hematology Disease Topics & Pathways: Anemias, Adult, Diseases, Pediatric, Biological Processes, Study Population, Clinically relevant, hematopoiesis
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Ioannis Milioglou, MD1*, Sanjay P Ahuja, MD2 and Nathan Richard Stehouwer, MD3*
1University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH
2University Hospitals Cleveland Medical Center, Rainbow Babies and Children’s Hospital, Cleveland, OH
3University Hospitals Rainbow Babies & Children’s Hospital, Cleveland, OH

2533 Health Care Burden of Monogammopathy of Renal Significance
Program: Oral and Poster Abstracts
Session: 904. Outcomes Research—Non-Malignant Conditions: Poster II
Hematology Disease Topics & Pathways: Biological Processes, Clinically relevant, Quality Improvement
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Jeries Kort, MD1, Paolo F Caimi, MD2, Pingfu Fu, PhD3, Shufen Cao3*, James Driscoll3*, Marcos de Lima, MD3,4 and Ehsan Malek, MD5
1University Hospitals Cleveland Medical Center, Cleveland, OH
2Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
3Case Western Reserve University, Cleveland, OH
4Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH

2563 Low Dose Daily Corticosteroid Tapering Regimen Allows Highly Effective and Practical Desensitization for Multiple Myeloma Patients with Skin Rash after Immunomodulatory Drugs
Program: Oral and Poster Abstracts
Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster II
Hematology Disease Topics & Pathways: Adverse Events, Clinically relevant
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Amin Firoozmand, MD6, Naveed Ali, MD2, Nausheen Ahmed, MD3, Pingfu Fu4*, Shufen Cao5*, George Brown5, Hannah Schmikla, RN1*, James J. Driscoll, MD, PhD7, Timothy O’Brien6, Paolo Caimi, MD8,9, Marcos de Lima, MD8,10 and Ehsan Malek, MD11,12
2567 Age-Based Probability of Ten-Year Overall Survival (OS) of Acute Myeloid Leukemia (AML): A National Cancer Database (NCDB) Analysis

Program: Oral and Poster Abstracts
Session: 906. Outcomes Research—Malignant Conditions (Myeloid Disease): Poster II
Hematology Disease Topics & Pathways: AML, Adult, Diseases, Study Population, Myeloid Malignancies, Clinically relevant
Sunday, Dec 6, 2020, 10:00 AM-6:30 PM
Vijaya R. Bhatt, MD1, Valerie K Shostrom2*, Nabin Khanal, MBBS3, Chakra P Chaulagain, MD4, Fiona He5 and Krishna Gundabolu, MBBS6
1Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE
2University of Nebraska Medical Center, Omaha, NE
3Franciscan Physician Network Oncology & Hematology Specialists, St Francis hospital, Indianapolis, IN
4Department of Hematology and Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL
5University of Minnesota, Minneapolis, MN
6Division of Oncology and Hematology, University of Nebraska Medical Center - Fred & Pamela Buffett Cancer Center, Omaha, NE

2577 Implication of Piga Genotype on Clinical Features of PNH

Program: Oral and Poster Abstracts
Hematology Disease Topics & Pathways: Anemias, Diseases, Bone Marrow Failure, Biological Processes, PNH, genomics, pathogenesis
Monday, Dec 7, 2020, 10:00 AM-6:30 PM
Carmelo Gurnari, MD1,2*, Simona Pagliuca, MD1,3, Bhumika J. Patel, MD4, Hassan Awada, MD5, Cassandra M Kerr, MS1,3, Sunisa Kongkiatkamon, MD1,3, Laila Terkawi1, Misam Zawit, MBBS5, Valeria Visconte, PhD1, Adam Wahida1*, and Jaroslaw P. Maciejewski, MD, PhD6
1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
2Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
3Université de Paris, Paris, France
4Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
5M. L. Munich Leukemia Laboratory, Munich, Germany
6Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2593 Efficacy and Safety of Amlodipine in Preventing Myocardial Iron Overload in Patients with Transfusion-Dependent Thalassemia Major: A Systematic Review and Meta-Analysis

Program: Oral and Poster Abstracts
Session: 102. Regulation of Iron Metabolism: Poster III
Hematology Disease Topics & Pathways: Non-Biological, Therapies, pharmacology
Monday, Dec 7, 2020, 10:00 AM-6:30 PM
Richi Kashyap, MD1*, Muhammad Ashar Ali, MD2, Saad Ullah Malik, MD3, Farhan Khalid, MBBS4, Ali Jaan, MD5, Awais Khalid, MBBS5, Abdul Jabbar Dar, MD6, Qasim Khurshid, MD7, Karun Neupane, MBBS, MD6, Moebeen Zaka Haider, MD, MBBS2, Syed Maaz Abdullah, MBBS5 and Faiz Anwer, MD7

ASH 2020 Annual Meeting 65
2603 Combinatorial Administration of Pharmacological Inhibitors Targeting DNMT1 and KDM1A Produces Synergistic and Additive Increases in F Retiulocytes and y-Globin Expression in Normal Baboons

Program: Oral and Poster Abstracts
Session: 112. Thalassemia and Globin Gene Regulation: Poster III
Hematology Disease Topics & Pathways: Non-Biological, Therapies, Combinations, pharmacology

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Vinzon Ibanez, B.S.1,2*, Kestis Vaitkus2*, Robert E. Molokie, MD3,4, Yogenthiran Saunthararajah, MD5,6 and Donald Lavelle, PhD2,7

1Department of Medicine, University of Illinois Chicago, Chicago, IL
2Department of Medicine, University of Illinois at Chicago, Jesse Brown VA Medical Center, Chicago, IL
3Jesse Brown VA Medical Center, Chicago, IL
4Department of Medicine, Division of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL
5Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
6Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
7Department of Medicine, College of Medicine, University of Illinois at Chicago, Chicago, IL

2610 Assessment of Red Blood Cell-Mediated Microvascular Occlusion in Sickle Cell Disease By a Novel Electrical Impedance-Based Microfluidic Device

Program: Oral and Poster Abstracts
Session: 113. Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Poster III
Hematology Disease Topics & Pathways: sickle cell disease, Adult, Diseases, sickle cell trait, bioengineering, Hemoglobinopathies, Technology and Procedures, Study Population, Clinically relevant

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Yuncheng Man1*, Debnath Maji, PhD1*, Ran An, PhD1, Sanjay P Ahuja, MD2, Jane A. Little, MD3, Pedram Mohseni, PhD1*, Michael A Suster, PhD1* and Umut A. Gurkan, PhD1

1Case Western Reserve University, Cleveland, OH
2University Hospitals Cleveland Medical Center, Rainbow Babies and Children's Hospital, Cleveland, OH
3University of North Carolina at Chapel Hill, Chapel Hill, NC

2756 Leveraging Whole Genome Sequencing to Define the Mutational Landscape in Paroxysmal Nocturnal Hemoglobinuria

Program: Oral and Poster Abstracts
Session: 508. Bone Marrow Failure: Poster III
Hematology Disease Topics & Pathways: Technology and Procedures, NGS, WGS

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Adam Wahida1*, Stephan Hutter, PhD2*, Manja Meggendorfer, PhD2, Cassandra M. Kerr, MS3*, Carmelo Gurnari, MD3, Elisabeth Weiss, PhD2*, Claudia Haferlach, MD2, Wolfgang Kern, MD2, Jaroslav P. Maciejewski, MD, PhD2 and Torsten Haferlach, MD2

1Torsten Haferlach Leukaemiadiagnostik Stiftung, Munich, Germany
2MLL Munich Leukemia Laboratory, Munich, Germany
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2776 Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles
2778 Venetoclax Inhibition of Pyrimidine Synthesis Guides Methods for Integration with Decitabine or 5-Azacytidine that are Non-Myelosuppressive

Program: Oral and Poster Abstracts
Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster III
Hematology Disease Topics & Pathways: AML, therapy sequence, CML, Diseases, Non-Biological, Therapies, Combinations, CMML, MDS, chemotherapy, MPN, Myeloid Malignancies, Clinically relevant, pharmacology
Monday, Dec 7, 2020, 10:00 AM-6:30 PM
Xiaorong Gu, PhD1,*, Rita Tohme, PhD1,*, Mendel Goldfinger, MD2,*, Benjamin K. Tomlinson, MD4,5, Nneha Sakre, PhD1,*, Shannon Hannmer2,*, Babal K. Jha, PhD2,*, Jaroslaw P. Maciejewski, MD, PhD2,*, Amit Verma, MBBS2 and Yogenthiran Saunthararajah, MD4
1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
2Taqsiag Cancer Institute, Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
3Hematology/Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
4Department of Hematology/Oncology, Montefiore Medical Center Albert Einstein College of Medicine, New York, NY
5Department of Hematology, MDT, OH
6Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
7Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2780 Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms

Program: Oral and Poster Abstracts
Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster III
Hematology Disease Topics & Pathways: AML, Biological, Diseases, Therapies, MDS, enzyme inhibitors, Myeloid Malignancies
Monday, Dec 7, 2020, 10:00 AM-6:30 PM
Simona Pagliuca, MD1,2,*, Yihong Guan, PhD2,*, Anand D. Tiwari, PhD3,*, Dale Grabowski, BS2,*, Carmelo Gunnari, MD2,3,*, Cassandra M Kerr, MS2,*, Sunisa Kongkiatkamon, MD2,4,*, Metis Hasipek, PhD2,*, Laila Terkawi2,*, Misam Zawit, MBBS2,*, Hassan Awada, MD2,*, Valeria Visconte, PhD2,*, Yogenthiran Saunthararajah, MD3, James G Phillips, PhD2,*, Jaroslaw P. Maciejewski, MD, PhD2,3 and Babal K. Jha, PhD2,3
1Université de Paris, Paris, France
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
3Department of Hematology, MDT, OH
4Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
5Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
6Department of hematology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
7Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
Patients Treated with Flotetuzumab

Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III

Hematology Disease Topics & Pathways: AML, antibodies, Biological, CRS, Adult, Diseases, Therapies, Adverse Events, Biological Processes, Study Population, Myeloid Malignancies, Clinically relevant, TKI

Monday, Dec 7, 2020, 10:00 AM

**Geoffrey L Uy, MD**, **Michael P. Retting, PhD**, **Stephanie Christ, MS**, **Ibrahim Aldoss, MD**, **Michael T. Byrne, DO**, **Harry P. Erba, MD, PhD**, **Martha L. Arellano, MD**, **Matthew C Foster, MD**, **John E. Godwin, MD**, **Farhad Ravandi, MBBS**, **Peter H. Sayre, MD, PhD**, **Anjali S Advani, MD**, **Matthew J. Wieduwilt, MD, PhD**, **Ashkan Emadi, M.D., Ph.D.**, **Lauri C. Michaelis, MD**, **Patrick J. Stiff, MD**, **Martin Wermke**, **Norbert Vey, MD**, **Patrice Chevalier, MD, PhD**, **Emmanuel Gyan, MD, PhD**, **Christian Recher, MD, PhD**, **Fabio Ciciri, MD**, **Matteo Giovanni Carrabba, MD**, **Antonio Curti, MD, PhD**, **Geert Huls, MD, PhD**, **Max S. Topp, MD**, **Mojca Jongen-Lavrencic, MD, PhD**, **John Muth, MS**, **Teia Curtis**, **Mary Beth Collins**, **Erik Timmeny**, **Guo, MSc**, **Jian Zhao, PhD**, **Kathy Tran**, **Patrick Kaminker, PhD**, **Priyanka Patel, PharmD**, **Ouiai Bakkacha, MD**, **Kenneth Jacobs, MD**, **Maya Kostova, PhD**, **Jennifer Seiler, PhD, RAC**, **Bob Lowenberg, MD, PhD**, **Sergio Rutella, MD, PhD**, **FRCPath**, **Roland B. Walter, MD, PhD, MS**, **Ezio Bonvini, MD**, **Jan K Davidson-Moncada, MD, PhD** and **John F. DiPersio, MD, PhD**

1. Washington University School of Medicine, Saint Louis, MO
2. Department of Internal Medicine, Division of Oncology, Washington Univ. School of Med., Saint Louis, MO
3. Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO
4. Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA
5. Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN
6. University of Alabama at Birmingham, Birmingham, AL
7. Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
8. Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, Chapel Hill, NC
9. Providence Portland Medical Center, Portland, OR
10. Department of Leukemia, University of Texas–MD Anderson Cancer Center, Houston, TX
11. University of California, San Francisco, San Francisco, CA
12. Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
13. Moores Cancer Center, University of California, San Diego, La Jolla, CA
14. University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
15. Division of Hematology/Oncology, Department of Medicine, The Medical College of Wisconsin Inc., Milwaukee, WI
16. Loyola University Chicago Stritch School of Medicine, Maywood, IL
17. NCT/UCC Early Clinical Trial Unit, University Hospital Carl Gustav Carus, Dresden, Germany
18. Hematologie clinique, Institut Pauli Lannettes, Marseille, France
19. Department of Hematology and Cell Therapy, CHU Nantes, Nantes, France
20. CHU de Tours – Hôpital Bretonneau, Tours, France
21. Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
22. Haematologica and BMT Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
23. Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
24. Hematology/Oncology “L. e A. Seràgnoli”, Sant'Orsola-Malpighi University Hospital, Bologna, Bologna, Italy
25. Department of Hematology, University Medical Center Groningen, Groningen, GZ, Netherlands
26. Medizinische Klinik Und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
27. Erasmus University Medical Center, Rotterdam, Netherlands
28. MacroGenics, Inc., Rockville, MD
29. MacroGenics, Inc., Frederick, MD
30. MacroGenics, Rockville, MD
31. MacroGeniccs, Inc., ROCKVILLE, MD
32. MacroGenics, Rockville, MD
33. MacroGenics, Inc, ROCKVILLE, MD
34. Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands
35. John van Geest Cancer Centre School of Science and Technology, Nottingham Trent University, Nottingham, ENG, United Kingdom
36. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
37. MacroGenics, Inc., Washington, DC
2840 Targeting NLRP3 Inflammasome-Induced Therapy Resistance in ALL
Program: Oral and Poster Abstracts
Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster III
Hematology Disease Topics & Pathways: Leukemia, ALL, Non-Biological, Diseases, Therapies, chemical interactions, chemotherapy, Lymphoid Malignancies
Monday, Dec 7, 2020, 10:00 AM-6:30 PM
Zhongbo Hu, MD, PhD1, Michael Sporn, MD2* and John Letterio, MD3*
1Rainbow Babies and Children’s Hospital, Cleveland, OH
2Dartmouth Medical School, Hanover, NH
3Department of Pediatrics, Case Western Reserve University, Cleveland, OH

2870 Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome
Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III
Hematology Disease Topics & Pathways: AML, Diseases, Non-Biological, Therapies, chemical interactions, MDS, Biological Processes, DNA damage, DNA repair, Myeloid Malignancies
Monday, Dec 7, 2020, 10:00 AM-6:30 PM
Lina Benajiba, MD, PhD1*, Hetty E. Carraway, MD, MBA2, Nada Hamad, MB.BS, FRACP, FRCPA3,4, Eytan M. Stein, MD5, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA6, Amy Burroughs7*, Scott Harris7*, Hayley Lane7*, Dorothy D. Nguyen, MD7*, Monic Stuart, MD, MPH7, Jesse Vargas, PhD8, Alexandre Puissant, PhD9, Kimberly Stegmaier, MD9 and Courtney D. Dinardo, MD, MSc10
1APHP, INSERM U944, Institute of Hematology - St Louis Hospital, PARIS, France
2Tausig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH
3Department of Hematology, St. Vincent's Hospital, Sydney, NSW, Australia
4University of New South Wales, Sydney, Australia
5Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
6Department of Molecular Oncology and Cancer Immunology, Epworth HealthCare, East Melbourne, VIC, Australia
7Cleave Therapeutics, Inc., San Francisco, CA
8Cleave Therapeutics, Inc., San Diego, CA
9Dana-Farber Cancer Institute, Boston, MA
10Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

2874 A Phase 1 Study of Sea-CD70 in Myeloid Malignancies
Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III
Hematology Disease Topics & Pathways: AML, Biological, antibodies, Diseases, Therapies, MDS, Myeloid Malignancies, Clinically relevant
Monday, Dec 7, 2020, 10:00 AM-6:30 PM
Ahmed Aribi, MD1,2, Anjali S Advani, MD3, William Donnellan, MD4, Amir T. Fathi, M.D.5, Marcello Rotta, MD6, Benjamin K. Tomlinson, MD7, Pankit Vachani, MD8*, Jay Yang, MD9, Phoenix Ho, MD10 and Guillermo Garcia-Manero, MD11
1Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA
2City of Hope National Medical Center, Duarte, CA
3Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
4Tennessee Oncology / Sarah Cannon Research Institute, Nashville, TN
5Massachusetts General Hospital, Harvard Medical School, Cambridge, MA
6Sarah Cannon Blood Cancer Network, Colorado Blood Cancer Institute, Denver, CO
7Case Western Reserve University, Cleveland, OH
8University of Alabama-Birmingham, Birmingham, AL
9Karmanos Cancer Institute, Detroit, MI
10Seattle Genetics, Bothell, WA
11Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2878 Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123xCD3 Bispecific Dart Molecule, in Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster III

Hematology Disease Topics & Pathways: AML, Biological, antibodies, Diseases, Therapies, Biological Processes, Technology and Procedures, immunotherapy, Myeloid Malignancies, genetic profiling, Clinically relevant, immune mechanism, microenvironment

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Jayakumar Vadakekolathu, PhD1*, Tung On Yau1*, Sarah E. Church, PhD2*, Michael P. Rettig, PhD3, Ibrahim Aldoss, M.D.4, Geoffrey L Uy, MD5, Norbert Vey, MD6, Ashkan Emadi, M.D., Ph.D.7*, Peter H. Sayre, MD, PhD8, Roland B. Walter, MD, PhD8, Matthew C Foster, MD10, Martha L. Arellano, MD11, John E. Godwin, MD12, Matthew J. Wieduwilt, MD, PhD13*, Michael T. Byrne, DO14, Laura C. Michaelis, MD15, Patrick J. Stiff, MD16, Matteo Giovanni Carrabba, MD17*, Patrice Chevalier, MD, PhD18*, Emmanuel Gyan, MD, PhD19, Christian Recher, MD, PhD20, Anjali S Advani, MD21*, Martin Wermke22*, Harry P. Erba23, Fabio Ciceri, MD24*, Geert Huls, MD, PhD25, Mojca Jorgen-Lavrencic, MD, PhD26, Farhad Ravandi, MBBS27, Antonio Curti, MD PhD28, Max S. Topp, MD29, John Muth, MS30*, Patrick Kaminker, PhD30*, Bob Lowenberg, MD, PhD31, Ivana Gojo, MD32, Leo Luznik, MD32, John F. DiPersio, MD, PhD5, Jan K Davidson-Moncada, MD, PhD30* and Sergio Rutella, MD, PhD, FRCP31,32

1John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom
2NanoString Technologies, Inc., Everett, WA
3Department of Internal Medicine, Division of Oncology, Washington Univ. School of Med., Saint Louis, MO
4University of Southern California, Duarte, CA
5BMT and Leukemia Program, Department of Medicine, Washington University School of Medicine, Saint Louis, MO
6Hematologie clinique, Institut Paoli Clamettes, Marseille, France
7University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
8University of California, San Francisco, San Francisco, CA
9Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
10Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, Chapel Hill, NC
11Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
12Providence Portland Medical Center, Portland, OR
13Moores Cancer Center, University of California, San Diego, La Jolla, CA
14Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN
15Division of Hematology/Oncology, Department of Medicine, The Medical College of Wisconsin Inc., Milwaukee, WI
16Loyola University Chicago Stritch School of Medicine, Maywood, IL
17Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
18Department of Hematology and Cell Therapy, CHU Nantes, Nantes, France
19CHU de Tours - Hôpital Bretonneau, Tours, France
20Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
21Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
22NCT/UCC Early Clinical Trial Unit, University Hospital Carl Gustav Carus, Dresden, Germany
23Duke University School of Medicine, Durham, NC
24Haematology and BMT Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
25Department of Hematology, University Medical Center Groningen, Groningen, Groningen, Netherlands
26Erasmus University Medical Center, Rotterdam, Netherlands
27Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
28Hematology/Oncology "L. e A. Seragøli", Sant’Orsola-Malpighi University Hospital, Bologna, Bologna, Italy
29Medizinische Klinik Und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
30MacroGenics, Inc., Rockville, MD
31Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands
32Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
33Centre for Health, Ageing and Understanding Disease (CHAUD), Nottingham Trent University, Nottingham, United Kingdom

2879 The Genomic Landscape of Wilms’ Tumor 1 (WT1) Mutant Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and
2884 Molecular Dissection of Normal Karyotype Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster III

Hematology Disease Topics & Pathways: Technology and Procedures, cytogenetics, Clinically relevant Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Jacob Shreve, BS, MD, MS1, Manja Meggendorfer, PhD2, Sudipto Mukherjee, MD, PhD, MPH3, Wencke Walter, PhD4, Stephan Hutter, PhD4*, Ahed Makhouli, MD5*, Nathan Radakovich, BA6, Hassan Awada, MD7, Yihong Guan, PhD7*, Teodora Kuzmanovic, BA8*, Jaroslaw P. Maciejewski, MD, PhD9, Claudia Haferlach, MD9, Mikkael A. Sekeres, MD, MS10, Torsten Haferlach, MD11 and Aziz Nazha, MD12

1Cleveland Clinic, Granger, IN
2Leukemia Program, Department of Hematology and Medical Oncology, Tausig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
4Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Bellingham, WA
5Department of Transitional Hematology and Oncology Research, Tausig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
6Leukemia Program, Department of Hematology and Medical Oncology, Tausig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
7Leukemia Program, Department of Hematology and Medical Oncology, Tausig Cancer Institute, Cleveland Clinic, Cleveland, OH
8Department of Hematology and Medical Oncology, Leukemia Program, Tausig Cancer Institute, Cleveland Clinic, Cleveland, OH
9Department of Systems biology and Bioinformatics, CWRU, Cleveland, OH
10Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
11Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
12Leukemia Program, Department of Hematology and Medical Oncology, Tausig Cancer Institute, Quantitative Health Sciences, Avon Lake, OH

2934 Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1e Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III

Hematology Disease Topics & Pathways: Follicular Lymphoma, Biological, Adult, Diseases, Marginal Zone Lymphoma, Therapies, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Biological Processes, Lymphoid Malignancies, Study Population, Clinically relevant, TKI, microenvironment, pathways Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Pier Luigi Zinzani, MD1, Felipe Samaniego, MD2, Wojciech Jurczak, MD, PhD3, Nilanjan Ghosh, MD, PhD4, Enrico Derenzini, MD, PhD5, James A Reeves, MD6, Wanda Knopinska-Posluszny, MD, PhD7, Chan Yoon Cheah, MBBS8, Tycle J. Phillips, MD9, Ewa Lech-Mararida, MD, PhD10*, Bruce D. Cheson, MD11, Paolo F Caimi, MD12, Sebastian Grosicki, MD, PhD13, Lori A. Leslie, MD14, Julio C. Chavez, MD15, Gustavo A. Fonseca, MD16, Sunil Babu17*, Daniel J. Hodson, MD, PhD18, Spencer H. Shao, MD19, John M. Burke, MD20, Jeff P Sharman, MD21, Jennie Y. Law, MD22, John M. Pagel, MD PhD23, Owen A. O’Connor, MD, PhD24, Hari P. Miskin, MS25*, Peter Sportelli, BS 25, Michael S. Weiss25* and Nathan H Fowler, MD2
2953: Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III

Hematology Disease Topics & Pathways: Diseases, Non-Biological, Mantle Cell Lymphoma, Therapies, Non-Hodgkin Lymphoma, Lymphoid Malignancies, Clinically relevant

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Yazeed Sawalha, MD, Subir Goyal, PhD**, Jeffrey M. Switchenko, PhD, MS**, Jason T. Romancik, MD*, Manali Kamdar, MD*, Irl Brian Greenwell, MD, Brian T. Hess, MD, Krista Isaac, DO, MS, Craig A. Portell, MD, Alex V. Mejia Garcia, MD, Scott R. Goldsmith, MD, Natalie S Grover, MD, Peter A. Riedell, MD, Reem Karmali, MD, MSc, Madelyn Burkart, MD***, Michael J Buege, PharmD**, Othman S. Akhtar, MD, Pallawi Torka, MD**, Anita Kumar, MD, Brian T. Hill, MD, Brad S. Kahl, MD, and Jonathan B. Cohen, MD, MS

1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
2Biostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, GA
3Winship Cancer Institute, Biostatistics and Bioinformatics, Emory University, Atlanta, GA
4Department of Hematology and Medical Oncology, Emory University - Winship Cancer Institute, Atlanta, GA
5Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Denver, CO
6Hollings Cancer Center, Medical University of South Carolina, Charleston, SC
7Division of Hematology and Medical Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC
8Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA
9Division of Hematology/Oncology, University of Virginia, Charlottesville, VA
10Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
11Division of Oncology, Washington University, Rock Hill, MO
12Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
13Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
14Division of Hematology Oncology, Northwestern University, Chicago, IL
15Northwestern University; Robert H. Lurie Comprehensive Cancer Center, Northwestern Hospital, Chicago, IL
16Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY
17Department of Medicine, State University of New York at Buffalo, Buffalo, NY
18Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
19Department of Medicine, Lymphoma Service, Memorial Sloan Kettering, Short Hills, NJ
20Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
21Division of Medical Oncology, Washington University School of Medicine, Saint Louis, MO
22Winship Cancer Institute, Emory University, Atlanta, GA
2976 Trial-in-Progress: Frontline Brentuximab Vedotin and CHP (A+CHP) in Patients with Peripheral T-Cell Lymphoma with Less Than 10% CD30 Expression

Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III
Hematology Disease Topics & Pathways: Biological, Diseases, Non-Biological, Therapies, chemotherapy, T-Cell Lymphoma, immunotherapy, Lymphoid Malignancies
Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Deepa Jagadeesh, MD, MPH1, Robert B. Sims, MD2 and Steven M. Horwitz, MD3
1 Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Solon, OH
2 Seattle Genetics, Inc., Bothell, WA
3 Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY

2981 Pharmacokinetic and Pharmacodynamic Correlates from the Phase I Study of Camidanlumab Tesirine (Cami) in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III
Hematology Disease Topics & Pathways: Diseases, Lymphoid Malignancies, Clinically relevant
Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Joseph Boni1*, Karin Havenith2*, Mehdi Hamadani, MD3, Paolo F Caimi, MD4, Katie Anderson5*, Tim Kopotsa6, Hans G Cruz7 and Jens Wuerthner5*
1 Clinical Development, ADC Therapeutics America, Inc., Murray Hill, NJ
2 Clinical Research, ADC Therapeutics (UK) Ltd, London, United Kingdom
3 Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
4 University Hospitals of Cleveland, Cleveland, OH
5 Clinical Development, ADC Therapeutics SA, Epalinges, Switzerland

2992 Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) – Updated Data from the Phase 2 ACE-536-MF-001 Study

Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III
Hematology Disease Topics & Pathways: Diseases, Biological Processes, MPN, erythropoiesis, Myeloid Malignancies, Clinically relevant
Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Aaron T. Gerds, MD, MS1, Alessandro M. Vannucchi, MD2, Francesco Passamonti3*, Marina Kremyanskaya4, Jason Gotlib, MD MS5*, Jeanne M. Palmer, MD6, Kelly McCaul7*, Vincent Ribrag, MD8, Adam J. Mead, MD, PhD9, Claire Harrison, DM, FRCP, FRCP, FRCPath10, Ruben Mesa, MD11, Jean-Jacques Kiladjian12, Giovanni Barosi13, Torsten G. Gerike14*, Jeevan K. Shetty15*, Joseph Pariseau14*, Gabriel Miranda14*, Martin Schwickart14*, Ana Carolina Giuseppi14*, Jennie Zhang14*, Jay T. Backstrom16* and Srdan Verstovsek, MD, PhD17
1 Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
2 Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Florence, Italy
3 Department of Medicine and Surgery, University of Insubria, Varese, Italy
4 Division of Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY
5 Stanford Cancer Institute, Stanford, CA
6 Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ
7 Avera Cancer Institute, Sioux Falls, SD
8 Institut Gustave Roussy, Villejuif, France
9 Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
10 Guy’s and Saint Thomas’ NHS Foundation Trust, London, United Kingdom
11 Mayo Cancer Center, UT Health San Antonio Cancer Center, San Antonio, TX
12 Hôpital Saint-Louis et Université Paris Diderot, Paris, France
13 IRCCS Policlinico San Matteo Foundation, Pavia, Italy
14 Bristol Myers Squibb, Princeton, NJ
15 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
3080 Molecular Response Patterns in Hydroxyurea (HU)-Resistant or Intolerant Polycythemia Vera (PV) during Treatment with Idasanutlin: Results of an Open-Label, Single-Arm Phase 2 Study

Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical: Poster III
Hematology Disease Topics & Pathways:
Diseases, Polycythemia vera, Technology and Procedures, Myeloid Malignancies, NGS
Monday, Dec 7, 2020, 10:00 AM-6:30 PM
Francesco Passamonti, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Tarec Christoffer El-Galaly, Aaron T. Gerds, MD, MS, Vikas Gupta, MD, FRCP, FRCPath, Brian Higgins, Ling-Yuh Huw, PhD, Margherita Maffioli, MD, Ruben Mesa, MD, Jeanne M. Palmer, MD, Alessandro Rambaldi, MD, David M Ross, MBBS, PhD, FRACP, FRCPA, Alessandro M. Vannucchi, MD, Abdulraheem Yacoub, MD and John Mascarenhas, MD

3100 Rare Germline Alterations of Myeloperoxidase Predispose to Myeloid Neoplasms and are Associated with Increased Circulating Burden of Microbial DNA

Program: Oral and Poster Abstracts
Session: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster III
Hematology Disease Topics & Pathways: AML, Diseases, Bone Marrow Failure, CMML, MDS, Myeloid Malignancies
Monday, Dec 7, 2020, 10:00 AM-6:30 PM
Sunisa Kongkiatkamon, MD, Samuel Li, BA, Tatiana Dombrovski, Laila Terkawi, Cassandra M Kerr, MS, Vera Adema, PhD, Yasunobu Nagata, MD, PhD, Wencke Walter, PhD, Hassan Awada, MD, Bartlomiej Przychodzen, Stephan Hutter, PhD, Carmelo Gurnari, MD, Simona Pagliuca, MD, Manja Meggendorfer, PhD, Claudia Haferlach, MD, Valeria Visconte, PhD, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD, PhD and Thomas LaFramboise, Ph.D.

3106 The Clonal Trajectories of SF3B1 Mutations in Myeloid Neoplasia
3111 Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the MEDALIST Study

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster III
Hematology Disease Topics & Pathways: Diseases, MDS, Myeloid Malignancies
Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Hassan Awada, MD1, Cassandra M. Kerr, MS2*, Vera Adema, PhD3, Carmelo Gurnari, MD4*, Simona Pagliuca, MD1, Heesun J. Rogers, MD, PhD5, Hetty E. Carraway, MD, MBA6, Mikkael A. Sekeres, MD, MS6, Jaroslaw P. Maciejewski, MD, PhD2 and Valeria Visconte, PhD1

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
2Department of Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
4Department of Hematology/Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH
5Department of Hematology, Mount Sinai Medical Center, New York, NY

3137 A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Program: Oral and Poster Abstracts
Session: 642. CLL: Therapy, excluding Transplantation: Poster III
Hematology Disease Topics & Pathways: Biological, Therapies, Combinations, Clinically relevant, TKI
Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Paul M. Barr, MD1, Shuo Ma, MD, PhD2, Clive S. Zent, MD1, Andrea M. Baran, MS1*, Andrew Bui1*, Philip J Meacham, PhD1*, Ashley Morrison, RN2*, Kelsey Holkovic, RN3*, Jane L. Liesveld, MD4, Deborah A Mulford, MD1, Peter Sportelli, BS4, Hari P. Miskin, MSc5*, Michael S. Weiss4*, Jonathan W. Friedberg, MD, MSc5 and Brian T. Hill, MD3

1Division of Hematology/Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
3149 The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study

Program: Oral and Poster Abstracts
Session: 642. CLL: Therapy, excluding Transplantation: Poster III
Hematology Disease Topics & Pathways: Leukemia, Adult, CLL, Non-Biological, Diseases, Therapies, Study Population, Lymphoid Malignancies
Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Max J. Gordon, MD1, Andy Kaempf, MS2*, Andrea Sitlinger, MD3, Tareaq Salous4*, Hamood Alqahtani, MBBS5*, Michael C. Churnetski6*, Paul Wisniewski, BS7*, Xavier Issac Rivera, BS8*, Krish Patel, MD1, Daniel O. Persky, MD9, Jonathan B. Cohen, MD, MS10, Michael Y. Choi, MD11, Brian T. Hill, MD12, Mazyar Shadman, MD13, Deborah M. Stephens, DO14, Danielle M. Brander, MD15, Byung Park, PhD16* and Alexey Danilov, MD17

1MD Anderson Cancer Center, Houston, TX
2Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR
3Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC
4Cleveland Clinic, Cleveland, OH
5Moores Cancer Center at UC San Diego, San Diego, CA
6Winship Cancer Institute, Emory University Medical Center, Atlanta, GA
7Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
8University of Arizona, Tucson, AZ
9Division of Hematology/Oncology, University of Arizona, Tucson, AZ
10Department of Hematology and Medical Oncology, Emory University, Atlanta, GA
11University of California-San Diego, San Diego, CA
12Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
13Uw/Fred Hutchinson Cancer Research Center, Seattle, WA
14University of Utah/Huntsman Cancer Institute, Salt Lake City, UT, Salt Lake City, UT
15Duke University, Durham, NC
16Oregon Health and Science University, Portland, OR
17Toni Stephenson Lymphoma Center, City of Hope Comprehensive Cancer Center, Duarte, CA

3191 A Novel Therapeutic Strategy for Preferential Elimination of Multiple Myeloma Cells by Targeting Protein Disulfide Isomerase

Program: Oral and Poster Abstracts
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster III
Hematology Disease Topics & Pathways: apoptosis, Diseases, Biological Processes, Technology and Procedures, Myeloid Malignancies
Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Metis Hasipek, PhD1*, Dale Grabowski, BS1, Yihong Guan, PhD1, Anand D. Tiwari, PhD1*, Xiaorong Gu, PhD1*, Jason Valient, MD2, Jaroslaw Maciejewski, PhD2*, Frederic Joel Reu3, James G Phillips, PhD1* and Babal K. Jha, PhD1*

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
2Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC, Tampa, FL

3281 Hematopoietic Progenitor Cell Mobilization and Collection for Autologous Hematopoietic Cell Transplantation in AL Amyloidosis: A Single Center Experience

Program: Oral and Poster Abstracts
Session: 711. Cell Collection and Processing: Poster III
Hematology Disease Topics & Pathways: HSCs, Diseases, Plasma Cell Disorders, Cell Lineage, Lymphoid Malignancies, Clinically relevant
**3305 Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study**

Program: Oral and Poster Abstracts


Hematology Disease Topics & Pathways: Biological, Non-Biological, Therapies, chemotheraphy, transplantation, stem cells

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Sagar S. Patel, MD, Kwang Woo Ahn, PhD, Manoj Khanal, BS, MS, Caitrin Fretham, MPH, Celalettin Ustun, MD, Betty K. Hamilton, MD, Navneet S. Majhail, MD, MS, Shin Mineishi, MD, Bipin N. Savani, MD, Mohamed S. Sorror, MD, MS, Edward A. Stadtmauer, MD, FACP, Brent Logan, PhD, Marcelo C. Pasquini, MD, MS, and Sourabh Chhabra, MD, MS

1 Blood and Marrow Transplant Program, University of Utah Health, Salt Lake City, UT
2 Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
3 Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI
4 National Marrow Donor Program/Be The Match, Minneapolis, MN
5 Division of Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL
6 Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
7 Penn State Cancer Institute, Penn State Hershey Medical Center, Hershey, PA
8 Department of Medicine, Division of Hematology-Oncology, Vanderbilt University, Brentwood, TN
9 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
10 Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA
11 University of Pennsylvania Abramson Cancer Center, Philadelphia, PA
12 CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
13 Froedtert & The Medical College Cancer Ctr., Milwaukee, WI
14 Department of Medicine, CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI
15 Medical College of Wisconsin, Milwaukee, WI

**3345 Younger HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Myelodysplastic Syndromes (MDS) Is Associated with Superior Disease-Free Survival Compared to Older HLA-Identical Sibling Donors: CIBMTR Analysis**

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster III

Hematology Disease Topics & Pathways: Diseases, MDS, Myeloid Malignancies

Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Guru Subramanian Guru Murthy, MD, Soyoung Kim, Zhen-Huan Hu, MPH, Noel Estrada-Merly, MS, Ryotaro Nakamura, M.D, Betul Oran, MD, MS, Bart L. Scott, MD, Ronald Sobecks, MD and Wael Saber, MD, MS

1 Medical College of Wisconsin, Milwaukee, WI
2 Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
3 Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI
4 CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
5 CIBMTR (Center for International Blood and Marrow Transplant Research) Medical College of Wisconsin, Milwaukee, WI
6 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
7 Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX
3361 Comparison of Outcomes and Quality-of-Life Measures Following Haploidentical Vs. Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster III
Hematology Disease Topics & Pathways: Adult, Study Population, Clinically relevant
Monday, Dec 7, 2020, 10:00 AM-6:30 PM
Sanghee Hong, MD1, Lisa Rybicki, MS2*, Linda McLellan, LISW2*, Jane Dabney, LISW-S2*, Aaron T. Gerds, MD, MS2, Seth J Rotz, MD2, Matt Kalaycio, MD2, Rabi Hanna, MD2, Betty K. Hamilton, MD3, Navneet S. Majhail, MD, MS3 and Ronald Sobecks, MD4
1University Hospitals/ Case Western Reserve University, Cleveland, OH
2Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
4Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

3470 Evaluation of Activation of a NCI National Clinical Trials Network (NCTN) Study S1826 for Hodgkin Lymphoma (HL) at Children’s Oncology Group (COG) Institutions

Program: Oral and Poster Abstracts
Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster III
Hematology Disease Topics & Pathways: Diseases, Hodgkin Lymphoma, Pediatric, Young Adult, Lymphoid Malignancies, Study Population, Clinically relevant, Quality Improvement
Monday, Dec 7, 2020, 10:00 AM-6:30 PM
Sharon M. Castellino, MD, MSC1,2,3, Angela Punnett, MD4, Susan K Parsons, MD, MRP5, Nicholas P. DeGroot, MPH4, Sally Muehlle2*, Hongli Li, MS3*, Michael E. Roth, MD3, Alex F. Herrera, MD9, Jonathan W. Friedberg, MD, MSSc10, Nita L. Seibel, MD11 and Kara M. Kelly, MD12
1Aflac Cancer and Blood Disorders Center, Emory University School of Medicine / Children’s Healthcare of Atlanta, Atlanta, GA
2Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Atlanta, GA
3Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
4Hospital for Sick Children, Toronto, ON, Canada
5Tufts Medical Center, Tufts University School of Medicine, Boston, MA
6University Hospital- Rainbow Babies and Children’s, Cleveland, OH
7SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA
8MD Anderson Cancer Center, Houston, TX
9City of Hope, Duarte, CA
10Division of Hematology/Oncology, University of Rochester, Rochester, NY
11Cancer Therapy Evaluation Prgm., NCI, Bethesda, MD
12Department of Pediatric Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY

3381 Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence

Program: Oral and Poster Abstracts
Session: 803. Emerging Diagnostic Tools and Techniques: Poster III
Hematology Disease Topics & Pathways: Diseases, CMML, MDS, MPN, Myeloid Malignancies, Clinically relevant
Monday, Dec 7, 2020, 10:00 AM-6:30 PM
Nathan Radakovich, BA1, Luca Malcovati, MD2, Manja Miegendamer, PhD3, Mikkael A. Sekeres, MD, MS4, Jacob Shreve, BS, MD, MS5, Cameron Beau Hilton, MD6, Yazan Rouphaeil7*, Wencke Walter, PhD9*, Stephan Hutter, PhD8*, Anna Galli9*, Sarah Pozzi10*, Aaron T. Gerds, MD, MS11, Sudipto Mukherjee, MD, PhD, MPH12, Cassandra M Kerr, MS13, Babal K. Jha, PhD13*, Claudia Haferlach, MD14, Jaroslaw P. Maciejewski, MD, PhD15, Torsten Haferlach, MD16 and Aziz Nazha, MD17
3383 Personalized Transcriptomic Analyses Identify Unique Signatures That Correlate with Genomic Subtypes in Acute Myeloid Leukemia (AML) Using Explainable Artificial Intelligence
Program: Oral and Poster Abstracts
Session: 803. Emerging Diagnostic Tools and Techniques: Poster III
Hematology Disease Topics & Pathways: AML, Diseases, Technology and Procedures, Clinically relevant, genetic profiling, Myeloid Malignancies
Monday, Dec 7, 2020, 10:00 AM-6:30 PM
Yazan Rouphail1, Nathan Radakovich, BA2, Jacob Shreve, BS, MD, MS3, Sudipto Mukherjee, MD, PhD, MPH4, Babal K. Jha, PhD5, Jaroslaw P. Maciejewski, MD, PhD6, Mikkael A. Sekeres, MD, MS7 and Aziz Nazha, MD8
1Ohio State University, Rocky River, OH
2Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Bellingham, WA
3Cleveland Clinic, Cleveland, OH
4Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5Department of Hematology Oncology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy
6Department of Hematology Oncology, IRCSS Policlinico S. Matteo Foundation, Pavia, Italy
7Centro Cellule Staminali E Terapia Cellulare, Genova, ITA
8Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
9Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
10Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
11Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
12MLL Munich Leukamie Labor GmbH, München, Germany
13Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Quantity Health Sciences, Avon Lake, OH

3405 Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method
Program: Oral and Poster Abstracts
Session: 901. Health Services Research—Non-Malignant Conditions: Poster III
Hematology Disease Topics & Pathways: Diseases, Bleeding and Clotting, Therapies, ITP, Clinically relevant
Monday, Dec 7, 2020, 10:00 AM-6:30 PM
Adam Cuker, MD1, Jenny M. Despotovic, DO2, Rachael F. Grace, MD3,4, Caroline Kruse5, Michele P. Lambert, MD, MSTR6,7, Howard Liebman, MD8, Roger M. Lyons, MD9, Keith R. McCrae, MD10, Vinod A. Pullarkat, MD11, Jeffrey Wasser, MD12, David Beenhouwer, MD13, Sarah N Gibbs, MPH13, Irina Yermilov, MD, MPH, MS12 and Michael S Broder, MD, MSHS13
1Department of Medicine, University of Pennsylvania, Philadelphia, PA
2Baylor College of Medicine, Houston, TX
3Harvard Medical School, Boston, MA
4Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA
5Platelet Disorder Support Association, Cleveland, OH
6Children’s Hospital of Philadelphia, Philadelphia, PA
7Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
8University of Southern California, Los Angeles, CA
9Texas Oncology/US Oncology Research, San Antonio, TX
10Cleveland Clinic, Cleveland, OH
11City of Hope, Duarte, CA
3441 Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic

Program: Oral and Poster Abstracts
Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster III
Hematology Disease Topics & Pathways: Coronaviruses, SARS-CoV-2/COVID-19, Leukemia, Diseases, Lymphoma (any), Bone Marrow Failure, Lymphoid Malignancies, Myeloid Malignancies, Quality Improvement
Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Kimberly C Jenkins, MSNM1, Emily C Zabor, DrPH2*, Lindsey A. R. Mooney, BS1*, Aaron T. Gerds, MD, MS3, Kerry O'Hop, BS4*, Makenzie Guy, BA4*, Megan Kilbane, MBA1*, Nathan A Pennell, MD, PhD4* and Mikkael A. Sekeres, MD, MS5

1Hematology and Medical Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
2Quantitative Health Sciences, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
3Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
4Lung Program, Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
5Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

3442 Real-World Investigation of Spleen, Symptom, and Hematologic Response in Patients with Myelofibrosis Treated with First-Line Ruxolitinib

Program: Oral and Poster Abstracts
Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster III
Hematology Disease Topics & Pathways: Biological, therapy sequence, Diseases, Therapies, Combinations, MPN, Myeloid Malignancies, TKI
Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Jonathan K. Kish, PhD, MPH1*, Arianna Kee2*, Pranav Abraham2*, Ronda Copher, PhD2*, Talia Miller1* and Aaron T. Gerds, MD, MS3

1Cardinal Health, Dublin, OH
2Bristol Myers Squibb, Princeton, NJ
3Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

3458 Thrombosis and Risk of Mortality in Newly Diagnosed High-Risk Polycythemia Vera: An Analysis of the Medicare Claims Database in the United States

Program: Oral and Poster Abstracts
Session: 904. Outcomes Research—Non-Malignant Conditions: Poster III
Hematology Disease Topics & Pathways: Diseases, Polycythemia vera, Myeloid Malignancies
Monday, Dec 7, 2020, 10:00 AM-6:30 PM

Naveen Pemmaraju, MD1, Aaron T. Gerds, MD, MS2, Shreekant Parasuraman, BPharm, PhD3*, Jingbo Yu, MD, PhD3, Anne Shah4*, Ann Xi, PharmD4*, Shambhavi Kumar, MS4*, Robyn M. Scherber, MD3 and Srdan Verstovsek, MD, PhD1

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
3Incyte Corporation, Wilmington, DE
4Avalere Health, Washington, DC